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Worldwide, the incidence and prevalence of chronic kidney disease is rising. When chronic
kidney disease evolves to end stage kidney failure, renal replacement therapy becomes
necessary. Although dialysis can replace kidney function, a new, transplanted kidney can
restore renal capacity in a continuous and more eﬀective way. The ﬁrst successful kidney
transplantation was performed in Boston 1954, by Murray and colleagues (1). A young man
with chronic kidney disease received a kidney from his identical twin brother. The graft and
recipient survived for eight years; Murray received the Nobel Prize for Medicine in 1990. Since
then, many medical breakthroughs have led to improved outcomes of kidney transplantation.
The development of immunosuppressive drugs solved part of the problems of rejection of
the graft, and enabled transplantation between genetically non-identical subjects. This also
paved the way for using organs from post-mortem donors for transplantation. Transplantation
has now become the preferred treatment for end stage kidney disease, with better quality of
life and longer survival when compared with patients on dialysis (2-6). Despite all this, donor
shortage is a still a major and persistent problem, and optimization of the donor pool is of
cardinal importance in transplantation medicine. The possibility of living kidney donation,
which is in line with the ﬁrst transplantation by Murray, provides a potentially huge donor
pool. However, a proper balance between optimal enlargement of the donor pool and long-
term donor safety must be ensured to justify the living kidney donor program. 
Living kidney donation
A single, healthy kidney has suﬃcient capacity to cover the entire workload of two kidneys.
Nevertheless, the single kidney state literally puts a lot of pressure on the remnant kidney,
making good health an important requirement for kidney donation. The fact that a donor
kidney can be retrieved from a healthy subject without detrimental eﬀect allows the practice
of kidney donation during life. Over the last decades, living kidney donors have become more
important for kidney transplantation programs worldwide (7;8), although there are large
international diﬀerences in the use of living donors. Nowadays, about half of the Dutch kidney
transplantations are performed with the use of living donors (9), while for example in the
United States living donors account for about one third of the transplantations (10). Kidneys
retrieved from living donors provide better function and longer half life after transplantation
than kidneys from post-mortem donors (11-14). In the past, living kidney donors were very
strictly selected, and accordingly represented the healthiest subjects of a population. This is
apparent from an iconic study entitled ”Kidney donors live longer”, by Dr Fehrman-Ekholm,
herself a kidney donor, showing that survival in kidney donors is better than in the general
population, obviously due to selection bias (15). Many other studies conﬁrmed that living
donor outcome is good (16-24). 
Under pressure of the ever growing waiting list for transplantation organs, the selection
criteria for potential donors have become more liberal (25;26). The current donor pool is
older, more overweight and has higher blood pressure, sometimes even in the hypertensive
range.  Figure 1 displays trends in donor characteristics in time for the University Medical
Center Groningen showing a trend towards older, more overweight and obese donors, with
since 2002, hypertension in a few cases. Since these characteristics are known risk factors for
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the development of kidney disease, this raises a new set of issues, and warrants increased
attention for living donor safety in the current era.  In addition, a trend to more male donors
is seen, which may be explained by the higher prevalence of kidney diseases among women
nowadays.
Eﬀect of donor risk factors on the kidney
Abovementioned changes in the donor pool may aﬀect the outcome of the donor as well as
the recipient. Whereas in the past living donors were in excellent health, nowadays donors
may be more representative of the population they are derived from, including a more
prominent risk proﬁle. This emphasizes the importance of thorough screening and accurate
follow-up. Subjects at risk for kidney function loss after donation should be identiﬁed in early
stages to have optimal eﬀect of preventative strategies. Donor renal risk proﬁle may also have
consequences in a diﬀerent context,  
i.e. the recipient kidney function. Hereafter, the potential eﬀects of donor characteristic s and
risk factors on the kidney are discussed.
Age
As the Dutch population is getting older, the mean age of potential donors is rising as well
(ﬁgure 1). With increasing age the prevalence of co-morbidities such as hypertension increases
as well (27-29), therefore the sole eﬀect of ageing is hard to study. With increasing age, kidney
function declines, albeit with large individual variation. Rate estimates vary around 0.75
mL/min per year (30-33). Co-morbidities like hypertension or arteriosclerosis may accelerate
kidney function loss (34). The decline in kidney function is attributed usually to nephron loss,
with obliteration of the glomerular capillary bed leading to glomerular and ensuing tubular
Figure 1: trends in donor characteristics in the University Medical Center Groningen over time. Bars represent









obliteration (35;36). Remnant glomeruli may increase in size, which is associated with
subsequent development of glomerular sclerosis (37-40). The tubulo-interstitium and the
kidney vasculature are aﬀected by ageing as well (41-43). Changes include for instance tubular
atrophy, a decrease in the number, volume and length of tubuli, and intima ﬁbrosis and
simpliﬁcation of the kidney vasculature. Even without morphological changes, the ageing
kidney is more vulnerable for kidney injury, especially when induced by ischemia. Although
age related changes occur with a large individual variance in presence and severity, the
abovementioned changes make a kidney more vulnerable for damage with decreased
adaptive capacity, which may be relevant for the remaining kidney in the donor, as well as to
the transplanted kidney. 
Gender
Several studies in deceased kidney donors suggested that female kidneys perform worse after
kidney transplantation compared to male kidneys, especially when transplanted in a male
recipient (44-47). There are several gender related diﬀerences in renal characteristics of
potential relevance to kidney donation. In absolute numbers, females have lower kidney
function than male subjects. This is in part due to the simple fact that in general females are
smaller, and, hence, have smaller kidneys and a lower nephron number (48). This is in  line
with a lower metabolic demand in females, due to a smaller body size and lower muscle mass.
Although in absolute mL/min kidney function may be lower, kidney function between males
and females appears to be more or less similar when kidney function is scaled to body size.
Furthermore, when kidney function is scaled to the extracellular ﬂuid volume, women have
similar (49) or even higher kidney function than men (50). Although women may have lower
absolute kidney function, men are more prone to the development of hypertension and
kidney disease (51-54). This appears to be, at least in part, hormonal, since post-menopausal
women show a similar of even higher rate of progression of kidney disease as male subjects
(55). Normal, age related kidney function decline, however, is higher is men (56), though there
does not seem to be a gender diﬀerence in the occurrence of age related glomerulosclerosis
(57). 
Body mass index
The increasing prevalence of overweight and obesity in the general population has also
aﬀected the potential donor population (ﬁgure 1). Overweight, and especially obesity, are
known risk factors for the development of kidney disease and even end stage renal disease
in the general population (51;58-63) as well as in renal transplantation (64;65). Excess body
weight is associated with the development of hypertension, diabetes mellitus and
cardiovascular disease, which in their turn may be harmful to the kidney. In addition to this
indirect eﬀects of overweight on kidney disease, overweight has independent, direct
detrimental eﬀects as well. Potential mechanisms lie in activation of the renin angiotensin
aldosterone system, with a subsequent increase in angiotensin II, which may be harmful to
the kidney; overweight induced glomerular hyperﬁltration with elevated ﬁltration rate and
ﬁltration fraction (64), which was an independent predictor of graft loss in transplant recipient
(66); and the production of pro-inﬂammatory cytokines by visceral fat tissue. Biopsy studies
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showed glomerulomegaly, enlarged glomeruli, and glomerulosclerosis (67) in obese subjects
(68-72), which may in turn lead to the development of proteinuria (71;73). Fortunately,
overweight is a modiﬁable risk factor, and, therefore, deserves extra attention in screening
and follow-up.  
Blood pressure and hypertension
High blood pressure is a known risk factor for the development of kidney damage and kidney
function loss (74-78). Hypertension coincides with other risk factors such as older age and
obesity, and with many kidney diseases. It may accelerate kidney function decline in subjects
with kidney disease (79), and is highly present in subjects with end stage renal disease (80).
Thus, adequate blood pressure control is of major importance for donor and recipient. High
blood pressure, necessitating the use of antihypertensive drugs, used to be an absolute
contraindication for living kidney donation. As hypertension, especially of the mild to
moderate category, is a frequent condition (42-51 % in the adult Dutch population) this
considerably limits the pool of potential donors. Since 2002, however, hypertensive donors
are allowed to donate, provided that there is reasonable blood pressure control on a
maximum of two antihypertensive drugs. Up to 2010, 39 pre-existent hypertensive donors
were found eligible to donate. Since long term follow-up is not available yet, it is important
to meticulously monitor outcome of kidney donation by hypertensive donors, both for donors,
in terms of safety, and recipient in terms of graft performance.
Smoking behavior
Smoking behavior is so far not a selection criterion for potential donors. Although donors may
be advised to stop smoking, there is no special attention for smoking behavior in screening
or follow-up. Smoking is, however, an important risk factor for the development of
cardiovascular disease and several forms of cancer. Furthermore, smoking is recognized as a
potential risk factor for the development of CKD as well.  Smoking may accelerate the aging-
related decline in glomerular ﬁltration rate (81), and increase albuminuria in subjects with
hypertension (82-84), in a dose-dependent manner (63;85;86). Autopsy studies suggested
that smoking may aﬀect the kidney vasculature, causing mild kidney damage. Previously, it
was found that such small lesions may make the kidney more prone to nephrotoxic eﬀects of
calcineurin inhibiting drugs (87), which are invariably used post-transplantation.  Of note, the
eﬀects of smoking on the renal susceptibility to damage appear to persist after cessation of
smoking, as shown by a considerably increased susceptibility to renal damage in formerly
smoking lung transplant recipients (88).  Furthermore, smoking of the recipient prior to kidney
transplantation increases the risk for graft loss (89) and mortality (89;90). 
Donor screening and post-donation follow-up
The changes of the donor pool and the acceptance of donors with potential risk factors for
kidney function loss emphasizes the importance of thorough donor screening. Extending of
the criteria has made decision making even harder. Where in the past donors with any risk
factor were rejected, nowadays, the actual risk for post-donation kidney damage in a donor









program is dependent on guaranteed donor safety on long term. This emphasizes the
importance of regular donor follow-up as well. If any problems do occur post-donation, early
detection can prevent further damage and kidney function loss. There are, however, no strict
guidelines for donor screening and follow-up, and programs diﬀer substantially between
centers. As to screening, centers diﬀer in cutoﬀs of donor characteristics. Where some
guidelines suggest an absolute cutoﬀ of 80 mL/min/1.73m2 for kidney function, others use
age adjusted cutoﬀs. Upper limits for age can be ampliﬁed by considering older donors (>70
years) only for older recipients (>60 years). BMI is mainly associated with surgical
complications, and is, therefore, not a strict selection criterion in all guidelines. Although
hypertension is no longer an absolute contraindication for kidney donation, deﬁnitions diﬀer
between centers.
For follow-up, the guidelines suggest 12 to 24 months active follow-up by the
transplantation center, and then life-long follow-up by local health care providers. Follow-up
should focus on kidney function, development of hypertension, diabetes and obesity. In
addition, most guidelines suggest psychosocial follow-up as well. Donors with a speciﬁc
disease history, for example stone disease, deserve special attention to avoid complications
on the long term.
Suitability of estimated kidney function for monitoring post-donation kidney function
Monitoring of kidney function is an important part of living donor follow-up. Gold standard
kidney function measurement, however, is laborious and expensive. Kidney function
equations estimate kidney function from a single serum creatinine sample, and are, thus,
cheaper and easier in use. The two most widely used equations, the Modiﬁcation in Diet and
Renal Disease (MDRD) Study equation (91)  and the Cockcroft-Gault equation (92), were both
derived from populations with reduced kidney function. This has resulted in a poor
performance in subjects with a kidney function > 60 ml/min, with considerable systematic
underestimation and low accuracy, in particular in subjects without renal function impairment
(93-100). A new equation was developed by the Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI), which was developed in a large data set in diﬀerent populations,
including subjects without renal disease (101). It performs better in normal and higher ranges
of GFR (102). 
Donor nephrectomy elicits a major drop in kidney function. Thus, although prior to
donation kidney function is normal, post-donation kidney donation becomes in range where
the estimating equations have their best performance. Therefore, the equations might be
suitable for use in longitudinal follow-up after donation. The validation of the equations,
however, so far mainly relies on cross-sectional data. Longitudinal studies are sparse, and
were mainly conducted in transplant recipients (103-108) and diabetic patients (109;110). In
non-diabetic CKD patients no studies are available with a follow-up beyond 4 years (111-113).
Use of biopsies for donor screening
To improve the process of donor screening, kidney biopsies can be performed prior to
donation, but for obvious reasons this has not become part of donor screening programs.
However, taking a kidney biopsy during the donation procedure can provide important
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information on renal morphology, without added invasiveness. Due to the large functional
reserve capacity of the kidney, minor morphological and histological damage can be present
without other signs of damage, such as proteinuria or decreased kidney function. Several
studies in potential donors showed that minor structural damage is present among healthy
subjects (22;40;114;115), although the consequences for donor outcome are unclear. Where
one study reported no relation between morphological kidney damage and the development
of kidney disease in the donor (116), many studies found associations between baseline
damage and graft performance in the recipient (117-125). Thus, kidney biopsies may
potentially provide  an important source of additional information on the donor kidney, that
may contribute to the assessment of renal risk for the donor and the recipient. 
Aims of the thesis
The aim of this thesis is to evaluate the eﬀects of the changing donor risk proﬁle pool on living
donor and recipient outcome. Part one of the thesis evaluates the feasibility of the use of
kidney function equations for screening and follow-up of living kidney donors.  Part two
focuses on long term post-donation outcome of the living donor, on the eﬀects of the current
donor risk proﬁle, and evaluates the value of time-of-donation biopsies in predicting donor
outcome. Part three extends the inﬂuence of the donor to recipient outcome. 
Outline of thesis
Part one: estimated GFR in screening and follow-up
Kidney function equations are known to perform poorly in subjects with normal kidney
function. It is unknown whether this poor performance is due to diﬀerences between subjects
with normal and impaired kidney function, or to the level of kidney function as such. Since
kidney donors have a major decrease in kidney function over donation, the latter may make
estimating equations more suitable in the post-donation follow-up. Furthermore, this setting
will allow to establish whether the performance of kidney function equations is related to
kidney function as such, as the other individual characteristics remain the same before and
after donation. In chapter one we compare the performance of three estimating equations
in an within individual analysis in kidney donors prior to and post-donation. Furthermore,
longitudinal use of the estimating equations has not been evaluated for long term follow-up.
To evaluate long term kidney function monitoring with kidney function equations, we
compared the use of these equations to gold standard kidney function measurement in long
term follow-up of CKD patients in chapter two. To further evaluate the use of estimated kidney
function in the follow-up of living kidney donors, in chapter three we compare the measured
and estimated course in kidney function in the post-donation setting in living kidney donors.
Part two: Eﬀect of donor risk proﬁle on donor renal outcome
Although previous studies showed excellent living donor outcome, the current donor pool
may be at increased risk for kidney function loss post-donation. Part two of this thesis
evaluates the eﬀect of several donor characteristics on donor outcome. Since 2002, donors









compare the short term and preliminary one and ﬁve year outcome of pre-existent
hypertensive donors to that of matched control donors. To look in a broader perspective,
chapter ﬁve evaluates the eﬀects of the donor risk proﬁle, i.e. older age, higher BMI and
smoking behaviour, on ﬁve year donor outcome, and establishes a model to predict post-
donation outcome. Since donors have lowered kidney function post-donation, many regard
former kidney donors as having CKD post-donation merely based on the level of kidney
function, which may have severe consequences on social level and welfare of the donor.
Chapter six compares post-donation course of former kidney donors to matched CKD patients
to evaluate whether the predicate is justiﬁed. Chapter seven evaluates the presence of pro-
ﬁbrotic and inﬂammatory changes in kidney biopsies performed during the donation
procedure, and evaluates associations with donor characteristics and the inﬂuence of these
changes on short term donor outcome.
Part three: Eﬀect of donor risk proﬁle on recipient renal outcome
Since the altered donor pool may not only aﬀect the donor but also the recipient, part three
of this thesis evaluates the eﬀect of donor characteristics on recipient outcome. Female
kidneys are often thought to be of inferior quality for use in kidney transplantation. Others,
however, believe that the donor kidney adapts to the body size and metabolic demands of
the recipient. In chapter eight we assess the inﬂuence of donor and recipient gender and the
match in donor/recipient body size on early and ﬁve year recipient outcome. Chapter nine
again looks at the eﬀect of the total donor risk proﬁle, but here we focus on the one and ﬁve
year outcome of the recipient. 
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Abstract
Background: MDRD study equation and Cockcroft-Gault (CG) equation perform poorly in the
(near-) normal range of GFR. Whether this is due to the level of GFR as such, or to diﬀerences
in individual characteristics between healthy subjects and CKD patient is unknown. 
Methods: We evaluated performance of MDRD, CG and CKD-EPI compared to measured GFR
(mGFR; 125I-iothalamate) at four months prior and two months following donation in 253 con-
secutive living kidney donors (mean age 50±11 years, mean BMI 26±4).
Results: mGFR declined from 103±15 to 66±11 mL/min/1.73m2 post-donation. All equations
underestimated mGFR at both time points (p<0.001). Arithmetic performance analysis
showed improved performance post-donation of all equations (p<0.05), with signiﬁcant re-
duction of bias post-donation, with median (IQR) values of 22 (20) vs 15(12) for MDRD, 14(18)
vs 11(12) for CKD-EPI and 10(21) vs 4(14) mL/min/1.73m2 for CG/BSA. Expressed as percent-
age diﬀerence mGFR-eGFR bias was reduced post-donation only for CG/BSA. Finally, in 295
unselected subjects screened for donation, mGFR was below the cut-oﬀ for donation of 80
mL/min/1.73m2 in 19 subjects, but in 166, 98 and 74 for MDRD, CKD-EPI, and CG/BSA.
Conclusion: A higher level of GFR as such is associated with larger absolute underestimation
of true GFR by eGFR. For donor screening purposes eGFR should be interpreted with great
caution, and in doubt, true GFR should be performed, in order to prevent unjustiﬁed decline










Nowadays, many centres rely on estimating equations to provide estimated GFR (eGFR) for
renal function assessment. Many laboratories automatically report eGFR when serum
creatinine is requested. The limitations, however, are well-established. In healthy subjects
and subjects with renal disease with (near-) normal renal function, performance is notoriously
poor, with considerable systematic underestimation of true GFR and low accuracy (1-8). 
The two most widely used equations, the Modiﬁcation of Diet in Renal Disease (MDRD)
study equation and the Cockcroft-Gault (CG) equation, were both derived from populations
with reduced GFR (9-11). Recently, a new equation was reported by the Chronic Kidney
Disease Epidemiology Collaboration (CKD-EPI), which was developed in a large data set in
diﬀerent populations, including renal patients as well as healthy subjects (12). It speciﬁcally
pursues better performance in normal and higher ranges of GFR. 
Poor performance of renal function equations in subjects without renal function
impairment has been subject of debate. Of note, the relationship between measured GFR
(mGFR) and eGFR is diﬀerent between healthy subjects and chronic kidney disease (CKD)
patients (2,5,7,13). Diﬀerences in body composition, in particular muscle mass, and creatinine
handling between healthy people and CKD patients were suggested to determine
performance (2,14). Alternatively, level of mGFR as such was shown to inﬂuence performance
of eGFR (7,13,15-17). However, these were cross-sectional observations, and level of mGFR
may reﬂect between individual diﬀerences in body composition. In longitudinal analysis of
CKD patients, Lee et al showed a strong negative association between bias of eGFR and mGFR
(18). Yet, these studies cannot dissect the eﬀects of CKD – with possible impact on body
composition – from those of diﬀerences in mGFR itself. 
In healthy kidney donors, removal of one kidney leads to a subsequent reduction in GFR
without disease associated changes in body composition. Therefore, our living kidney donor
program could provide a unique opportunity to compare the pre- and early post-donation
performance of eGFR in high and lower ranges of GFR in the same individuals within a limited
time frame. In the current study, we evaluated whether performance of eGFR in healthy
subjects is dependent on the level of mGFR.
Methods
We evaluated 253 consecutive living kidney donors who donated kidneys between 1996 and
2007 in the University Medical Center Groningen. mGFR was measured as described below
four months prior to and two months after kidney donation as part of the screening program
and post-donation evaluation (19). eGFR was calculated from creatinine samples drawn at
these same days. Procedures were conducted in accordance with the Helsinki declaration.
For evaluation of practical consequences for donor screening, data from 295 subsequent
subjects screened for donation, without selection criteria other than referral for donation
were analysed: the abovementioned 253 subjects and 42 subjects who all completed the full
screening program, but did not donate for a variety of medical and non-medical reasons.
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GFR measurement
mGFR was measured by constant low-dose infusion of the radio-labelled tracer 
125I iothalamate as described by Apperloo et al (20). Simultaneously, eﬀective renal plasma
ﬂow was measured as the clearance of 131I-hippurate. For the measurements, subjects were
seated in a quiet room in, in a semi-supine position. After drawing a blank blood sample, the
priming solution containing 0.04 mL/kg body weight of the infusion solution (0.04 MBq of 
125I iothalamate and 0.03 MBq of 131I-hippurate per mL saline) plus an extra of 0.6 MBq of 
125I iothalamate was given, followed by constant infusion at 12 mL/h. To attain stable plasma
concentrations of both tracers, a 2 hour stabilization period followed, after which the
clearance periods start. Clearances were measured over the next 2 hours and calculated as
(U*V)/P and (I*V)/P, respectively. U*V represents the urinary excretion of the tracer, I*V
represents the infusion rate of the tracer and P represents the tracer value in plasma at the
end of each clearance period. mGFR was calculated from UV/P of 125I-iothalamate and
corrected for voiding errors by multiplying the urinary clearance of 125I iothalamate with the
ratio of the plasma and urinary clearance of 131I-hippurate. The day-to-day variability for mGFR
is 2.5%. 
Calculations
The four variable MDRD Study equation was used, which is standard for creatinine samples
traceable to the Isotope Dilution Mass Spectrometry (IDMS).  MDRD Study, and CG equations
were calculated as follows (serum creatinine (SCr) in mg/dL and bodyweight in kg). (9).
MDRD = 175 * (SCr)-1.154 * (age) 0.203 (* 0.742 if female). 
Cockcroft-Gault = (140 – age) * body weight ∕ (72 * SCr) (* 0.85 if female). 
For CKD-EPI equation the following calculations were used (12):
Female with SCr ≤0.7: GFR = 144 * (0.993)age * (SCr / 0.7)-0.329
Female with SCr > 0.7: GFR = 144 * (0.993)age * (SCr / 0.7)-1.209
Male with SCr ≤ 0.9: GFR = 141 * (0.993)age * (SCr / 0.9)-0.4111
Male with SCr > 0.9: GFR = 141 * (0.993)age * (SCr / 0.9)-1.209
Both the MDRD Study and CKD-EPI equations, no correction for ethnicity was applied
as none of the donors were African Americans. BSA was calculated as according to DuBois
(21). mGFR and CG were normalized by dividing the raw sample by BSA and multiplying it
with 1.73, giving mGFR/BSA and CG/BSA. Mean arterial pressure (MAP) was calculated as:
MAP = ((2 * diastolic pressure) + systolic pressure)/3.
Analysis of predictive performance
Performance of MDRD study, CKD-EPI and CG/BSA against mGFR/BSA was analyzed as
proposed by Bostom (22) and Stevens (23), presenting bias, precision, and accuracy. Bias was
calculated as median of the absolute diﬀerence (mGFR - eGFR) and of the percentage
diﬀerence ((mGFR – eGFR) / mGFR * 100), giving a numeric or arithmetic value and a relative









represented by the interquartile range (IQR) of (mGFR- eGFR), and the R2 of the linear
regression of eGFR on mGFR. Accuracy reﬂects the proportion of subjects with eGFR values
within +/- 30% of mGFR (P30). 
Calibration of creatinine samples
In our centre, from blood samples drawn after 1st March 2006, serum creatinine was
measured by enzymatic assay on the Roche Modular. Before this date, samples had been
measured by Jaﬀé alkaline picrate assay, on the MEGA, Merck KGaA, Darmstadt, Germany.
Both methods were calibrated to the reference standard, i.e. Cleveland Clinic Laboratory
measurements, as proposed by Coresh et al (24). To this purpose, a total of 516 blood samples
with a broad range of creatinine were sent to the Cleveland Laboratory, of which 177 were
from before March 1, 2006. Samples for calibration purposes were stored at -80°C until
measured on the Roche <P> module Enzymatic assay with veriﬁed traceability to the reference
standard IDMS. Calibration equations were as follows: calibrated serum creatinine = [-0.300
+ 1.217 * (UMCG Jaﬀé creatinine values in mg/dL)] for measurements before 1st March and
[0.011 + 1.087 * (UMCG Roche creatinine values in mg/dL)] for measurements after 1st March. 
Statistical analysis
Analyses were performed using SPSS software version 16.0 and GraphPad Prism version 5 for
Windows. Data are given as mean ± standard deviation or median [IQR]. Paired Sample’s t
Test and Wilcoxon Signed Ranks test were used to analyse diﬀerences between pre- and early
post-donation values. To compare accuracy at both time points, Chi2 test was used. For all
three equations, eGFR was plotted on true mGFR/BSA and linear regression was performed
to display diﬀerences in the relationship from pre- to post-donation. To limit inﬂuence of
extreme outliers, 95% of the data was used for regression analysis. Furthermore, pre- and
post-donation biases were stratiﬁed according to tertiles of pre donation mGFR/BSA.
Univariate and backward multivariate analysis were performed to evaluate determinants of
pre- and post-donation bias. 
To evaluate the value of eGFR for donorscreening, Bayes’ theorem was applied to predict
probability of an mGFR<80 given an eGFR<80 mL/min/1.73m2. Calculations were as follows:
posterior change = (prior * likelihood) / evidence, i.e. p(A│B) = [p(A) * p(B│A)] / p(B). For the
analysis a break-up by gender, median age (50) and normal weight or overweight was made.
Results
Donor characteristics before and early after donation are given in Table 1. Estimates from
MDRD Study, CKD-EPI and CG/BSA equations all signiﬁcantly underestimated mGFR/BSA, at
both time points (all p< 0.001).  Over donation, blood pressure (MAP) increased slightly but
signiﬁcantly (p<0.001), BMI was unchanged. In a subset of 91 donors, paired measurements
of 24 hour urinary creatinine excretion were available. Pre-donation 24 hour creatinine
excretion was similar to post-donation values, 1.60 ± 0.53 and 1.61 ± 0.67 g/day respectively,
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consistent with stable muscle mass as a partial index of body composition at both time-points.
After donation, all donors had lower kidney function and higher serum creatinine,
reﬂecting loss of one kidney (table 2). The absolute mGFR decline as well as the percentage
decrease after donation was signiﬁcantly underestimated by each of the tested equations (all
p<0.02), although the percentage decrease of MDRD and CKD-EPI were virtually constant to
the change in mGFR. 
Performance of renal function equations
Performance of MDRD study, CKD-EPI and CG/BSA before and after donation is given in Table
3. For the arithmetic values, performance was better post-donation (p<0.01). This is consistent
with the higher R2 of regression of eGFR on mGFR post-donation. The relative diﬀerence
Pre-donation Post-donation P Value
Mean ± SD Median [IQR] Mean ± SD Median [IQR]
% Female 57 - 57 - -
Age (years) 49.5 ± 10.5 49.8 [13.0] 50.0 ± 10.5 50.5 [12.7] By default
MAP (mmHg) 92± 9 92 [11] 93 ± 9 94 [14] 0.008/0.024
Body mass index (kg*m–2) 26 ± 4 26 [5] 26 ± 4 26 [5] NS
Serum creatinine (mg/dL) 0.88 ± 0.16 0.87 [0.23] 1.32 ± 0.26 1.30 [0.35] p<0.001
mGFR (mL/min) 115 ± 20 114 [27] 73 ± 13 72 [16] p<0.001
mGFR/BSA (mL/min/1.73m2) 103 ± 15 102 [22] 66 ± 11 66 [14] p<0.001
Estimated GFR(mL/min/1.73m2)
MDRD Study 81 ± 15a 78 [18]a 51 ± 9b 49 [12]b p<0.001
CKD-EPI 89 ± 14a 88 [22]a 56 ± 11b 54 [15]b p<0.001
CG/BSA 95 ± 20a 94 [26]a 63 ± 13b 62 [16]b p<0.001
Table 1: Donor characteristics before and short term after donation. p-Values in table represent post-donation
values compared to pre-donation values
Data in mean ± SD or median [inter quartile range]. MAP: mean arterial pressure; mGFR: measured GFR.
p<0.001 compared to a pre-donation and b post-donation mGFR/BSA.
mL/min/1.73m2 % of pre-donation (e)GFR
Mean ± SD Median [IQR] Mean ± SD Median [IQR]
Change in mGFR/BSA 37 ± 10 37 [12] 36 ± 7 36 [9]
Change in MDRD 31 ± 11* 29 [13]* 37 ± 9* 37 [11]
Change in CKD-EPI 33 ± 10* 33 [13]* 37 ± 9* 38 [10]*
Change in CG/BSA 32 ± 12* 31 [14]* 34 ± 8* 34 [10]*
Table 2: Change in mGFR and eGFR before and after donation










however suggests similar performance of MDRD Study and slightly worse performance post-
donation for CKD-EPI with a larger median diﬀerence and IQR (p<0.05). Overall accuracy, as
estimated by the P30 remains stable for MDRD Study and CKD-EPI equations, whilst it increases
for CG/BSA (p<0.001 by Chi square).  The individual values of the change in bias over donation
are given in ﬁgure 1, for bias in mL/min (left panel), and for bias as a percentage change (right
panel).
Correlation of delta relative bias and the amount of decrease of mGFR over donation
showed positive relations for all equations, i.e. a larger drop in mGFR correlates to a larger
decrease of relative bias. R2 for the drop in mGFR in mL/min were 0.22, 0.30 and 0.31, and
for the change in mGFR as percentage of pre-donation mGFR 0.23, 0.25 and 0.33 for MDRD,
CKD-EPI and CG/BSA respectively (all p<0.01).
Regression between mGFR/BSA and eGFR
Diﬀerence between mGFR 
and eGFR (mL/min/1.73m2) 
Percentage diﬀerence 
between mGFR and eGFR
Median IQR Median IQR R2 P30 (%)
Pre-donation
MDRD Study 22 (20-25) 20 (14-26) 22 (20-24) 17 (12-21) 0.16 73 (68-79)
CKD-EPI 14 (11-16) 18 (14-22) 13 (11-16) 16 (13-21) 0.20 89 (85-93)
CG/BSA 10 (7-12) 21 (16-29) 10 (7-12) 21 (16-28) 0.14 90 (86-94)
Post-donation
MDRD Study 15 (14-16)* 12 (9-15) 23 (21-25)* 17 (12-21) 0.31 71 (65-76)
CKD-EPI 11 (9-11)* 12 (10-16) 16 (14-19)* 20 (15-23) 0.35 89 (85-93)
CG/BSA 4 (2-5)* 14 (11-18) 6 (3-9)* 22 (11-27) 0.31 93 (90-96)
Table 3: Pre- and post-donation performance for MDRD, CKD-EPI and CG/BSA.
Data in median (95% CI) and inter quartile range (95% CI).  mGFR: measured GFR. * p<0.05 compared to pre-
donation value. 
Figure 1. Individual values of the change (delta) in bias over donation (Unx). Delta was calculated as [pre-donation
bias – post-donation bias] in mL/min/1.73m2 for arithmetic values (left panel) and as a percentage diﬀerence
for relative values (right panel). Error bars represent median bias. 
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An overlay scatter plot for both time points was made for all three equations (ﬁgure 2),
showing the regression of GFR/BSA and eGFR before and after donation in the same plot. It
shows a steeper regression slope after donation for all three equations. 
Inﬂuence of level of mGFR on eGFR bias
Pre- and post-donation bias was divided according to tertiles of pre-donation mGFR/BSA.
Figure 3 shows median bias for pre- and post donation arithmetic and relative values for each
equation. Pre- and post donation arithmetic bias was higher in the higher tertiles of mGFR
for all equations. For relative values, post-donation CKD-EPI and CG/BSA showed stable bias
over the tertiles.  
Figure 2. Regression of eGFR on mGFR/BSA for all three equations for pre- (dark dots; solid line) and post dona-
tion (grey diamonds; dotted line) values. Pre- and post-donation slopes of the regression lines are 
respectively 0.36 ± 0.05 and 0.55 ± 0.05 for MDRD study, 0.43 ± 0.06 and 0.47 ± 0.04 for CKD-EPI and 0.26 ±
0.04 and 0.39 ± 0.04 for CG/BSA equation.
Figure 3. Pre- and post-donation bias as arithmetic (left) and relative values. Arithmetic bias was calculated as
[mGFR – eGFR], relative bias as [(mGFR – eGFR) / mGFR * 100]. Bias was divided according to tertiles of pre-do-
nation mGFR/BSA, thus pre- and post-donation tertiles contain the same donors. Tertile median [IQR] values of
pre donation mGFR/BSA were 87 [82-92], 102 [99-106] and 118 [113-125] respectively. Corresponding values
for post donation mGFR/BSA were 56 [53-62], 66 [61-71] and 73 [68-77] mL/min/1.73m2. Bars represent median









Anthropometric determinants of bias before and after donation
Univariate analysis of determinants of pre- and post-donation bias is listed in table 4. Multiple
signiﬁcant factors on univariate analysis were combined in backward multivariate analysis.
Bias in the MDRD Study equation post-donation was best predicted by a model with age and
BMI (R2 0.03; p<0.01). Pre- and post-donation bias of CG/BSA was predicted by all tested
factors: age, BMI and gender (R2 0.28 and 0.26 respectively, both p<0.001). Bias of CKD-EPI
was not signiﬁcantly inﬂuenced by these factors. 
Age (R2; p) BMI (R2; p) Gender (R2; p)
Pre-donation
MDRD Study 0.012; 0.04 NS NS
CKD-EPI NS NS NS
CG/BSA 0.067; <0.001 0.067; <0.001 0.024; <0.01
Post-donation
MDRD Study 0.017; 0.02 0.011; 0.05 NS
CKD-EPI NS 0.017; 0.02 NS
CG/BSA 0.102; <0.001 0.127; <0.001 0.026; <0.01
Table 4: Univariate analysis of pre- and post-donation bias
Data represent R2 and P-value from linear regression. BMI: body mass index.
Figure 4. Predicted probability of mGFR < 80 when eGFR <80 mL/min/1.73m2 by Bayes’ theorem. Percentages
represent probabilities calculated by Bayes’ theorem, for MDRD (M) study, CKD-EPI (C-E) and CG/BSA (CG) equa-
tion respectively in 295 subsequent subjects referred for donor screening without prior selection. Break-ups are
made for gender, age and BMI. The number of subjects in each subgroup is as follows: a n=20, b n=41, c n=25,
d n=45, e n=39, f n=43, g n=34 and h n=48. 
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Practical consequences for donor selection by a Bayesian approach
Finally, to address practical consequences for donor selection, we calculated the probability
that a potential donor with an eGFR < 80 mL/min/1.73m2 indeed has an mGFR < 80
mL/min/1.73m2. Of the 295 potential donors analysed (44% male, mean age 50 ± 11 years,
BMI 27 ± 5 kg/m2). Mean mGFR, MDRD, CKD-EPI and CG/BSA were 103 ± 16, 81 ± 15, 88 ± 14
and 95 ± 21 mL/min/1.73m2 respectively. In 19 subjects mGFR was < 80 mL/min/1.73m2, for
MDRD this were 166, CKD-EPI 98 and CG/BSA 74 subjects. The predicted probabilities of mGFR
< 80 when eGFR was < 80 mL/min/1.73m2, were 8, 14 and 18% for MDRD study, CKD-EPI and
CG/BSA equation. Analyses for subgroups deﬁned by gender, age and BMI are shown in ﬁgure
4, showing that the prediction of true GFR < 80 is slightly improved by taking into account
these demographic parameters.
Discussion
This paper discusses the inﬂuence of level of mGFR on performance of eGFR in a situation of
normal and lower mGFR in the same healthy individual. When expressed in mL/min, bias of
eGFR is reduced at lower values of mGFR, i.e. after kidney donation. For bias expressed as
percentage diﬀerence, this was only true for CG/BSA. In the limited time frame, donor
characteristics remained similar. The previously described determinants of bias: age, BMI and
gender inﬂuenced bias, though only limited. Therefore, these data support the assumption
that mGFR is a determinant of performance of eGFR.  
This study is the ﬁrst to compare performance of eGFR in high and lower ranges of mGFR
within the same subjects. Although we can not exclude subtle changes in body composition,
anthropometric parameters stayed virtually constant over this time frame, and age increased
similarly for all subjects. Therefore, our setting allows dissecting the eﬀect of mGFR as such. 
For arithmetic calculated bias (mL/min), all equations showed improved performance
post-donation. The relationship between eGFR and mGFR improved, although the diﬀerence
for CKD EPI is markedly lower than for MDRD and CG/BSA (ﬁgure 2). Inﬂuence of mGFR on
arithmetic bias was conﬁrmed (ﬁgure 3). 
For relative values (percentage diﬀerence), CG/BSA performance signiﬁcantly improved
post-donation, although inﬂuence of mGFR post-donation was less. MDRD study equation
was stable in performance analysis, though mGFR inﬂuenced MDRD bias at both time-points.
CKD-EPI performs slightly worse for post-donation values, reﬂected by a loss of inﬂuence of
mGFR on bias (ﬁgure 3). 
Although our data support an important role of the absolute level of GFR on performance
of eGFR, we cannot ascribe deviation from mGFR in these healthy subjects to mGFR alone.
Healthy people may diﬀer in body composition and physiology of creatinine handling from
CKD patients, leading to a more dominant eﬀect of protein intake and muscle mass on serum
creatinine in healthy subjects, whereas in CKD patients true GFR may have a more dominant
eﬀect (2,14). Comparing performance in healthy subjects with lower mGFR to matched CKD









from populations with a reduced GFR (9,10), they may overstate the strength of the
relationship between GFR and serum creatinine in healthy subjects (14). The CKD-EPI equation
was developed and validated in populations with a broader range of renal function and
contains a spline function which enables it to diﬀerentially capture this relationship and
therefore shows to be less inﬂuenced by mGFR in this study. 
To account for variation in muscle mass as a variable in creatinine production,
demographic and/or other anthropometric data have been included in GFR estimating
equations.The MDRD algorithm was shown to inadequately represent variance in muscle mass
(26), and produces systematic errors in estimation of GFR. Performance of CG was found to
deviate with age and body mass index (16,25). Studies in renal transplant recipients conﬁrmed
age, gender and BMI, to be signiﬁcant determinants of bias in MDRD study and CG equation
(15,17,25). 
Variation among laboratories in reporting serum creatinine has been proposed as an
important cause of deviation of eGFR (11,24,27). We therefore used calibration equations to
calibrate our serum samples to the Cleveland laboratory. 
For MDRD Study and CG/BSA, inﬂuence of level of mGFR could be explained by the
approximately hyperbolic curve of the relation between mGFR and serum creatinine, which
translates to a stronger relationship between the equations and mGFR at lower levels of
mGFR, here reﬂected by steeper slope of regression of eGFR on mGFR post-donation. 
The new CKD-EPI equation seems to be more stable in diﬀerent conditions. mGFR had
less inﬂuence on group performance of CKD-EPI compared to the other two equations. In
individual analysis CKD-EPI however showed a similar variation as the other equations. Bias
of CKD-EPI was not inﬂuenced by age, BMI or gender. 
All three equations signiﬁcantly underestimated kidney function at both time points. This
is in line with prior studies on the MDRD and CG equation. Therefore, recently the CKD EPI
equation was proposed (12). Pre-donation values of 43 donors included in this study were
used in the external validation set of the CKD EPI equation as well (12,19). In these 253 donors,
CKD-EPI showed to be the most precise equation. Our current analysis does support better
performance of the CKD/EPI equation in healthy kidney donors when compared to MDRD,
albeit not optimal. CKD-EPI does show more stable performance than the other two equations
which is an important characteristic for clinical use.  
For donor screening the underestimation by eGFR at normal or higher values of mGFR
can have large consequences, especially when taking in account that generally under 90% of
results are even within +/- 30% of the measured result. Our Bayesian analysis illustrates large
impact of the GFR-dependent underestimation of mGFR by eGFR in a population of
prospective donors, where the prior probability of impaired renal function is low. For all three
equations the probability that an eGFR <80 mL/min/1.73m2 indicated an mGFR <80
ml/min/1.73m2 was low. Thus, eGFR should be interpreted with extreme caution when used
for donor screening purposes, lest a substantial proportion of subjects are declared unﬁt for
donation based on a ﬂawed renal function estimate. 
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In summary, level of mGFR is an important modulator of performance of eGFR. Whereas
previously it was suggested that physiological diﬀerences in creatinine handling between
subjects with a higher and lower GFR were the main cause of deviation of eGFR, we believe
level of mGFR is important as well. Whereas for clinical use, use of eGFR has been discouraged
at a value > 60 (7), epidemiological research tends to use eGFR above this level. We believe
application of eGFR in the healthy should be used with caution. All three equations discussed
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Performance of MDRD Study and
CKD-EPI Equations for long term 
follow-up of non-diabetic patients




Background: Chronic kidney disease (CKD) typically extends over decades. Longitudinal
monitoring of kidney function in CKD is thus of great importance. Here we retrospectively
evaluate use of the MDRD Study and CKD-EPI equations to monitor long term course of kidney
function, and to identify individuals with progressive kidney function loss. 
Methods: Patients were selected from our outpatient clinic for having ≥4 GFR measurements
(mGFR, 125I-iothalamate) and ≥4 years follow-up. Renal function slopes were obtained by
within-individual linear regression.
Results: 65 non-diabetic CKD patients (40 male, mean baseline age 44±12) with a median
(range) of 9 (4-16) mGFR measurements and a median follow-up of 11 (4-33) years were
included. Both equations signiﬁcantly underestimated mGFR/BSA at baseline and end of
follow-up. mGFR slope was signiﬁcantly underestimated by MDRD Study, but not by CKD-EPI
equation (slopes -1.41 ± 2.06, -1.07 ± 1.72 and -1.39 ± 1.77 mL/min/1.73m2 per year
respectively). Sensitivity and speciﬁcity to identify progressive kidney function loss (mGFR/BSA
slope >1.5 mL/min/1.73m2 per year, n = 23) were 78 and 88% for MDRD Study and 91 and
80% for CKD-EPI equation. In the subgroup of progressors both MDRD Study and CKD-EPI
equation underestimated the rate of mGFR loss (p<0.05) 
Conclusion: Long term course of mGFR is reasonably well estimated by CKD-EPI and slightly
underestimated by MDRD Study equation. Patients with progressive kidney function loss may











Reliable monitoring of kidney function over time is of major importance for the treatment
and prevention of progressive kidney function loss. For simple assessment of kidney function,
several creatinine-based kidney function equations have been developed. The Modiﬁcation
of Diet in Renal Disease (MDRD) Study equation (1,2) is most extensively used. Although this
equation has proven its performance in patients with kidney impairment, performance in
subjects with better kidney function (mGFR > 60 mL/min/1.73 m2) is poor (3-10). For this
reason the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) (11) recently
presented a new equation. This CKD-EPI equation was empirically developed from a large
cross-sectional data set in diﬀerent populations, including renal patients as well as healthy
subjects and speciﬁcally pursues a better performance in the higher ranges of GFR. 
For the clinical applicability of these equations in the management of CKD it is crucial
that they provide a reliable estimate of the changes in kidney function over time over an
extended period, as CKD typically evolves and progresses over decades. Their validation
however, mainly relies on cross-sectional data. Longitudinal performance studies are sparse
so far, and were mainly conducted in transplant recipients (12-17) and diabetic patients
(18;19). In non-diabetic CKD patients no studies are available with a follow-up beyond 4 years
(20-22). 
In this study we aim to assess, ﬁrst, the performance of the MDRD Study and CKD-EPI
equations compared to gold standard kidney function measurement in the long term follow-
up of non-diabetic CKD patients. Moreover, we studied their performance in detecting
individuals with progressive kidney function loss. 
Methods
We retrospectively evaluated data on kidney function of renal patients of the nephrology
outpatient clinic of the University Medical Center Groningen. To ensure long term follow-up,
we retrieved data from all patients enrolled in renal hemodynamic studies performed
between 1972 and 1995 at our centre. Of these 156 patients, 99 had follow-up of renal
function at our center, of which 15 had a renal transplant at baseline and were excluded from
this study. We further selected patients for having a minimum of 4 GFR measurements and
at least 4 years follow-up, giving 72 eligible patients. Seven patients were lost due to missing
data on weight or length. Of the 65 patients enrolled in this study, 27 had essential
hypertension, 17  membranous glomerulopathy, 5 focal glomerulosclerosis, 5 IgA
nephropathy, 3 a single kidney after nephrectomy for reasons other than kidney donation, 2
polycystic kidney disease and 6 other diagnoses like ischemic lesions and Barrter syndrome.
Patients with diabetes mellitus were excluded to preclude eﬀects of temporary hyperﬁltration
on slope analysis. Follow-up was ended from the moment patients received renal replacement
therapy or a kidney transplant to avoid eﬀect on kidney function of dialysis and
immunosuppressant drugs. 
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GFR measurement
Glomerular ﬁltration rate (GFR) was measured by constant infusion of low-dose 
125I iothalamate as described by Apperloo et al. (23). Simultaneously, eﬀective renal plasma
ﬂow is measured as the clearance of 131I-hippurate. For the measurements subjects are seated
in a quiet room, in a semi-supine position. After drawing a blank blood sample, the priming
solution containing 0.04 mL/kg body weight of the infusion solution (0.04 MBq of 
125I-iothalamate and 0.03 MBq of 131I-hippurate per mL saline) plus an extra of 0.6 MBq of 
125I-iothalamate was given, followed by constant infusion at 12 mL/h. To attain stable plasma
concentrations of both tracers, a 2 hour stabilization period follows, after which the clearance
periods start. Clearances are measured over the next 2 hours and calculated as (U*V)/P and
(I*V)/P, respectively. U*V represents the urinary excretion of the tracer, I*V represents the
infusion rate of the tracer and P represents the tracer value in plasma at the end of each
clearance period. GFR is calculated from U*V/P of 125I-iothalamate and corrected for voiding
errors by multiplying the urinary clearance of 125I iothalamate with the ratio of the plasma
and urinary clearance of 131I-hippurate. The day-to-day variability for GFR is 2.5% (23).
Creatinine was determined from blood samples drawn at the start of the GFR measurement.
This procedure was unaltered over the duration of the observation period.
Calculations
We used the abbreviated, four variable MDRD Study equation that was reexpressed for
standardized serum creatinine (SCr) samples (2), which was calculated as follows:
MDRD = 175 * (SCr mg/dL)-1.154 * (age)0.203 (* 0.742 if female)  
CKD-EPI equation was calculated gender speciﬁc, and stratiﬁed by creatinine levels. The
following calculations were used (11):
Female with SCr ≤0.7 mg/dL: GFR = 144 * (0.993)age * (SCr/0.7)-0.329
Female with SCr > 0.7 mg/dL: GFR = 144 * (0.993)age * (SCr/0.7) -1.209
Male with SCr ≤ 0.9 mg/dL: GFR = 141 * (0.993)age * (SCr/0.9)-0.4111
Male with SCr > 0.9 mg/dL: GFR = 141 * (0.993)age * (SCr/0.9)-1.209
No correction for ethnicity was applied in both the MDRD Study and CKD-EPI equations,
as none of the patients were of African ethnicity. From here, these equations are referred to
as estimated GFR (eGFR). BSA was calculated as according to DuBois (24). mGFR was
normalized by dividing the raw sample by BSA and multiplying it with 1.73, giving mGFR/BSA.
The slope of kidney function loss was calculated by within-individual linear regression.  
Analysis of predictive performance
Performance of MDRD Study and CKD-EPI equations against mGFR/BSA was analyzed as
proposed by Bostom (25) and Stevens(26), presenting bias, precision, and accuracy. Bias was
calculated as median of the absolute diﬀerence (mGFR/BSA - eGFR) and of the percentage
diﬀerence ((mGFR/BSA – eGFR)/ mGFR/BSA * 100), giving a numeric or arithmetic value and









standard. It is represented by the interquartile range (IQR) of (mGFR/BSA - eGFR). Accuracy
reﬂects the proportion of subjects with eGFR values within +/- 30% of mGFR/BSA (P30). 
Calibration of serum creatinine samples 
Serum creatinine was measured by enzymatic assay on the Roche Modular in blood samples
drawn after 1st March 2006. Before this date, samples had been measured by Jaﬀé alkaline
picrate assay, on the MEGA, Merck KGaA, Darmstadt, Germany. Both methods were calibrated
to the reference standard, i.e. Cleveland Clinic Laboratory measurements, as proposed by
Coresh et al (27). To this purpose, a total of 516 blood samples with a broad range of creatinine
were sent to the Cleveland Laboratory, of which 177 were from before March 1, 2006. Samples
for calibration purposes were stored at -80°C until measured on the Roche <P> module
Enzymatic assay with veriﬁed traceability to the reference standard IDMS. Calibration
equations were as follows: calibrated serum creatinine = [-0.300 + 1.217 * (UMCG Jaﬀé
creatinine values in mg/dL)] for measurements before 1st March 2006 and [0.011 + 1.087 *
(UMCG Roche creatinine values in mg/dL)] for measurements after 1st March 2006. MDRD
Study, and CKD-EPI equations were calculated from calibrated creatinine values.
Calculation of kidney function slope and deﬁnition of progressive kidney function loss
Individual slopes of kidney function loss were calculated by within-individual linear regression.
To conﬁrm linearity of individual kidney function slopes, we collected all creatinine samples
available within the study period for each patient, and performed residual analysis on the
individual creatinine slopes. Two patients had a non-linear creatinine slope, though mGFR
slope was conﬁrmed to be linear. As control of the abovementioned method, kidney function
loss was also estimated by means of linear mixed eﬀect models with random coeﬃcients and
random intercepts. Since both methods provided very similar estimates of mean slopes,
within-individual linear regression was used for further analysis. To evaluate the performance
of the equations to detect progressive kidney function loss, we identiﬁed “progressors”,
deﬁned as patients with a rate of renal function loss of at least two-fold higher than in the
general population. In the Baltimore Longitudinal Study of Aging the normal age-related renal
function decline was -0.75mL/min/year (28), so we classiﬁed a GFR decline > 1.5
mL/min/1.73m2/year as progressive function loss. We tested the sensitivity and speciﬁcity of
both equations to identify progressors.  Additionally, we studied the predictive performance
of the equations in the subgroup of progressors as described above.
Statistical analysis
Analyses were performed using SPSS software version 16.0, SAS version 9.1, Stata version
10.0, Microsoft Oﬃce Excel 2003, and GraphPad Prism version 5 for Windows. Data are given
as mean ± standard deviation or median [inter quartile range (IQR)]. Paired Sample’s T Test
and Wilcoxon Signed Ranks test were used to analyse diﬀerences between baseline and last
observation values, and to analyse diﬀerences between mGFR/BSA and eGFR, and MDRD
Study and CKD-EPI equations. Diﬀerences between groups were tested by independent
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samples t-test, Mann Whitney U test and Kruskal Wallis test. Diﬀerences between accuracy
were tested with Chi square. 
For baseline and last observation values of MDRD Study and CKD-EPI equations, Bland
Altman analyses were performed. Determinants of bias at baseline and end of follow-up and
bias of slope were examined by backward linear regression.
Results
Data on kidney function measurements of 65 patients (42 male) were obtained for analyses.
The median (IQR) number of GFR measurements was 9 [6-11] with a median follow-up time
of 11 [7-18] years. Patient characteristics for baseline and last observation values are listed in
table 1. CKD-EPI equation provided signiﬁcantly higher values than the MDRD Study equation
(p<0.01), but both equations signiﬁcantly underestimated mGFR/BSA at both time points
(p<0.01).
Table 2 compares the cross-sectional performance of the equations at baseline and end
of follow-up. At baseline, bias of the MDRD Study equation, expressed in mL/min/1.73m2 was
Baseline Last observation P value
Age (years) 45 ± 11 58 ± 13 <0.01
BMI (kg/m2) 25.6 ± 3.7 26.4 ± 4.2 <0.01
Serum creatinine (mg/dL) 1.30 ± 0.52 1.84 ± 1.12 <0.01
mGFR/BSA (mL/min/1.73m2) 78 ± 27 58 ± 29 <0.01
MDRD study equation (mL/min/1.73m2) 63 ± 24* 47 ± 23* <0.01
CKD-EPI (mL/min/1.73m2) 70 ± 26*† 51 ± 25*† <0.01
Baseline Last Observation
MDRD study CKD-EPI MDRD study CKD-EPI
.mL/min/1.73m2 Bias 15 (7-19) 8 (1-13)† 9 (6-13)* 6 (4-9)†
Precision 22 (0-32) 21 (-8-25) 16 (0-22) 16 (-3-19)
% Bias 21 (11-28) 12 (2-21)† 20 (12-23) 12 (7-19)†
Precision 28 (0-35) 31 (-10-29) 22 (-1-32) 23 (-10-27)
P30 (%) 66 82† 77 82†
Table 1: Patient characteristics at baseline and end of follow-up.
Data are expressed as mean ± standard deviation. * p<0.01 compared to mGFR value; † p<0.01 compared to
MDRD stuy equation value.
Table 2: Overall performance of MDRD Study and CKD-EPI equations.
Bias values represent median (95% CI), precision values IQR (95% CI). * p<0.05 compared to baseline value;









signiﬁcantly larger than for the CKD-EPI equation (p<0.05). At the end of follow-up, bias of
the MDRD Study equation had decreased signiﬁcantly (p<0.05), whereas for the CKD-EPI
equation it had remained stable. Expressed as percentage diﬀerence, bias was stable during
follow-up for both equations. At both time-points, CKD-EPI had higher accuracy than the
MDRD Study equation (all p<0.001). The biases of both the MDRD Study and the CKD-EPI
equations were best predicted by mGFR/BSA (adjusted R2=0.23 and 0.12 respectively, p<0.01
for baseline bias and adjusted R2=0.47, and 0.25 p<0.01 for end of follow-up). In all analyses,
age, duration of follow-up and 24 hour urinary creatinine excretion had no inﬂuence on bias
(data not shown). 
Slopes for change in mGFR/BSA and eGFR over time are shown in table 3. mGFR/BSA
slope and CKD-EPI equation slope were not signiﬁcantly diﬀerent. Both slopes were
signiﬁcantly steeper than the MDRD Study equation slope (p<0.05). Figure 1 displays scatter
plots for the regression of respectively the MDRD Study and CKD-EPI equation slope on
mGFR/BSA slope. The CKD-EPI slope had a stronger relation with mGFR/BSA than the MDRD
Study slope (R2 0.52 and 0.45 respectively, p<0.01). Figure 2 displays the performance of
eGFR/BSA slope by Bland Altman analysis: no systematic error was found for either of the
equations. 
Figure 3 displays distribution of within subject bias between MDRD Study and CKD-EPI
equations slope and mGFR slope, and median mGFR/BSA slope values for the diﬀerent
Slopes (mL/min/1.73m2 per year)
mGFR/BSA -1.5 ± 2.0
MDRD study -1.1 ± 1.7*
CKD-EPI -1.4 ± 1.8†
Table 3: Slopes of mGFR and MDRD Study and CKD-EPI equations.
Data are expressed as mean ± standard deviation. * p< 0.05 compared to mGFR/BSA slope; † p<0.01 
compared to MDRD study equation slope.
Figure 1: Scatter plots of regression of MDRD Study equation slope on mGFR/BSA slope (left panel) and CKD-EPI
equation slope on mGFR/BSA slope (right  panel). R2 for MDRD Study and CKD-EPI equations are 0.52 and 0.45
(both p<0.05).
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categories. The majority of subjects had bias between -1.5 and 1.5 mL/min/1.73m2 per year,
69 and 72% for MDRD Study and CKD-EPI equations. Respectively 20 and 14% had bias above
1.5 mL/min/1.73m2, and thus an eGFR slope more positive than mGFR/BSA slope. In 11 and
14% eGFR slope bias was below -1.5 mL/min/1.73m2. For both equations, median mGFR/BSA
slope decreased over the groups (p<0.01).
Next, we studied the performance of the equations in the detection of progressive kidney
function loss. A mean loss of mGFR/BSA > 1.5 mL/min/1.73m2/year was present in 23/65
patients, classiﬁed as progressors. Individual values for the slopes of mGFR and eGFR are
given in ﬁgure 4 with a break-up by progressor-status. Sensitivity and speciﬁcity for detection
of progression were 78 and 88% for the MDRD Study and 91 and 81% for the CKD-EPI
equation. No diﬀerences in baseline patient characteristics, duration of follow-up, number of
kidney function measurements, kidney function or 24 hour creatinine excretion were found
Figure 2: Bland Altman analysis of performance of MDRD Study equation slope against mGFR slope (left panel)
and CKD-EPI equation slope against mGFR slope (right panel). Solid line represents mean bias, dotted lines 
represent ± 2 SD interval.
Figure 3: Distribution of bias of slope (mGFR/BSA slope – eGFR slope) for MDRD Study (left, grey bars) and CKD-
EPI equations and median mGFR/BSA slope for the particular categories. Bars represent % of total (left y-axis),









between patients correctly and wrongly classiﬁed as progressor (data not shown). Positive
and negative predictive values for progression were 78 and 88% for the MDRD Study and 72
and 94% for the CKD-EPI equation. In progressors the slope of mGFR/BSA (-3.6±1.7
mL/min/1.73m2/year) was signiﬁcantly underestimated by both equations, with values of -
2.4±1.8 and -2.8±1.8 ml/min/1.73m2 for the MDRD Study and CKD-EPI equations respectively
(p<0.05, ﬁgure 4), whereas in the stable subjects the slopes were similar for mGFR, MDRD
Study and CKD-EPI equations: 0.3±0.8 vs. -0.4±1.2 and -0.6±1.2 mL/min/1.73m2 per year,
respectively. Baseline level of mGFR and both equations were similar between the groups
(data not shown). Performance analysis showed that bias remained stable between baseline
and the end of follow-up in the non-progressors, whereas in the progressors bias was
signiﬁcantly smaller at end of follow-up (table 4).
Discussion
This study evaluated the MDRD Study and CKD-EPI equations for long term follow-up of non-
diabetic CKD-patients. The MDRD study equation underestimated kidney function decline,
but the CKD-EPI equation more accurately quantiﬁed the mean rate of kidney function loss
over time. The sensitivity and speciﬁcity of both equations to detect progressive kidney
function loss were limited, and in progressors the rate of kidney function loss is
Progressive slopes (n=23) Stable slopes (n=42)
Baseline Last observation P value Baseline Last observation P value
MDRD Study 22 (20-25) 20 (14-26) 22 (20-24) 17 (12-21) 0.16 73 (68-79)
CKD-EPI 14 (11-16) 18 (14-22) 13 (11-16) 16 (13-21) 0.20 89 (85-93)
Table 4: Bias (mL/min/1.73m2) of MDRD Study and CKD-EPI equations by break-up by rate of kidney function
loss. 
Values represent median (95% CI).† p<0.01 compared to corresponding MDRD study equation value.
Figure 2: Bland Altman analysis of performance of MDRD Study equation slope against mGFR slope (left panel)
and CKD-EPI equation slope against mGFR slope (right panel). Solid line represents mean bias, dotted lines 
represent ± 2 SD interval.
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underestimated. This warrants caution in the application of the equations in the monitoring
of kidney function in clinical practice.  
Previous studies evaluating the performance of MDRD Study equation for longitudinal
follow-up focused mainly on transplant recipients. In kidney (12-15), lung (16) and liver (17)
transplant recipients, the MDRD Study equation had a reasonable performance on group
level. However, it tended to underestimate the rate of kidney function loss and the number
of patients developing kidney function impairment. Two studies in patients with type II
diabetes mellitus showed underestimation of kidney function slope, with especially large
underestimation in in early stages of nephropathy (hyperﬁltration and normal kidney function)
(18,19). 
In our study, CKD-EPI equation performed well in the prediction of mean mGFR, while
MDRD Study equation showed slight underestimation. However the sensitivity and speciﬁcity
to detect individuals with progressive kidney function loss were limited. In particular, the
positive predictive values were suboptimal, and in progressors, the rate of kidney function
loss was underestimated. This is consistent with previous studies (13,16,18,19,22) where the
MDRD Study equation underestimated kidney function loss as well, and did not reliably detect
progressive function loss. In the original MDRD population Xie et al. evaluated longitudinal
performance of the MDRD Study equation. In 542 patients with a follow-up of 2.6 years the
mean rate of mGFR decline, being -3.9 mL/min/1.73m2/year, was underestimated by the
MDRD Study equation by some 28% (22). In the African American Study of Kidney Disease
and Hypertension’ (AASK) population, Lewis et al. showed that in their four year study period
the AASK equation underestimated kidney function loss as well (-1.6 vs. -1.9 mL/min/1.73m2
per year) (21).
Our data demonstrate that underestimation of mGFR slope is due to the change in bias
over time, with less underestimation at the end of follow-up. This is more likely due to loss of
kidney function rather than time-span as such, since it was only found in progressors. It is
well established by cross-sectional studies that underestimation of mGFR by eGFR is smaller
at lower absolute levels of mGFR, as also the case in our population. Recent studies by Lee
and our own group, in predialysis patients and healthy kidney donors, respectively, showed
that a within individual decrease in mGFR is associated with a decrease in bias as well (20,29).
Inherent to this mGFR dependency of bias, eGFR bias decreases over time in subjects with
progressive kidney function loss and thus eGFR slope will be less steep compared to mGFR
slope. Other kidney function related factors, like diminished creatinine excretion, and altered
muscle mass over time may further inﬂuence eGFR performance. 
In our population the CKD-EPI equation performed better than MDRD Study equation,
both cross-sectionally and longitudinally. It was less inﬂuenced by the level of mGFR/BSA, in
line with its development and validation in datasets with a broad range in mGFR and a spline
for creatinine. Therefore, bias is more stable over the range of kidney function, and
accordingly the deviation of its slope from mGFR slope is stable over time as well. 
What could be the implications of our ﬁndings? In clinical practice reliable monitoring of
kidney function is important to assess long term prognosis, and accordingly allocation of









The shortcomings of creatinine and the reciprocal of creatinine to this purpose are well-
established (30). Our data show that eGFR has shortcomings for longitudinal monitoring as
well. In particular the distinction between stable patients and progressors, which is essential
for applicability in clinical practice, is hampered by the limited sensitivity and speciﬁcity of
eGFR to detect progressive renal function loss, which occurred in spite of a prolonged
observation period and multiple measurements. For individual patients, positive and negative
predictive values are the relevant characteristics of a diagnostic test to consider, and these
are strongly aﬀected by the a priori probability of progression in the population. Thus, whereas
the positive and negative predictive values for progression were rather acceptable in our
university hospital population with one-third progressors, in the general population or in
general practice identiﬁcation of progressors will be blurred by the lower proportion of
progressors. For instance, in a population with 10% progressors, the positive and negative
predictive value for MDRD Study and CKD-EPI equations would be 42 and 97% and 35 and
99% respectively. This will result in an unwarranted number of falsely-positive identiﬁed
progressors whereas on the other hand true progressors still escape from being detected.
For a more severe deﬁnition for progression, i.e 2 mL/min/1.73m2/year, the results were
essentially similar (data not shown). This performance is reason for concern as regards the
use of eGFR for follow up of renal function in general practice.  
It should be noted that to evaluate kidney function slopes, often linearity is assumed.
Although in this study all but two patients were shown to have a linear kidney function slope,
this does not always apply. The two patients with the non-linear creatinine slope were not
among the missed progressors. 
The use of creatinine-based parameters as an outcome parameter in clinical trials in CKD
has been criticized and it has been argued that hard end point studies would be preferable
(31,32). However, this is not feasible for intervention studies in earlier stages of CKD.
Accordingly, and supported by our current data, it has been argued (14) that reference
methods should be used for monitoring kidney function in clinical trials.
Our study has several limitations, the most important being the relatively small sample-
size, the mono centric character, and the lack of standardized timing of measurements. The
conclusions do not apply to patients with African ethnicity, diabetic patients and kidney
transplant recipients all of whom were not included. Due to our inclusion criteria of a
minimum of 4 mGFR measurements and 4 year follow-up, subjects with an extreme
progressive slope, reaching ERSD and the need of renal replacement therapy within this time
span, were excluded. All this limitations hamper generalisability. Still, these data derived from
clinical practice may have better applicability than data derived from clinical trials.
In conclusion, this study shows acceptable performance of CKD-EPI equation and slight
underestimation of mean function loss by MDRD Study equation in long term follow-up of
CKD-patients. Individual patients with more progressive kidney function loss might however
be missed. Thus, caution is warranted in the application of the equations in the monitoring
of kidney function in individual patients. 
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Background: Due to more liberal selection criteria, living kidney donors nowadays are more
marginal. This emphasizes the need for proper and accurate kidney function follow-up in
former donors, preferably by simple methods. This study evaluates the use of creatinine-
based estimating GFR equations for living donor follow-up.
Methods: Included were 132 consecutive living kidney donors. All had GFR (125I-iothalamate)
measured prior to, and two months and 5.4 ± 1.5 years post-donation. GFR was estimated by
MDRD Study, Cockcroft-Gault (CG) and CKD-EPI equations. GFR decline exceeding 1.0
mL/min/1.73m2 per year was classiﬁed as a progressive kidney function slope.
Results: Over donation, GFR fell from 104 ± 15 to 67 ± 11, and then increased to 73 ± 11 
mL /min/1.73m2 at long term post-donation. The equations signiﬁcantly underestimated GFR
at all time points. The equations showed moderate performance to estimate mean GFR slope
(1.16 ± 1.4 mL/min/1.73m2 per year), although the diﬀerence from the GFR slope was larger
for CG equation (0.89 ± 1.72) than for MDRD study (1.03 ± 1.43) and CKD-EPI equation 
(1.03 ± 1.66). Thirteen donors had a progressive GFR slope (median[IQR] slope 
-1.3 [-1.4 ~ -1.2] mL/min/1.73m2 per year). In these donors, all equations showed a positive
median slope.
Conclusion: In conclusion, MDRD Study and CKD-EPI equation perform moderately at group
level to estimate long term GFR slope in former kidney donors. All equations, however, have










Living kidney donation is of major importance for kidney transplantation programs nowadays.
Over the last years, selection criteria have become less strict (1;2), enabling more marginal
donors to enroll in the screening process and donate a kidney. This strengthens the need for
thorough screening, with reliable kidney function measurements. Furthermore, donor follow-
up has become more important to ensure long term donor safety. 
Since gold standard glomerular ﬁltration rate (GFR) measurement is laborious and
expensive, creatinine-based equations providing estimates of GFR (eGFR) are most often used
for donor screening and post-donation follow-up. The most widely used equations, the
Modiﬁcation of Diet in Renal Disease (MDRD) study equation and Cockcroft Gault (CG)
equation, however, are known to perform poorly in subjects with normal or only mildly
impaired kidney function (3-9), and several studies reported them inappropriate for use in
living donor screening (6;8;10-13). The more recently developed Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI) equation performs better at higher levels of kidney
function, and, hence, performs more stable before and early after kidney donation (14). For
long term post-donation follow-up, however, no data are available yet. Most data on predictive
performance of creatinine-based equations in general were obtained cross-sectionally, and
performance for longitudinal follow-up is less well documented. A limited number of studies
in CKD patients tested longitudinal performance of eGFR equations, and found reasonable
performance on group level. However, the rate of kidney function loss was underestimated
by all tested equations (15-20), and the sensitivity and speciﬁcity to detect progressive
function loss were not optimal.
For former kidney donors, longitudinal data are lacking altogether. Therefore, in the
current study, we analyzed the performance of three estimating equations, as compared to
gold standard GFR measurement, for long term follow-up of former living kidney donors.
Methods
In this study, 132 consecutive living kidney donors were evaluated. All donated between 1984
and 2006 in the University Medical Center Groningen. GFR was measured (mGFR) four months
prior and two months following donation as part of the screening program and early post-
donation evaluation. Since 2007, all former donors in our centre are invited for a second
post-donation kidney function measurement ﬁve year post-donation. Donors who donated
before 2002 were all invited in one follow-up round. For inclusion in the current analysis, we
selected all donors for whom complete data on all three time points were available. At long
term follow-up, mean duration since donation was 5.4 ± 1.5 year, with a range of 2.0 to 11.6
years. Procedures were conducted in accordance with the Helsinki declaration. 
Measurements
GFR was measured by constant low-dose infusion of the radio-labeled tracer 125I iothalamate,
as originally described by Donker, and more recently by Visser et al. (21-23). Simultaneously,
eﬀective renal plasma ﬂow (ERPF) was measured as the clearance of 131I-hippurate. For the
measurements, subjects were seated in a quiet room in, in a semi-supine position. After
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drawing a blank blood sample, the priming solution containing 0.04 mL/kg body weight of
the infusion solution, (0.04 MBq of 125I iothalamate and 0.03 MBq of 131I-hippurate per mL
saline) plus an extra 0.6 MBq of 125I iothalamate, was given, followed by constant infusion at
twelve mL/h. To attain stable plasma concentrations of both tracers, a two hour stabilization
period followed, after which the clearance periods start. Clearances were measured over the
next two hours and calculated as (U*V)/P and (I*V)/P, respectively. U*V represents the urinary
excretion of the tracer, I*V represents the infusion rate of the tracer, and P represents the
tracer value in plasma at the end of each clearance period. GFR was calculated from UV/P of
125I iothalamate and corrected for voiding errors by multiplying the urinary clearance of 
125I iothalamate with the ratio of the plasma and urinary clearance of 131I-hippurate. The day-
to-day variability for GFR is 2.5%.
In our centre, before 1st March 2006, creatinine was measured by Jaﬀé alkaline picrate
assay, on the MEGA, Merck KGaA, Darmstadt, Germany. Thereafter, creatinine was measured
by enzymatic assay on the Roche Modular. Both methods were calibrated to the reference
standard, i.e. Cleveland Clinic Laboratory measurements, as described before(12). 
Calculations
Estimated GFR by MDRD Study (24;25), and CG (26) equations were calculated as follows,
with serum creatinine (SCr) and body weight in mg/dL and kg.
MDRD = 175 * (SCr)-1.154 * (age) 0.203 (* 0.742 if female). 
Cockcroft-Gault = (140 – age) * body weight ∕ (72 * SCr) (* 0.85 if female). 
CKD-EPI equation was calculated gender speciﬁc, and stratiﬁed by creatinine levels (14). The
following calculations were used:
Female with SCr ≤0.7: GFR = 144 * (0.993)age * (SCr / 0.7)-0.329
Female with SCr > 0.7: GFR = 144 * (0.993)age * (SCr / 0.7)-1.209
Male with SCr ≤ 0.9: GFR = 141 * (0.993)age * (SCr / 0.9) -0.4111
Male with SCr > 0.9: GFR = 141 * (0.993)age * (SCr / 0.9) -1.209
Both for the MDRD Study and CKD-EPI equations, no correction for ethnicity was applied as
none of the donors were African Americans.
BSA was calculated as according to DuBois (27). mGFR and CG were normalized by dividing
the raw sample by BSA and multiplying it with 1.73, giving mGFR/BSA and CG/BSA. Mean
arterial pressure (MAP) was calculated as: MAP = (1/3 [systolic pressure - diastolic pressure]
+ diastolic pressure). Kidney function slopes were calculated as: slope = ([long term value –
early post-donation value]/ duration of follow-up); giving a slope in mL/min/1.73m2 per year. 
Analysis of predictive performance
Performance of MDRD Study and CKD-EPI equations against mGFR/BSA was analyzed as
proposed by Bostom (28) and Stevens (29), presenting bias, precision, and accuracy. Bias was
calculated as the median diﬀerence (mGFR/BSA - eGFR) and of the percentage diﬀerence
((mGFR/BSA – eGFR)/ mGFR/BSA * 100), giving a numeric or arithmetic value and a relative
value. Precision represents the overall ‘ﬁt’ of the new model against the gold standard, and
is represented by the interquartile range (IQR) of (mGFR/BSA - eGFR). Accuracy reﬂects the









systematic error, the level of eGFR slopes were plotted against the diﬀerence between the
mGFR/BSA slope and eGFR slope as described before by Stevens at all (29). 
The main reason to monitor kidney function after donation is to detect possible kidney
function loss over time. In the Nijmegen Biomedical Study, normal age-related kidney function
decline of the Dutch population was -0.4 mL/min/1.73m2 peryear (30). Thus, we classiﬁed a
mGFR/BSA decline twice as fast, i.e. > 1 mL/min/1.73m2 peryear, as a progressive kidney
function slope. 
Statistical analysis
Analyses were performed using PASW Statistics version 18 and GraphPad Prism version 5 for
Windows. Data are given as mean ± standard deviation or median [IQR]. Independent samples
t-Test, Mann-Whitney test and chi-square test were used to analyse for diﬀerences between
groups. Diﬀerences within groups were tested with paired samples t-Test and Wilcoxon Signed
Ranks Test.
Results
Donor characteristics and measured and estimated kidney function prior to and post-donation
are shown in table 1. After nephrectomy, mGFR/BSA fell to 64 ± 11% of the pre-donation value
early post-donation. At long term, mean GFR increased to 70 ± 11% of the pre-donation value.
Nineteen donors had a mGFR/BSA <60 mL/min/1.73m2 at long term. Kidney function course
by measured and estimated GFR is shown in ﬁgure 1. With exception of the CG/BSA value
early post-donation, all three estimating equations signiﬁcantly underestimated mGFR/BSA
at all time points (all p<0.01 compared to mGFR/BSA values, table 1). 
Performance of the equations at the two post-donation time points is displayed in ﬁgure
2. For all equations, bias, relative bias, accuracy and precision were similar at both time points.
Table 1: donor characteristics prior to and early and long term post-donation. 






Duration follow-up (years) -0.5 ± 0.6 0.2 ± 0.0 5.4 ± 1.5
Age (years) 48 ± 11 49 ± 11 54 ± 11
BMI (kg/m2) 26 ± 4 27 ± 4 27 ± 4
MAP (mmHg) 91 ± 9 92 ± 9 93 ± 9
Serum creatinine (mg/dL) 0.9 ± 0.2 1.3 ± 0.3 1.2 ± 0.2
mGFR/BSA (mL/min/1.73m2) 104 ± 15 67 ± 11 73 ± 11
Estimated GFR
MDRD Study (mL/min/1.73m2) 81 ± 15* 50 ± 9* 55 ± 10*
CG/BSA (mL/min/1.73m2) 96 ± 19* 63 ± 13 68 ± 15*
CKD-EPI (mL/min/1.73m2) 89 ± 14* 55 ± 12* 60 ± 12*
59
Use of eGFR for living donor follow-up
3
CG/BSA had the lowest bias, relative bias and highest accuracy, followed by CKD-EPI equation.
Table 2 shows the mean kidney function slopes in measured and estimated GFR,
calculated from the ﬁrst and second post-donation time point for all donors (top panel). The
average measured GFR increased with 1.16 ± 1.4 mL/min/1.73m2 per year over this period,
indicating an appropriate compensatory rise in kidney function. The mean slopes calculated
from the equations were numerically less steep than the slope of mGFR/BSA but the
diﬀerences did not reach statistical signiﬁcance. The slopes of MDRD study and CKD-EPI
Figure 1: Kidney function course determined by mGFR and eGFR equations. Except for CG/BSA prior to donation,
GFR/BSA was signiﬁcantly underestimated by all three equations at all time points (p<0.01, paired samples 
t-test).
Figure 2: Performance of MDRD Study, CG/BSA and CKD-EPI equations. Figures display a) bias (mGFR-eGFR); 
b) bias as percentage of mGFR and c) 30% accarucy. * p<0.05 vs. corresponding MDRD value; ‡ p<0.05 vs. 









equations however were signiﬁcantly diﬀerent from the CG/BSA slope (p=0.03 and 0.02
respectively). 
The lower panel of Table 2 shows renal function slopes from a subgroup analysis in
donors with a negative slope indicating renal function loss exceeding the anticipated age-
related renal function decline between the ﬁrst and second time point. This was deﬁned as
an mGFR/BSA decline larger than 1 mL/min/1.73m2 per year. This occurred in thirteen donors,
in whom the average rate of renal function decline was -1.3 ml/min/1.73m2 per year. There
were no diﬀerences in baseline age, BMI, blood pressure or kidney function between these
donors and the rest of the population. mGFR/BSA at long term post-donation was lower (65
[58-68] vs. 73 [66-80] mL/min/1.73m2, p < 0.01). Slopes for mGFR/BSA and the three
estimating equations are shown in table 2. The three equations all signiﬁcantly
underestimated measured kidney function decline in this subgroup. Furthermore, in a
substantial proportion of these donors with a negative mGFR/BSA slope, the slopes based on
equations were positive, amounting to 9/13 donors for the MDRD Study and CKD-EPI
equations, and in 8/13 donors for CG/BSA equation, indicating that the equations cannot
reliably identify subjects with renal function loss.To detect systematic error, the slopes of all
three equations were plotted against the diﬀerence in slope between mGFR/BSA and the
equation (ﬁgure 3). All three equations show a systematic error, with overestimation of
negative slope, implicating that renal function loss is assessed as being less severe in subjects
with the steepest rate of renal function loss, and underestimation of positive slopes,
implicating that the compensatory rise in renal function after donation is underestimated. By
correlation analysis we aimed to identify determinants of the bias of the slopes, but no
signiﬁcant determinants of bias could be identiﬁed.
Table 2: Kidney function slopes per year for mGFR and the eGFR equations, for all donors (top panel) and for
the subgroup of donors with a kidney function slope < -1 mL/min/1.73m2 per year.
Slope (mL/min/1.73m2 per year) P value
All donors (N=132)
mGFR/BSA 1.16 ± 1.4 -
MDRD Study 1.03 ± 1.43 0.38
CG/BSA 0.89 ± 1.72 0.12
CKD-EPI 1.03 ± 1.66 0.40
Donors with kidney function slope < -1 ml/min/1.73m2 per year (N=13)
mGFR/BSA -1.3 [-1.4 – -1.2] -
MDRD Study 0.6 [-0.1– 1.4] <0.01
CG/BSA 0.5 [-0.2– 1.3] <0.01
CKD-EPI 0.6 [-0.3 – 1.4] <0.01
Values represent mean ± SD or median [IQR].  p-value represents comparison to GFR/BSA slope (paired 
samples t-test, and Wilcoxon Signed Ranks test).
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Discussion
This study evaluates the use of MDRD study, CG and CKD-EPI equations for long term post-
donation follow-up of former living kidney donors. Overall, donor kidney function at long term
was at a good level, and most donors showed a stable or positive kidney function course post-
donation. Mean mGFR slope was reliably estimated by MDRD Study and CKD-EPI equation.
Nevertheless, donors with a steep kidney function decline were missed by all three equations.
Studies reporting outcome of former kidney donors all show reassuring results with
preserved kidney function at long term and a low risk for the development of CKD (31-37).
Due to a more liberal donor selection, current donor populations, however, have a less
favorable renal risk proﬁle regarding age, overweight and blood pressure. The current donor
population may, therefore, be at a higher risk for kidney function loss and impairment post-
donation. This stresses the need for proper and accurate follow-up of former kidney donors.
Previous studies on the use of eGFR in kidney donors focused mainly on cross-sectional
performance of eGFR, applied for screening of potential donors or for post-donation kidney
function assessment. Our current study is the ﬁrst to evaluate the performance of eGFR for
longitudinal follow-up over several years. Performance on group level appeared to be
moderately well, but in the small subset of donors with a negative kidney function slope, all
eGFR slopes diverged from mGFR/BSA slope, and failed to identify subjects with progressive
kidney function loss. These ﬁndings are in line with prior studies on longitudinal use of eGFR
in diabetic (15;18)  and non-diabetic CKD-patients (16;17;19;20). In these studies, longitudinal
performance was acceptable in subjects with an mGFR <60 mL/min (15;16), but poor in
subjects with higher GFR (15;16;18-20).
All donors studied here had suﬃcient kidney function at long term. None of the donors
developed kidney function impairment. A recent study by Fehrman-Ekholm et al. showed that
post-donation kidney function may increase up to 15 years post-donation (38). The donors
studied here, however, were strictly selected for having a pre-donation GFR > 80 ml/min.
Thus, this is a highly selected population with subsequently good kidney function post-
donation. Thirteen donors showed an increased rate of kidney function loss. All three
equations failed to identify the increased rate of kidney function loss in these donors. Since
many nowadays population are less strictly screened, and have more comorbidities than the
population presented here, the risk for kidney function loss at long term may be increased.
Thus, the capacity of the equations to detect rapid function loss becomes increasingly
important. The performance of the equations in this study on identifying subjects with rapid
function loss, therefore, is alarming.
Limitations of this study are the relative short duration of follow-up and the fact that
only two kidney function measurements were performed post-donation. Thus, the kidney
function slopes presented here were only based on two time points. Since the ﬁrst kidney
function measurement was early post-donation, the compensatory increase was not
complete. Only three donors, however, had an increase in creatinine >0.05mg/dL between
one and ﬁve year post-donation (data not shown). Thus, although the use of this early time
point may misrepresent the compensatory grow, most donors had a stable or positive slope
up to ﬁve year post-donation. Furthermore, we would like to mention our donors represent









only 10% of donors was above 60 years of age, 17% was obese and 10% used antihypertensive
drugs prior to donation. Our data, however, are in line with previous cross sectional studies
in kidney donors, and with longitudinal studies in other populations. 
What are the implications of our study for kidney function measurement in living donor
follow-up? At group level, the performance is acceptable. However, the poor sensitivity and
speciﬁcity to detect negative slopes is a reason for concern. It is in line with recent ﬁndings in
CKD, supporting its robustness.  Although the donors studied here all have good post-donation
kidney function and on average a stable or positive kidney function slope, the current donor
population has a less favorable renal risk proﬁle, due to the more liberal donor selection
regarding age, overweight and blood pressure (1;2). The current donor population may,
therefore, be at a higher risk for kidney function impairment post-donation than subjects who
donated a kidney previously, and, thus, proper and accurate follow-up is of main importance
in the current era. Our data indicate that creatinine-based equations are not entirely reliable
to detect post-donation kidney function loss and that their results should be interpreted with
appropriate caution.
In summary, this study shows acceptable performance of MDRD study and CKD-EPI
equation to estimate post-donation kidney function slope in former kidney donors. All
equations, however, have low capability to detect individual donors with a negative kidney
function slope. This raises questions for the suitability of estimating equations for donor
follow-up, especially in the current era with more marginal donors. If gold standard kidney
function measurement is not available, estimating equations should be used with caution. 
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Part two:
Eﬀect of donor risk proﬁle on donor
renal outcome
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Eﬀects of preexistent hypertension
on blood pressure and residual renal




Background: Living kidney donor selection has become more liberal with acceptation of
hypertensive donors. Here we evaluate short-term and one and ﬁve year renal outcome of
living kidney donors with pre-existent hypertension.
Methods: We compared outcome of hypertensive donors to sex, age and BMI matched
control donors. Hypertension was deﬁned as pre-donation antihypertensive drug use.  All
donors had GFR (125I-iothalamate) and ERPF (131I-hippuran) measured four months prior to
and two months post-donation. A subset of donors had serum creatinine measured one year
post-donation or a renal function measurement ﬁve year post-donation. 
Results: Included were 46 hypertensive donors and 94 control donors (both 53% male, mean
age and BMI 57±7 years and 28±4 kg/m2). Pre- and early post-donation, systolic blood pressure
and MAP were signiﬁcantly higher in hypertensive donors. Control donors showed a rise in
diastolic blood pressure post-donation, and thus the pre-donation diﬀerence was lost post-
donation. Both at one year (29 hypertensive donors, 58 controls) and ﬁve year post-donation
(13 hypertensive donors and 26 controls) blood pressure was similar. Renal function was
similar at all time-points.
Conclusion: In summary, hypertensive living kidney donors have similar outcome in terms of











The number of patients reaching end stage renal disease and, thus, in need for renal
replacement therapy has increased over the past decades. Due to both a shortage in deceased
donor organs and the recognition of superior results, living kidney donors have become more
important. To enlarge the donor pool, selection criteria for potential donors have become
less strict, leading to an older and more overweight donor population (1). Many centers
extended their criteria further and accept potential donors with well-regulated hypertension
as well. This situation raises a new set of issues. Hypertension is a known risk factor for renal
disease. Furthermore, previous studies have shown an increase in blood pressure post-
donation in non-hypertensive donors (2-5). Nevertheless, longitudinal studies have shown
that living kidney donors are not at increased risk of developing hypertension post-donation
compared to the general population. However, little is known about the post-donation course
of blood pressure of donors with pre-existent hypertension. Moreover, it is unknown whether
hypertensive donors are at increased risk of impaired residual renal function post-donation.
Textor et al. have shown that at one year post-donation, the presence of pre-existent
hypertension has no adverse eﬀects on blood pressure or GFR (6). Data on eﬀective renal
plasma ﬂow (ERPF) and ﬁltration pressure are, however, not available. 
Here we evaluate short-term and one and ﬁve year outcome in terms of blood pressure
and renal function of living kidney donors with pre-existent hypertension, compared to
matched control donors. 
Methods
In this study, 49 consecutive living donors with pre-existent hypertension and 98 matched
controls were included. Controls were matched by gender, age and BMI. All donors donated
at the University Medical Center Groningen between 1998 and 2010. Hypertension was
deﬁned as antihypertensive drug use pre-donation. Donors were found eligible to donate
with a well-regulated blood pressure achieved by a maximum of two antihypertensive drugs.
Blood pressure could was not allowed to exceed 145/85 mmHg at repeated measurements
and/or ambulatory blood pressure measurement. Kidney function was measured as described
below, four months prior to and two months after donation. In the abovementioned period,
a cutoﬀ of 80 mL/min of true GFR was used for acceptation of a potential donor in our center.
There was no absolute upper limit for donor age, an upper limit for BMI has been set at 30
kg/m2 at 2008. Beforehand, no upper limit for BMI was used. Furthermore, proteinuria
exceeding 0.5g/24h, or signs or end organ damage due to hypertension such as left ventricular
hypertrophy, led to rejection of potential donors. One year after donation, donors came for
an outpatient visit without measurement of GFR. Data were available for 29 subjects and 48
controls. For 13 subjects and 26 controls, ﬁve year follow-up, with kidney function
measurement, was available as well. Procedures were conducted in accordance with the
Helsinki declaration.
Kidney function measurements
Glomerular ﬁltration rate (GFR) was measured by constant low-dose infusion of the radio-
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labelled tracer 125I iothalamate, as originally described by Donker, and more recenly by Visser
et al. (7-9) Simultaneously, eﬀective renal plasma ﬂow (ERPF) was measured as the clearance
of 131I-hippurate. For the measurements, subjects were seated in a quiet room in, in a semi-
supine position. After drawing a blank blood sample, the priming solution containing 0.04
mL/kg body weight of the infusion solution, (0.04 MBq of 125I iothalamate and 0.03 MBq of
131I-hippurate per mL saline) plus an extra 0.6 MBq of 125I iothalamate, was given, followed by
constant infusion at twelve mL/h. To attain stable plasma concentrations of both tracers, a
two hour stabilization period followed, after which the clearance periods start. Clearances
were measured over the next two hours and calculated as (U*V)/P and (I*V)/P, respectively.
U*V represents the urinary excretion of the tracer, I*V represents the infusion rate of the
tracer, and P represents the tracer value in plasma at the end of each clearance period. GFR
was calculated from UV/P of 125I iothalamate and corrected for voiding errors by multiplying
the urinary clearance of 125I iothalamate with the ratio of the plasma and urinary clearance
of 131I-hippurate. The day-to-day variability for GFR is 2.5%. Next to basal kidney function,
renal reserve capacity was measured pre- and two months post-donation as part of the
screening and early follow-up. To obtain reserve capacity, the above-mentioned baseline
procedure was extended for two hours. During this period, dopamine was infused at a rate
of 1.5 µg/kg per minute. At ﬁve year post-donation, reserve capacity was not measured. Blood
pressure was measured for thirty minutes during the kidney function measurement, in rest
and semi-supine positions, with a semi-automated device (Dinamap® 1846; Critikon Inc,
Tampa, FL, USA). 
Calculations
Filtration fraction (FF) was calculated as the ratio of GFR and ERPF; FF = ([GFR/ERPF]*100).
Mean arterial pressure (MAP) was calculated as MAP = (1/3[systolic blood pressure – diastolic
blood pressure] + diastolic blood pressure). Renal reserve capacity was calculated as the
response in renal function to dopamine (ΔGFRDOPA and ΔERPFDOPA) as: (stimulated renal
function – basal renal function). Since at the out-patient visit one year post-donation no kidney
function measurement was performed, we estimated GFR from serum creatinine by use of
the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation (10). The following
calculations were used (serum creatinine (SCr) in mg/dL):
Female with SCr ≤0.7 mg/dL: GFR = 144 * (0.993)age * (SCr / 0.7)-0.329
Female with SCr > 0.7 mg/dL: GFR = 144 * (0.993)age * (SCr / 0.7) -1.209
Male with SCr ≤ 0.9 mg/dL: GFR = 141 * (0.993)age * (SCr / 0.9) -0.4111
Male with SCr > 0.9 mg/dL: GFR = 141 * (0.993)age * (SCr / 0.9) -1.209
Statistical analysis
Analyses were performed using PASW Statistics version 18 and GraphPad Prism version 5 for
Windows. Data are given as mean ± standard deviation or median [IQR]. Independent samples
t Test, Mann-Whitney test and chi-square test were used to analyse for diﬀerences between










Hypertensive donors Control donors P value
N (% female) 47 (47) 94 (47) 1.00
Age at donation (years) 57 ± 7 56 ± 7 0.71
BMI at donation (kg/m2) 28 ±3 28 ± 3 0.58
Pre-donation
Systolic bp (mmHg) 139 ± 16 129 ± 12 <0.01
Diastolic bp (mmHg) 82 ± 10 77 ± 8 <0.01
MAP (mmHg) 101 ± 11 94 ± 8 <0.01
GFR (mL/min) 118 ± 19 113 ± 25 0.23
ERPF (mL/min) 419 ± 87 406 ± 91 0.45
FF (%) 29 ± 4 28 ± 4 0.40
ΔGFRDOPA (mL/min) 10 ± 10 9 ± 11 0.96
ΔERPFDOPA (mL/min) 95 ± 70 92 ± 56 0.81
Urinary protein excretion (g/24h) 0.1 [0.0-0.3] 0.1 [0.0-0.2] 0.42
Two months post-donation
Systolic bp (mmHg) 135 ± 13 128 ± 12 <0.01
Diastolic bp (mmHg) 81 ± 9 80 ± 9 0.36
MAP (mmHg) 99 ± 9 96 ± 9 0.03
GFR (mL/min) 73 ± 13 70 ± 13 0.21
ERPF (mL/min) 267 ± 48 263 ± 53 0.61
FF (%) 28 ± 3 27 ± 3 0.30
ΔGFRDOPA (mL/min) 1.3 ± 4.1 1.8 ± 4.0 0.29
ΔERPFDOPA (mL/min) 38 ± 32 35 ± 22 0.68
Urinary protein excretion (g/24h) 0.0 [0.0-0.2] 0.0 [0.0-0.2] 0.45
Five year post-donation
N 13 (46) 26 (46) 1.00
Systolic bp (mmHg) 137 [132-143] 131 [121-136] 0.07
Diastolic bp (mmHg) 80 [74-90] 77 [74-84] 0.50
MAP (mmHg) 102 [90-106] 94 [90-101] 0.27
GFR (mL/min) 81 [72-94] 78 [64-95] 0.53
ERPF (mL/min) 258 [250-299] 258 [223-306] 0.74
FF (%) 30 [29-33] 31 [28-32] 0.74
Urinary protein excretion (g/24h) 0.0 [0.0-0.1] 0.0 [0.0-0.2] 0.26
Table 1: Donor characteristics prior to and two months post-donation. The bottom part shows ﬁve year post-
donation values for a smaller subset of donors. Characteristics prior to and early post-donation of this smaller
group were similar as presented below.
Values represent mean ± SD; median [IQR] or n (%). bp: blood pressure; ΔGFRDOPA: stimulated GFR – basal GFR;
ΔERPFDOPA: stimulated ERPF – basal ERPF.
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Results
Donor characteristics prior to and two months post-donation are shown in table 1. There was
no diﬀerence in mean age or BMI at donation, reﬂecting a good match between hypertensive
and control donors. Despite the use of in mean 1.3 ± 0.7 antihypertensive drugs, hypertensive
donors had higher blood pressures prior to donation (all p<0.01). Post-donation, control
donors showed a signiﬁcant increase in diastolic blood pressure (p<0.05) while hypertensive
donors had stable blood pressure. The diﬀerence in diastolic blood pressure was, thus, lost
post-donation. Figure 1a shows the change in blood pressure from pre- to early post-donation.
In hypertensive donors, no rise in blood pressure occurred, while the control donors showed
a signiﬁcant rise in diastolic blood pressure and non-signiﬁcant rise in MAP. Basal renal
function and renal reserve capacity were similar both pre- and post-donation, as well as
urinary protein excretion. None of the donors had urinary protein excretion exceeding 0.5
g/24h. Figure 2a displays pre- and post-donation renal function graphically. The change in
renal function of hypertensive donor parallels the change of control donors. 
Figure 1: Changes in donor blood pressure over time. Figures display blood pressure from pre-donation to two
months post-donation (left, n=141); from two months post-donation to one year post-donation (middle, n=87);
from two months post-donation to ﬁve year post-donation (right). Bars represent mean ± SEM,  and for the right
grapgh median [IQR]. bp: blood pressure; * p<0.05 vs. hypertensive donors. 
Figure 2: Change in GFR over time. Figures display pre- and two months post-donation GFR for the whole group
(left, n=141), values represent mean ± SD; pre- and two months and ﬁve year post-donation GFR for a subset of









Use of antihypertensive drugs is shown in table 2. On average, hypertensive donors used
1.3± 0.5 antihypertensive drugs, preferably an angiotensin converting enzyme inhibitor (ACEi)
or angiotensin receptor blocker (ARB). The mean number of antihypertensive drugs did not
increase over time, though there was a slight shift to more use of diuretics. Furthermore,
Hypertensive donors Control donors
Pre-donation (n) 47 94
Number of donor using AH drugs 47 (100) 0 (0)
Number of AH drugs 1.3 ± 0.7 0 ± 0
Use of ACEi/ARB 27 (57) 0 (0)
Use of β-blocker 19 (40) 0 (0)
Use of calcium channel blocker 8 (17) 0 (0)
Use of diuretic 9 (19) 0 (0)
Two months post-donation (n) 47 94
Number of donor using AH drugs 42 (89) 0 (0)
Number of AH drugs 1.3 ± 0.5 0 ± 0
Use of ACEi/ARB 26 (55) 0 (0)
Use of β-blocker 15 (32) 0 (0)
Use of calcium channel blocker 7 (15) 0 (0)
Use of diuretic 12 (26) 0 (0)
One year post-donation (n) 29 58
Number of donor using AH drugs 17 (59) 1 (2)
Number of AH drugs 0.8 ± 0.8 0 ± 0.1
Use of ACEi/ARB 10 (34) 0 (0)
Use of β-blocker 8 (28) 0 (0)
Use of calcium channel blocker 2 (7) 1 (2)
Use of diuretic 4 (14) 0 (0)
Five year post-donation (n) 13 26
Number of donor using AH drugs 12 (92) 4 (15)
Number of AH drugs 2 [1-3] 0 [0-0]
Use of ACEi/ARB 8 (62) 2 (8)
Use of β-blocker 7 (54) 2 (8)
Use of calcium channel blocker 2 (15) 0 (0)
Use of diuretic 8 (62) 0 (0)
Table 2: Use of antihypertensive medication prior to and two months and one or ﬁve year post-donation. There
were no diﬀerences in pre- and early post-donation drugs use between donors available and unavailable 
for one and ﬁve year post-donation follow-up. 
Values represent mean ± SD; median [IQR] or n (%). AH drugs: antihypertensive medication; ACEi: angiotensin
converting enzyme inhibitors; ARB: angiotensin receptor blockers.
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several donors stopped their antihypertensive medication, especially at one year post-
donation. At ﬁve year post-donation, however, all but one hypertensive donors were using
antihypertensive drugs again. Prior to and two months post-donation, none of the control
donors used antihypertensive drugs. At one year post-donation, one control used a calcium
channel blocker, while at ﬁve year post-donation four donors used one antihypertensive.
Pre- and post-donation characteristics for donors with one year follow-up are shown in
table 3. Again, pre-donation systolic blood pressure and MAP were higher in hypertensive
donors (p<0.01). This diﬀerence was again lost post-donation, though the diﬀerence in MAP
reached statistical signiﬁcance again at one year post-donation. Diastolic blood pressure was
similar between hypertensive and control donors at all time-points. Figure 1b displays blood
pressure course from two months post-donation to one year post-donation. In hypertensive
donors, diastolic blood pressure showed a non-signiﬁcant rise to one year post-donation,
Hypertensive donors Control donors P value
N (% female) 29 (41) 58 (41) 1.00
Age at donation (years) 58 ± 6 57 ± 7 0.81
Pre-donation
Systolic bp (mmHg) 138 ± 18 130 ± 12 0.02
Diastolic bp (mmHg) 80 ± 10 77 ± 8 0.09
MAP (mmHg) 100 ± 12 95 ± 8 0.03
Serum creatinine (mg/dL) 0.9 ± 0.2 1.0 ± 0.2 0.10
CKD-EPI (mL/min/1.73m2) 85 ± 13 79 ± 13 0.03
Urinary protein excretion (g/24h) 0.1 [0.0-0.3] 0.0 [0.0-0.2] 0.23
Two months post-donation
Systolic bp (mmHg) 134 ± 14 129 ± 12 0.10
Diastolic bp (mmHg) 80 ± 9 81 ± 8 0.61
MAP (mmHg) 98 ± 10 97 ± 9 0.65
Serum creatinine (mg/dL) 1.4 ± 0.3 1.4 ± 0.3 0.56
CKD-EPI (mL/min/1.73m2) 51 ± 11 49 ±  9 0.46
Urinary protein excretion (g/24h) 0.0 [0.0-0.2] 0.0 [0.0-0.2] 0.37
One year post-donation
Systolic bp (mmHg) 134 ± 15 129 ± 15 0.10
Diastolic bp (mmHg) 84 ± 10 80 ± 8 0.08
MAP (mmHg) 101 ± 10 96 ± 8 0.05
Serum creatinine (mg/dL) 1.3 ± 0.2 1.3 ± 0.2 0.31
CKD-EPI (mL/min/1.73m2) 58 ± 10 55 ± 11 0.22
Urinary protein excretion (g/24h) 0.1 [0.0-0.1] 0.1 [0.0-0.1] 0.64
Table 3: Donor characteristics prior to and two months and one year post-donation.









control donors remained stable. Renal function at one year post-donation, expressed as serum
creatinine and estimated GFR by CKD-EPI equation, was similar between the groups, as well
as urinary protein excretion. 
A small subset of donors had data on renal function and blood pressure ﬁve year post-
donation. Characteristics are shown in table 1. From two months post-donation up to ﬁve
year post-donation, blood pressure remained stable for hypertensive donors and controls
(ﬁgure 1c). At ﬁve year post-donation, no diﬀerence in renal function or urinary protein
excretion was observed. Figure 2b shows a parallel course in renal function to ﬁve year post-
donation.
To evaluate the eﬀect of blood pressure as such, correlation and regression analysis was
performed. No associations were found between pre-donation GFR and blood pressure. Pre-
donation systolic blood pressure correlated negatively with early post-donation GFR (R -0.22,
p<0.01). This association was lost after correction for age. Neither diastolic blood pressure,
nor MAP were signiﬁcantly related to renal function. No signiﬁcant associations were found
between serum creatinine and CKD-EPI at one year and pre- and post-donation blood
pressures. The group with ﬁve year follow-up was too small for continues analysis. 
Discussion
In this study, we compared post-donation outcome of living kidney donors with pre-existent
hypertension to matched control donors. Although hypertensive donors had higher blood
pressure prior to and two months post-donation, these diﬀerences were lost at one and ﬁve
year post-donation. At none of the evaluated time points diﬀerences were seen in renal
function or urinary protein excretion between hypertensive and normotensive donors. Where
normotensive donors showed a rise in diastolic blood pressure, hypertensive donors retained
stable blood pressure throughout the follow-up. Thus, post-donation course of renal function
and blood pressure of hypertensive donors is comparable to normotensive donors, including
the long term adaptive increase of  GFR between year one and ﬁve following donor
nephrectomy. 
Earlier studies evaluating the post-donation follow-up of living kidney donors had some
conﬂicting results. While several studies reported an increase in blood pressure post-donation
of 5-10 mmHg (2-5,11) others found no increase (12,13). The latter studies, however, had
rather short follow-up (maximum one year) which may explain the lack in increase in blood
pressure. The incidence rate of post-donation hypertension varies from 15 % (14), to 22% (15)
and 45% (16). This incidence appears to increase with increasing time post-donation, and
indeed the highest reported incidence was after a mean follow-up of fourteen years (16).
Although hypertension is, thus, present post-donation, incidence rates are similar to the
general population when correcting for age and gender (3,17-19). One study, however, found
a higher incidence of hypertension in male donors compared to matched controls. Donors
with post-donation hypertension had higher macro albuminuria and urinary protein excretion
than normotensive donors in three studies (5,15,17). Here, however, we found no diﬀerence
in urinary protein excretion. Textor et al. as well compared donors with pre-existent
hypertension to normotensive donors, and found no increase in blood pressure or diﬀerences
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in renal function or urinary protein excretion (6). However, the deﬁnition of hypertension was
made on blood pressure cut-oﬀs, and only three patients used antihypertensive drugs pre-
donation. One study reported that donors with post-donation hypertension are at increased
risk for an estimated GFR <60 ml/min/1.73m2 (20). In this study, however, we found no
diﬀerence in renal function in the short and long term post-donation.
The ﬁnding that hypertensive donors are not at increased risk for renal function impairment
post-donation is reassuring for the current donor selection practice. Due to a shortage in
donor organs, many centers accept more marginal donors nowadays. Although this study
shows no deleterious eﬀects of pre-donation hypertension, we like to emphasize that donors
in our center undergo strict selection, comprising renal function measurements and strict
blood pressure management. Where one might expect lower renal function in middle-aged
hypertensive subjects, our donors actually had very good renal function pre-donation. This
contradiction can be explained by the selection bias due to the screening. Thus, we stress the
need for thorough donor screening before accepting donors with hypertension. Furthermore,
post-donation follow-up of living kidney donors remains important, and enables identiﬁcation
of subjects at risk for renal function loss or hypertensive complications. 
Previous studies have shown the importance of ambulatory blood pressure
measurements as part of the donor screening (21-23). Unfortunately, ambulatory
measurements were not available for all donors of this study. Prior to, two months post-
donation and ﬁve year post-donation, blood pressure was measured during renal function
measurement. Donors were seated in a quiet environment in semi-supine positions, and were
at rest for at least two hours before the blood pressure measurement started. Blood pressure
was recorded for at least halve an hour. At one year post-donation, only oﬃce blood pressures
were available. 
Our study has several limitations, the most important being the relatively small sample-
size, the mono centric character, and the lack of standardized ambulatory blood pressure
measurements. Furthermore, the conclusions cannot be extrapolated to patients with African
ethnicity. 
In conclusion, hypertensive living kidney donors show a similar course in post-donation
renal function and blood pressure as normotensive donors. Thus, hypertensive donors are
not at increased risk of renal function loss up to ﬁve year post-donation. More long-term
studies, with longer follow-up of donors with hypertension prior to donation, are necessary
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Five year follow-up of living kidney















Background: To increase the living donor pool, selection criteria have become less strict,
enabling acceptation of older, overweight, hypertensive and smoking donors. This study
evaluates the eﬀect of the donor risk proﬁle on donor renal outcome ﬁve years post-donation. 
Methods: Evaluated were 133 living kidney donors. Kidney function (GFR, 125I-iothalamate)
was measured at 6±7 months prior to and 2±0 months and 5.4±1.5 years after donation. 
Results: Mean GFR at ﬁve years was 82±15 mL/min. At donation, 25% of donors was aged>55
years, 17% was obese, and 20% used antihypertensive drugs or had a blood pressure> 145/85
mmHg. Donor age associated negatively with ﬁve years GFR (R-0.27, p<0.01). Donors older
than 55 years had lower GFR at all time-points, but kidney function course was similar to that
of younger donors. Donor BMI, hypertension or smoking behavior showed no inﬂuence on
post-donation kidney function course. In multivariate analysis, pre- and early post-donation
GFR were the strongest predictors of ﬁve years GFR (R2 0.65 and 0.69), followed by age and
gender. 
Conclusion: Overall ﬁve years outcome is good. When pre-donation kidney function is assured
to be good, the current practice of accepting older, overweight, hypertensive and smoking










During the last decade, living kidney donors have become of major importance for transplant
programs, supplying up to half of the donor organs (1-3). Many studies reported excellent
donor outcome on short- and long term post-donation (4-9). These donors, however, were
strictly screened, and represent a very healthy part of the population. To increase the donor
pool, donor selection criteria have become less strict (10;11). Nowadays, older subjects,
subjects with overweight or obesity, and even hypertensive subjects may be accepted for
living kidney donation. These traits are known risk factors for the development of kidney
disease. Higher age and body mass index (BMI) were previously shown to results in lower
early post-donation kidney function (12-15), though others showed no eﬀect. Nevertheless,
the altered donor characteristics warrant close monitoring of long term donor safety, in
particular regarding kidney function.
In this study, therefore, we evaluate the eﬀect of the donor risk proﬁle, i.e. donor age,
BMI, blood pressure and smoking behavior, on donor outcome ﬁve year post-donation. 
Methods
In this study, 133 living kidney donors were evaluated. All donated between 1984 and 2006
in the University Medical Center Groningen. Kidney function measurements were performed
as part of the routine donor screening and early follow-up program at 6±7 months prior to
and 2±0 months after donation. Since 2007, all former donors in our centre are invited for a
second post-donation kidney function measurement, approximately ﬁve years after
nephrectomy.  Donors who donated before 2002 (n=93) were all invited in one follow-up
round, several oﬀ these donors already had a second follow-up on their own request. Of the
262 invited donors, 170 (65%) responded for follow-up. For inclusion in the current analysis,
we selected all donors for whom complete data on all three time points were available, 37
donors were excluded. At long term follow-up, mean duration since donation was 5.4 ± 1.5
year, with a range of 2.0 to 11.6 years. Procedures were conducted in accordance with the
Helsinki declaration. 
Routine donor screening
All potential donors at our center undergo gold standard kidney function measurement, as
described below. The basal kidney function measurement is extended by two hours in which
the kidney function is stimulated by dopamine, to measure the so called reserve capacity.
Donors were eligible to donate with a glomerular ﬁltration rate (GFR) > 80 mL/min. For older
subjects or small females, an exception could be made based on a good response to dopamine
infusion, with a stimulated GFR > 80 mL/min. Furthermore, the response in dopamine is
judged, especially when GFR is close to 80 mL/min. Since 2002, donors who use
antihypertensive drugs are allowed to donate. A maximum of two antihypertensive drugs is
tolerated, provided ambulatory blood pressure does not exceed 150/85 mmHg. Donors with
a body mass index (BMI) exceeding 30 kg/m2 are encouraged to lose weight. There is no
maximum for age, but many older potential donors are excluded due to low GFR or
comorbidities. Potential donors with a disturbed glucose tolerance test are rejected, as well
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as donors with severe atherosclerotic lesions. Mainly for anatomical concerns, an abdominal
CT scan is performed for all donors. Smoking behavior has never been a selection criterion at
our center.
Kidney function measurements during screening and follow-up
GFR was measured by constant low-dose infusion of the radio-labelled tracer 125I iothalamate
as described previously (44-46). Simultaneously, eﬀective renal plasma ﬂow (ERPF) was
measured as the clearance of 131I-hippurate. Filtration fraction (FF) was calculated as
GFR/ERPF. For the measurements, subjects were seated in a quiet room in a semi-supine
position. After drawing a blank blood sample, the priming solution containing 0.04 mL/kg
body weight of the infusion solution (0.04 MBq of 125I iothalamate and 0.03 MBq of 
131I-hippurate per mL saline) plus an extra of 0.6 MBq of 125I iothalamate was given, followed
by constant infusion at 12 mL/h. To attain stable plasma concentrations of both tracers, a 2
hour stabilization period followed, after which the clearance periods started. Clearances were
measured over the next 2 hours and calculated as (U*V)/P and (I*V)/P, respectively. U*V
represents the urinary excretion of the tracer, I*V represents the infusion rate of the tracer
and P represents the tracer value in plasma at the end of each clearance period. GFR was
calculated from UV/P of 125I-iothalamate and corrected for voiding errors by multiplying the
urinary clearance of 125I iothalamate with the ratio of the plasma and urinary clearance of 
131I-hippurate. The day-to-day variability for GFR is 2.5%. Next to basal kidney function, kidney
reserve capacity was measured pre- and two months post-donation as part of screening and
early follow-up. To obtain reserve capacity, the above-mentioned procedure was extended
for two hours. During this period, dopamine was infused at a rate of 1.5 µg/kg per minute.
Calculations and classiﬁcation
Mean arterial pressure (MAP) was calculated as: MAP = (1/3 [systolic pressure - diastolic
pressure] + diastolic pressure). The change in GFR and ERPF due to stimulation by dopamine
was calculated as (stimulated kidney function – basal kidney function), giving ΔGFRDOPA and
ΔERPFDOPA. Since donor selection, surgical techniques and follow-up procedures have
changed over time, we wanted to evaluate the eﬀect of time of donation on donor
characteristics and ﬁve year GFR. Therefore, a continuous variable was developed by
calculating the duration between donation and an artiﬁcial date: January 1st, 2007; in years.
Thus, a donor who donated at September 12, 2006 has a value of 0.3 years and a donor who
donated at November 28, 2000 has a value of 6.1 years. Cut-oﬀs for high risk donors were
pre-donation age ≥ 55 years, BMI > 30 kg/m2 (47), current smoking of the donor, and
antihypertensive drug use or a donor blood pressure > 145/85 mmHg. 
Statistical analysis
Analyses were performed using PASW Statistics version 18 and GraphPad Prism version 5 for
Windows. Data are given as mean ± standard deviation or median [IQR]. Independent samples
t Test, Mann-Whitney test and chi-square test were used to analyse for diﬀerences between
groups. Linear regression was used for prediction of ﬁve year GFR. For gender, male gender










Donor characteristics pre- and both early and ﬁve years post-donation are shown in table 1.
On average, this donor population is approximately 50 years old, slightly overweight and
normotensive. Early post-donation GFR fell to 64 ± 6 % of the pre-donation value. Five years
post-donation, GFR had increased to 71 ± 8 % of the pre-donation value. ERPF remained
stable, at 67 ± 7 % early post-donation, and 66 ± 10 % ﬁve year post-donation.
Selection habits of our center have changed over time, causing a change in donor
characteristics, as displayed in ﬁgure 1. Over time, our center accepted more donors aged
over 55 years, with overweight or obesity and/or with antihypertensive drugs use or a blood
pressure > 145/85. Donor age and BMI at time of donation both related negatively with time
since the date of donation (calculated as duration between donation and January 1st 2007;
R -0.19 and -0.24, both p<0.01), indicating that the most recent donors were older and more
overweight than donors who donated longer ago. Table 2 shows the donor risk proﬁle of the
whole cohort prior to donation. Seventeen percent of donors was obese, and 20% used
antihypertensive drugs or had a blood pressure > 145/85 mmHg. 
Inﬂuence of donor risk factors on post-donation kidney function
Univariate associations between pre-donation risk factors age, BMI and systolic blood pressure
with GFR at ﬁve years after donation are shown in ﬁgure 2. The strongest association with
GFR at ﬁve years was provided by pre-donation GFR (R2 0.65, p<0.01). Age at donation was
negatively associated to ﬁve year GFR (R2 0.25, p<0.01), while BMI and blood pressure showed
no association. Smoking behavior showed no inﬂuence on ﬁve year post-donation GFR. 
Total Male Female
Duration of follow-up (years) -0.5 ± 0.6 0.2 ± 0.0 5.4 ± 1.5
Age (years) 48 ± 11 49 ± 11 54 ± 11
BMI (kg/m2) 26 ± 4 26 ± 4 27 ± 4
Systolic blood pressure (mmHg) 124 ± 12 125 ± 13 126 ± 12
Diastolic blood pressure (mmHg) 75 ± 9 76 ± 8 77 ± 8
Serum creatinine (mg/dL) 0.9 ± 0.2 1.3 ± 0.3 1.2 ± 0.2
GFR (mL/min) 116 ± 20 74 ± 13 82 ± 15
ERPF (mL/min) 438 ± 80 291 ± 52 284 ± 58
FF (%) 27 ± 3 26 ± 3 29 ± 4
GFRDOPA (mLmin) 13 ± 11 3 ± 5 -
ERPFDOPA (mLmin) 118 ± 54 50 ± 30 -
Table 1: Donor characteristics prior to, and early and ﬁve year post-donation. 
Values represent mean ± SD. ΔGFRDOPA: change in GFR by stimulation with dopamine: (stimulated GFR – basal
GFR); ΔERPFDOPA: change in ERPF by stimulation with dopamine: (stimulated ERPF – basal ERPF).
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Figure 1: Change in donor characteristics over time. Bars represent percentage of donors by break-up in age,
BMI, hypertension and smoking behavior. Numbers per group are: ≤ 2000 n= 27; 2001-2003 n= 38; and 2004-
2006 n=68.










<55 100 (75) 41 47 [40-52] 26 [23-28] 118 [104-129] 14 [8-19]
>55 33 (25) 48 60 [57-63]a 27 [25-29] 105 [90-121] a 9 [1-16] a
BMI (kg/m2)
<25 49 (37) 39 48 [43-54] 23 [22-24] 107 [102-122] 14 [7-19]
25-30 61 (46) 46 51 [43-55] 27 [26-28]a 118 [103-130] 13 [7-18]
≥30 23 (17) 43 52 [43-55] 32 [31-33]a 121 [108-140] 13 [1-19]
Hypertension
Normotensive 107 (80) 41 49 [42-55] 26 [24-28] 116 [102-127] 13 [7-18]
Hypertensive 26 (20) 50 53 [49-59]* 28 [25-30]* 122 [110-128] 15 [7-19]
Smoking
Never 50 (38) 44 51 [44-58] 26 [22-28] 112 [100-127] 11 [6-18]
Former 39 (29) 41 51 [45-56] 27 [25-28] 117 [101-130] 14 [5-18]
Current 44 (33) 43 48 [41-54] 26 [24-29] 118 [104-128] 13 [8-20]
Table 1: Donor characteristics prior to, and early and ﬁve year post-donation. 
Values represent N (%) and median [IQR]. a diﬀerence by default; *p<0.05 vs. corresponding value. ΔGFRDOPA:









Figure 3 shows the time course of post-donation kidney function by a break-up in donor
risk factors. Older donors had lower kidney function at all time points (all p<0.01), but the
adaption to ﬁve years was similar to that of younger donors. Donors with a BMI >25 kg/m2
had higher GFR early post-donation than normal weight donors, but this diﬀerence was lost
after correction for body surface area (data not shown). Normotensive donors and
Figure 2: scatter plots for ﬁve year donor GFR with A) pre-donation GFR, B) age at donation; C) pre-donation
BMI); and D) pre-donation systolic blood pressure. R2 represents adjusted R2 by linear regression analysis.
Figure 3: Change in GFR  by break-up in A) pre-donation age; B) pre-donation BMI; C) pre-donation hypertensive
status; D) pre-donation smoking behavior. Values represent median [IQR]. * p<0.05 vs. corresponding lowest
category . Hypertension was deﬁned as use of antihypertensive drugs, or a blood pressure >145/85 mmHg prior
to donation. GFR prior to donation (pre-Unx) is shown as ‘single kidney GFR’: (basal GFR / 2).
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hypertensive donors had a similar course in kidney function, as had donors with diﬀerent
smoking habits. 
Prediction of ﬁve year donor outcome
Five year GFR was 73 ± 12 mL/min, with a range of 50 to 124 mL/min. Of pre-donation
characteristics, pre-donation GFR associated the strongest with ﬁve years GFR (adjusted [a]
R2 0.65, standardized [std.] β 0.81; p<0.01; ﬁgure 1). On univariate analysis, other predictors
of ﬁve year GFR were GFRDOPA (aR2 0.61, std. β 0.78; p<0.01); pre-donation age (aR2 0.26, std.
β-0.52; p<0.01) and gender (aR2 0.13, std. β -0.37 [reference male gender]; p<0.01). Pre-
donation BMI, blood pressure and smoking behavior did not associate signiﬁcantly to ﬁve
year GFR. The time of donation also did not aﬀect ﬁve year outcome. On multivariate analysis,
ﬁve year GFR was best predicted by the model with pre-donation GFR and age (aR2 0.69,
p<0.01; std. β 0.71 and -0.23, both p<0.01). Due to co-linearity with crude GFR, GFRDOPA was
removed from the model.
Early post-donation characteristics had their inﬂuence on ﬁve year GFR as well. Again,
the strongest association was provided by early post-donation GFR (aR2 0.69, std. β 0.83 ;
p<0.01). Early post-donation GFRDOPA associated with ﬁve year GFR as well (aR2 0.63, std. β
0.80 ; p<0.01). There were no associations with early post-donation BMI or blood pressure.
In combination with the pre-donation characteristics, ﬁve year GFR was predicted by a model
with pre- and early post-donation GFR, age and gender (aR2 0.75, p<0.01; std. β 0.32, 0.46, -
0.15 and -0.11, all p<0.05). Again, GFRDOPA was removed due to co-linearity with crude GFR. 
Discussion
This study evaluated the eﬀect of the donor risk proﬁle on donor outcome ﬁve year post-
donation. As expected, donor age and pre-donation kidney function were the most important
modulators of post-donation kidney function. Other risk factors, BMI, blood pressure and
smoking behavior, did not inﬂuence donor outcome. Overall donor outcome was good; all
donors had suﬃcient kidney function at ﬁve year post-donation, without development of
proteinuria. 
This is the ﬁrst study that evaluates the eﬀect of the total donor risk proﬁle on ﬁve years
post-donation outcome with gold standard kidney function measurements. Previous studies
mainly focused on one or two risk factors, mainly age and BMI. Below, we will discuss the
separate eﬀects of the donor risk factors ﬁrst.
Kidney function is known to decline with age (16;17), mean reported decline is about
0.75 mL/min per year, though rates of decline may diﬀer (18). This translates in lower pre-
and post-donation kidney function in older donors (14). Post-donation kidney function course,
however, is similar between older and younger donors (19;20). This is in line with our ﬁndings.
A previous study from our center found that while pre-donation reserve capacity is similar
between older and younger donors, early post-donation reserve capacity is lower in older
donors (15). Apparently, this does not disturb the adaptive response to ﬁve years post-
donation. 









population (21-24), and especially after donor nephrectomy (12;13;15). Obesity was linked
to glomerulomegaly and glomerulosclerosis in very severe cases (25-27). In this study, we
found no detrimental eﬀects of overweight and obesity. In the Netherlands, however, the
current mean body mass index is about 26 kg/m2, and 17% of our donors had a BMI > 30
kg/m2. Though this is almost one ﬁfth of the population, and the prevalence is still growining,
the prevalence may be lower than in other western countries. Nevertheless, our ﬁndings are
in line with previous studies focusing on the eﬀects of overweight on donor outcome (28;29).
Since 2002, our center accepts potential donors with pre-existent hypertension. The
actual number of donors that donated that were accepted despite the use of antihypertensive
drugs, however, is still low. Hypertension is an important risk factor for kidney damage and
kidney function loss in the general population (30-32). In kidney donors, so far one study
focused on the eﬀect of pre-existent hypertension on donor outcome (33). Fortunately, no
detrimental eﬀects were found. While several studies reported a rise in blood pressure post-
donation (14;34), blood pressure remained stable in this study. 
Smoking is an important risk factor for the development of cardiovascular disease and
cancer. Previous studies showed that smoking is also a risk factor for kidney damage, because
of both vascular and direct endothelial damage (35-37). Smoking may accelerate the aging-
related decline kidney function (38) and increase albuminuria in hypertensive patients (36).
Here, however, we observed no diﬀerence in kidney function between current smokers and
current non-smokers, neither on short nor on ﬁve year follow-up. Thus, smoking behavior
does not appear to inﬂuence post-donation kidney function course. At our center, smoking
behavior is not a criterion in kidney donor selection. Although donors may be advised to stop
smoking, there is no further special attention for smoking behavior in screening or follow-up. 
Where many studies focus on one or two potential risk factors, for the individual donor
it is the whole risk proﬁle that counts. When we combined all risk factors in regression
analysis, pre-donation GFR and donor age were the only signiﬁcant factors for prediction of
ﬁve year kidney function. This is in line with abovementioned discussion. Thus, as long as
kidney function is at a suﬃcient level prior to donation, the current practice of accepting
older, more overweight and even hypertensive donors appears to be safe. Here we like to
note, however, that the donors described here all had gold standard kidney function
measurements as part of the screening program. Since a cutoﬀ of 80 ml/min was applied, all
donors had excellent kidney function prior to donation, including donors with an unfavorable
risk proﬁle. Furthermore, the measurement of renal reserve capacity by use of dopamine
ascertained adaptive capacity, even when GFR was near 80 mL/min. Although this is an
important strength of screening with the use of gold standard kidney function measurements,
it may hamper generalizability to other populations in which an estimation of kidney function
is used. Since the pitfalls of screening with estimating equations are well known (39-43) –
59% of donors presented here have an estimated GFR by MDRD Study equation <
80mL/min/1.73m2 (data not shown) –, we like to emphasize the importance of thorough
kidney function measurement prior to donation. 
Other limitations of this study are the rather short duration of follow-up and the
moderate risk proﬁle of our donors. Although our center does not use an absolute cutoﬀ for
donor age, only 14 donors were aged above 60 years. As mentioned earlier, only 17% of
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donors had a BMI > 30kg/m2. 
In summary, overall ﬁve year donor outcome is good. Although older donors have lower
kidney function post-donation, adaption to ﬁve year post-donation is similar to younger
donors. When kidney function prior to donation is assured to be good, the current practice
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Background: many living kidney donors have an estimated kidney function <60
mL/min/1.73m2 post-donation, and, thus, meet to the criteria of CKD stage 3. However, the
prognostic impact of a given GFR in two diseased kidneys may not be equivalent to the same
GFR in one healthy kidney. To test this assumption, we compared kidney function course of
former donors to age, gender and baseline GFR matched CKD patients.
Methods: included were 57 kidney donors, with baseline values obtained 2 months post-
donation, and 57 CKD patients. All had repeated GFR (125I-iothalamate) and ERPF
(131I-hippuran) measurements after 4.7±1.5 years. 
Results: at baseline, 25% of donors met with criteria for CKD stage 3. In donors, GFR increased
over time despite a slight fall in ERPF, while GFR and ERPF both fell in CKD (both p<0.01 vs.
donors). CKD stage improved to stage 2 or less in 7/14 donors with stage 3 at baseline,
whereas it worsened in 15 CKD patients. 
Conclusion: kidney function course diﬀers substantially in kidney donors and CKD patients.
Although many donors meet criteria of CKD stage 3, their prognosis diverges from true CKD











Living kidney donors are of great importance in kidney transplantation. Donor nephrectomy
is known to be a safe procedure, and studies reporting donor outcome all show reassuring
results (1-6). Many former kidney donors, however, have an estimated kidney function <60
mL/min post-donation, and, thus, meet the criteria of chronic kidney disease (CKD) stage 3.
CKD staging is based on prognostic impact of kidney function and markers of kidney
damage and/or pathological abnormalities (7). For kidney function, estimated glomerular
ﬁltration rate (eGFR) is most often used, whereas additional incorporation of albuminuria in
the classiﬁcation has been claimed to improve its prognostic impact. For former kidney
donors, the use of CKD stages based of eGFR, however, raises two problems. First, the
prognostic impact of the CKD stages is based on the presence of two kidneys. The prognostic
impact of a given GFR in two diseased kidneys, however, may not be equivalent to the same
GFR in one healthy kidney. Furthermore, it is known that eGFR tends to underestimate true
kidney function, especially in healthy subjects (8-12). Based on the literature, it can be
anticipated that the prognosis for a given eGFR, and hence CKD classiﬁcation, is much more
favorable in former kidney donors. Barri et al. showed that a substantial part of former donors
has an GFR <60 mL/min/1.73m2 at short term after donation, and that especially older donors
are aﬀected. Nevertheless, Ibrahim et al. showed in a large cross-sectional study that the risk
of developing end stage renal disease is not increased in former donors, and that their health
status at a mean of twelve year post-donation was comparable to that of matched controls.
Taken together, use of CKD stages in former donors could lead to undue labeling of healthy
kidney donors as ‘patients’, with possible adverse consequences, for instance in insurance
matters.
Therefore, we evaluated the prognostic impact of CKD classes in former kidney donors
determined two months post-donation, for predicting donor outcome at ﬁve year post-
donation. Furthermore, we compared post-donation kidney function course to that of CKD
patients, matched for gender, age and baseline kidney function.
Methods
In this study, 57 living kidney donors who donated at our centre between 1987 and 2006 were
included. As part of the routine screening and follow-up, kidney function was measured four
months prior and two months following donation. Since 2007, all former donors in our centre
are invited for a second post-donation kidney function measurement ﬁve year post-donation.
Donors who donated before 2002 were all invited in one follow-up round. Donors were
selected for having complete data on the three time points, and on availability of a suitable
match. Of the 202 donors that donated before 2007, 100 donors had complete data on all
three time-points. There were no diﬀerences between donors that could be matched and
donors whom could not be matched in terms of age, BMI, blood pressure and kidney function
at baseline and end of follow-up. As controls, 57 non diabetic CKD patients were included.
Donors and patients were matched for age, gender, baseline GFR and duration of follow-up.
For the CKD patients, we retrieved data from all patients enrolled in renal hemodynamic
studies performed between 1972 and 1995 at our center (13). Of the 77 patients with
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complete data, 57 could be matched to a former donor. Of the CKD patients, 18 had essential
hypertension; 10 membranous glomerulopathy; 8 focal glomerulosclerosis; 5 polycystic kidney
disease; 4 IgA nephropathy; 3 had kidney disease of unknown origin; and 9 had other causes
like Barrter syndrome and ischemic lesions. Procedures were conducted in accordance with
the Helsinki declaration.
Measurement of kidney function
Glomerular ﬁltration rate (GFR) was measured by constant low-dose infusion of the radio-
labelled tracer 125I iothalamate as described by Donker (14), Visser (15) and Apperloo et al.
(16). Simultaneously, eﬀective renal plasma ﬂow (ERPF) was measured as the clearance of
131I-hippurate. Filtration fraction (FF) was calculated as GFR/ERPF. For the measurements,
subjects were seated in a quiet room in a semi-supine position. After drawing a blank blood
sample, the priming solution containing 0.04 mL/kg body weight of the infusion solution (0.04
MBq of 125I iothalamate and 0.03 MBq of 131I-hippurate per mL saline) plus an extra of 0.6
MBq of 125I iothalamate was given, followed by constant infusion at 12 mL/h. To attain stable
plasma concentrations of both tracers, a 2 hour stabilization period followed, after which the
clearance periods start. Clearances were measured over the next 2 hours and calculated as
(U*V)/P and (I*V)/P, respectively. U*V represents the urinary excretion of the tracer, I*V
represents the infusion rate of the tracer and P represents the tracer value in plasma at the
end of each clearance period. GFR was calculated from UV/P of 125I-iothalamate and corrected
for voiding errors by multiplying the urinary clearance of 125I iothalamate with the ratio of the
plasma and urinary clearance of 131I-hippurate. The day-to-day variability for GFR is 2.5%. 
Calculations
In our centre, before 1st March 2006, creatinine was measured by Jaﬀé alkaline picrate assay,
on the MEGA, Merck KGaA, Darmstadt, Germany. Thereafter, creatinine was measured by
enzymatic assay on the Roche Modular. Both methods were calibrated to the reference
standard, i.e. Cleveland Clinic Laboratory measurements, as described before (17). We used
the CKD-EPI equation (18) for estimation of GFR (eGFR). CKD-EPI equation was calculated
gender speciﬁc, and stratiﬁed by serum creatinine (SCr) levels. The following calculations were
used:
Female with SCr ≤0.7 mg/dL: GFR = 144 * (0.993)age * (SCr / 0.7)-0.329
Female with SCr > 0.7 mg/dL: GFR = 144 * (0.993)age * (SCr / 0.7) -1.209
Male with SCr ≤ 0.9 mg/dL: GFR = 141 * (0.993)age * (SCr / 0.9) -0.4111
Male with SCr > 0.9 mg/dL: GFR = 141 * (0.993)age* (SCr / 0.9) -1.209
No correction for ethnicity was applied, as none of the patients were of African ethnicity.
Mean arterial pressure (MAP) was calculated as (1/3[systolic blood pressure – diastolic blood
pressure] + diastolic blood pressure). Body surface area (BSA) was calculated as according to
DuBois (19). GFR and ERPF were normalized by dividing the raw sample by BSA and multiplying
it with 1.73, giving GFR/BSA and ERPF/BSA. The slope of kidney function loss was calculated











Analyses were performed using PASW Statistics version 18 and GraphPad Prism version 5.
Data are given as mean ± standard deviation or median [IQR]. Independent samples t Test,
Mann-Whitney test and chi-square test were used to analyze for diﬀerences between groups.
Diﬀerences within groups were tested with paired samples t-test and Wilcoxon Signed Ranks
Test. We ﬁtted linear regression models using a backward selection method to evaluate
inﬂuence of baseline characteristics on donor outcome: GFR/BSA, ERPF/BSA and MAP at end
of follow-up. Covariates were age, gender and baseline BMI, MAP, GFR/BSA and ERPF/BSA.
Results
Characteristics at baseline and end of follow-up for donors and CKD patients are displayed in
table 1. As donors and CKD patients were matched for gender, in both groups 63% (n= 36)
was male. Baseline age, glomerular ﬁltration rate (GFR) and duration of follow-up were also
similar between the groups, reﬂecting a good match. Compared to the CKD patients, living
donors had higher body mass index (BMI) and lower blood pressure, urinary protein excretion
(UPE) and eﬀective renal plasma ﬂow (ERPF) adjusted for body surface area (BSA) at baseline.
At end of follow-up, donors had lower blood pressure, lower serum creatinine and UPE, and
higher GFR/BSA and CKD-EPI values. Since long term ERPF was similar between donors and
CKD patients, donors had a higher ﬁltration fraction (FF) at end of follow-up. At baseline, 7
donors used antihypertensive drugs compared to 51 CKD patients. Most subjects used one
drug, 4 donors and 25 CKD patients used and angiotensin converting enzyme inhibitor or
angiotensin receptor blocker. The use of antihypertensive drugs increased to 11 donors and
all 57 CKD patients at end of follow-up.  Early post-donation, 14 donors had a GFR/BSA <60,
and 35 a CKD-EPI <60 mL/min/1.73m2. Long term post-donation 7 donors had a GFR/BSA <60,
and 30 a CKD-EPI <60 mL/min/1.73m2. Of the CKD patients, 11 had died up to 2011. Mean
age at death was 65 ± 10 years, time since end of follow-up was 10 ± 4 years, none had died
during follow-up. Up to 2011, none of the former donors had died.
Change in kidney function over time was signiﬁcantly diﬀerent between donors and CKD-
patients (table 2 and ﬁgure 1). Where donors showed a negative serum creatinine slope and
positive GFR/BSA and CKD-EPI slope, CKD patients showed a decrease in kidney function over
Figure 1: kidney function course for living kidney donors and CKD patients. Graphs represent GFR/BSA (top
graph), CKD-EPI and ERPF/BSA (bottom graph). Donors show a positive kidney function course for GFR/BSA and
CKD-EPI, and less steep negative course for ERPF/BSA than CKD patients. Symbols represent mean ± SD.
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time. Though ERPF/BSA decreased in both donors and CKD patients, the decrease in donors
was less steep. For 22 donors, intermittent creatinine values were available between baseline
and end of follow-up. Of these 22 donors, 16 showed a gradual decrease in creatinine
between baseline and end of follow-up, while 6 showed a decrease between baseline and
one year post-donation and had stable creatinine values (± 0.05 mg/dL) up to end of follow-
up. 
Donors CKD patients P value
Baseline
Age (years) 48 ± 12 48 ± 11 1.00
BMI (kg/m2) 27 ± 4 25 ± 3 0.02
Systolic blood pressure (mmHg) 126 ± 13 137 ± 18 <0.01
Diastolic blood pressure (mmHg) 77 ± 9 83 ± 12 <0.01
Serum creatinine (mg/dL) 1.4 ± 0.2 1.3 ± 0.4 0.57
UPE (g/24h) 0.0 [0.0-0.1] 0.7 [0.0-2.9] <0.01
GFR/BSA (mL/min/1.73m2) 67 ± 11 71 ± 18 0.21
CKD-EPI (mL/min/1.73m2) 56 ± 11 63 ± 22 0.08
ERPF/BSA (mL/min/1.73m2) 264 ± 48 304 ± 128 0.03
FF (%) 26 ± 3 25 ± 6 0.34
Subjects on antihypertensive drugs (n [%]) 7 (12) 51 (89) <0.01
End of follow-up
Duration of follow-up (years) 4.9 ± 0.9 4.6 ± 1.9 0.27
Systolic blood pressure (mmHg) 124 ± 12 144 ± 31 <0.01
Diastolic blood pressure (mmHg) 77 ± 9 86 ± 14 <0.01
Serum creatinine (mg/dL) 1.2 ± 0.2 1.5 ± 0.5 <0.01
UPE (g/24h) 0.0 [0.0-0.2] 1.0 [0.0-2.5] <0.01
GFR/BSA (mL/min/1.73m2) 73 ± 12 63 ± 21 <0.01
CKD-EPI (mL/min/1.73m2) 63 ± 13 54 ± 20 <0.01
ERPF/BSA (mL/min/1.73m2) 247 ± 48 258 ± 95 0.44
FF (%) 30 ± 4 25 ± 7 <0.01
Subjects on antihypertensive drugs (n [%]) 11 (19) 57 (100) <0.01
Table 1: donor and patient characteristics at baseline and end of follow-up.
Values represent mean ± SD and median [IQR]. In both groups, 63% of subjects was male. All subjects completed










Classiﬁcation of kidney function according to the K/DOQI guidelines is displayed in ﬁgure 2.
The top panel shows classiﬁcation based on kidney function and UPE; the lower panel is solely
based on kidney function. The top ﬁgure shows that where donors tend to move up in stage
over time, CKD patients show progression. Furthermore, classiﬁcation with CKD-EPI leads to
more subjects with stage 3 CKD compared to classiﬁcation with GFR in both groups. Since
only very few donors have UPE > 0.5 g/day, CKD stage 2 is sparse in former donors. When
classiﬁcation is solely based on kidney function (lower panel), the percentage of kidney donors
and CKD patients with stage 2 GFR or CKD-EPI shows a major increase, though the further
pattern is similar to the top panel.
Implication of classiﬁcation is displayed in ﬁgure 3. Kidney function course is shown for
donors and CKD patients separately, by break-up in baseline kidney function. Subjects are not
matched for this analysis; to obtain more equal group sizes, crude GFR was used instead of
GFR/BSA, when GFR/BSA was used a similar pattern was seen (data not shown). The ﬁgure
shows that donors show an opposite course in kidney function than CKD patients (p< 0.05
Donors CKD patients P value
Creatinine (mg/dL/year) -0.03 ± 0.03 0.03 ± 0.07 <0.01
GFR/BSA (mL/min/1.73m2/ year) 1.8 ± 1.6 -1.4 ± 3.4 <0.01
CKD-EPI (mL/min/1.73m2/ year) 1.2 ± 1.6 -1.7 ± 2.8 <0.01
ERPF/BSA (mL/min/1.73m2/ year) -3.2 ± 6.5 -9.8 ± 15.7 <0.01
Table 2: slopes of serum creatinine, GFR/BSA, CKD-EPI equation and ERPF/BSA. 
Values represent mean ± SD. BSA: body surface area.
Figure 2: CKD stages by GFR/BSA (left graphs) and CKD-EPI equation. For ﬁgure a CKD stages were deﬁned as: 1)
(e)GFR >90 and UPE>0.5 g/day; 2) (e)GFR 60-90 and UPE>0.5 g/day; 3) (e)GFR 30-60; 4) (e)GFR<30. For ﬁgure b
CKD stages were deﬁned solely by kidney function. B: baseline; E: end of follow-up.
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for change in kidney function), independent of baseline kidney function. When the break-up
was made for CKD classiﬁcation with proteinuria, a similar pattern was seen (data not shown). 
Prediction of donor outcome
GFR/BSA at end of follow-up was best predicted by baseline GFR/BSA (adjusted R2 0.71,
standardized (std.) beta 0.85, p<0.01). Addition of baseline ERPF/BSA (std. beta 0.40) increased
the R2 to 0.77. Other donor characteristics had no signiﬁcant inﬂuence on donor outcome.
ERPF /BSA at end of follow-up was best predicted by baseline ERPF/BSA (adjusted R2 0.68,
std. beta 0.83, p<0.01). None of the other donor characteristics added signiﬁcantly to the
model. MAP at end of follow-up was best predicted by MAP at baseline (adjusted R2 0.43,
std. beta 0.67, p<0.01), without inﬂuence of other characteristics. 
Discussion
This study compares kidney function course of former living kidney donors to that of matched
CKD patients. Whilst CKD patients show a decline in both GFR and ERPF over time, former
donors show an increase in GFR between two months and ﬁve year post-donation, and a less
steep decline in ERPF compared to the CKD patients. Prognostic impact of early post-donation
CKD staging for prediction kidney function impairment in former donors is low. Thus, living
kidney donors are not CKD patients post-donation.
Several studies evaluating long term donor outcome reported excellent long term results
(1;3-6). One study even showed that post-donation kidney function can keep increasing up
to ﬁfteen year post-donation (2). In this study GFR increased to long term, but ERPF showed
a slight decrease. This diﬀerent course increases the ﬁltration pressure in the kidney,
expressed by an increase in FF of 25% to 30%. At ﬁve year post-donation, however, we ﬁnd
no detrimental eﬀects of this higher ﬁltration pressure. Although it has been suggested that
post-donation kidney function increases up to one year post-donation and then slowly
Figure 3: kidney function course from baseline (B) to end of follow-up (E) for donors and CKD patients, with a
break up for baseline kidney function. Subjects were not matched. Group sizes are: n=11, 41 and 5 for donors
and n=17, 30 and 10 for CKD patients. Symbols represent median [IQR] values. * p<0.05 vs. CKD patients. The









declines, here we ﬁnd improvement or stabilization of kidney function between one and ﬁve
year post-donation in a subset of donors. 
Although many studies report excellent long term results, many kidney donors have an
eGFR<60 mL/min/1.73m2 post-donation (12,20-25). This marks former donors as CKD
patients, with possible negative socio-economic consequences in some countries. The current
CKD staging, as proposed by the KDIGO (7), is based on the prognostic impact of a given GFR
in two kidneys. A low GFR in a subject with two kidneys may reﬂect kidney disease, while the
same GFR in a former donor reﬂects a perfectly healthy single kidney. Other staging systems
have been proposed (23-25), based more strongly on the actual presence of kidney damage.
In this study, classiﬁcation based on proteinuria and kidney function classiﬁes nearly all former
donors with a kidney function > 60 mL/min/1.73m2 as healthy, whereas classiﬁcation solely
on base of kidney function shows more variation. Furthermore, use of estimated GFR may
lead to a far worse pattern in classiﬁcation than with measured GFR.  Although CKD-EPI
performs better than MDRD study equation in the range > 60 mL/min/1.73m2 (26), it still
underestimates measured kidney function. In this study, use of CKD-EPI for classiﬁcation led
to a higher CKD stages in both former donors and CKD patients. As many centers rely on eGFR
rather than gold standard kidney function measurements, the prevalence of CKD may be
overestimated.
Our study has several limitations, the most important being the small sample size and
rather short duration of follow-up. Furthermore, our donors were screened by use of gold
standard kidney function measurement prior to donation, which makes them highly selected
for good kidney function. This may hamper comparison to donor populations screened by
eGFR. Due to the shortage in donor organs, selection criteria for potential donors have
become more liberal over the last decade, with acceptation of older, overweight and even
hypertensive donors (Mandelbrot). Of the donors described in this study, 7 (12%) were aged
above 60 years, 10 (18%) had a BMI exceeding 30 kg/m2 and 7 (12%) used antihypertensive
drugs prior to donation. Current donor populations may have less favorable risk proﬁles, which
may inﬂuence long term outcome. Since kidney function was only measured twice post-
donation, slope analysis in this study was based on only two time points. Since the ﬁrst time
point was early post-donation, the compensatory increase in kidney function was probably
not complete at the time of measurement, which may have biased the slope assessment. In
a subset of donors in whom creatinine measurements at more time points were available,
creatinine decreased up to one year post-donation, and kept decreasing or stabilized up to
ﬁve year post-donation. Thus, the use of this early time point may have led to a more positive
slope in former donors, but based on our subgroup analysis this cannot explain the large
diﬀerence in slope between former donors and CKD patients. Since all donors at our center
were Caucasian, the conclusions may not be representative for donors with other ethnicities. 
What are the implications of this study? First, we like to emphasize that former living
kidney donors are healthy, and even with a low kidney function should not be regarded as
patients. As shown here, for a given GFR the course in kidney function is very diﬀerent for
donors and true CKD patients. Thus, current CKD staging for prognostic purposes is not
applicable in former kidney donors. Nevertheless, it should be pointed out that CKD staging
has purposes other than estimating renal and overall prognosis, namely guiding safety
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precautions related to the excretory capacity of the kidney for potentially toxic
pharmacological and radiological agents. This related to clearance capacity per se, and for
such purposes, actual kidney function should be taken into account.
In summary, for a given GFR former kidney donors have a substantially diﬀerent course
in kidney function than CKD patients. Even though many kidney donors may have an eGFR <
60 mL/min/1.73m2 post-donation, they should not simply be regarded as CKD patients. To
acknowledge the special nature of the former kidney donor, we suggest to consider former
kidney donors a special category in future proposals for CKD classiﬁcation .
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Renal structural changes in living
donor biopsies: associations with
donor characteristics and short term














Background: Living donors are indispensible for kidney transplantation programs. More liberal
donor criteria prompted us to evaluate the presence of early renal damage at time of donation
and associations with donor characteristics and outcome. 
Methods: We evaluated 82 living donors. All underwent GFR (125I-iothalamate) and ERPF (131I-
hippurate) measurements four months prior and two months post-donation. Needle biopsies
were taken during the donation procedure. Sections were stained for inﬂammation
(neutrophillic granulocytes, macrophages), and pre-ﬁbrosis (α-smooth muscle actin (α-SMA)).
The degree of glomerulosclerosis, interstitial ﬁbrosis, vascular hyalinosis and intima thickness
were scored in PAS stained sections.
Results: The extent of interstitial α-SMA expression associated with donor age (R 0.32, p<0.01)
and GFR and ERPF prior to donation (R -0.38 and -0.39, p<0.01) and early post-donation (R -
0.36 and -0.41, p<0.01). The associations with kidney function were independent of donor
age, the associations with post-donation kidney function were, however, dependent on pre-
donation kidney function. No other associations with outcome were found.
Conclusion: Mild pre-existent renal damage is present in kidneys of living kidney donors at
the time of donation. These changes, however, show no inﬂuence on adaptive capacity. Early











Over the past decade, living donors have become more and more important for kidney
transplantation worldwide (1-3). Kidneys retrieved from living donors provide better function
and longer half life after transplantation than kidneys from post-mortem donors (4-7). In the
past, living kidney donors were strictly selected, and consequently represented the healthiest
subjects of the population (8). Based on the growing need for organs, the selection criteria
for potential donors, however, have become more liberal (9;10), with the inclusion of older,
more overweight and even moderately hypertensive donors. Since aging, overweight and
hypertension are well known risk factors for the development of kidney disease, these altered
donor characteristics raise questions about the safety of living donation.  
Due to the large reserve capacity of the kidney, minor interstitial, vascular and glomerular
damage can already be present without clinical signs of deterioration such as proteinuria or
decreased kidney function. In the single kidney situation following donation, pre-existent
renal damage may, however, become of signiﬁcant clinical importance. Several studies in
potential donors showed that minor renal morphological damage, like glomerulosclerosis,
interstitial ﬁbrosis and tubular atrophy is present in subjects with good kidney function (11-
16). The consequences in time of pre-existent damage for donor outcome are, however,
unclear. It would, therefore, be of great interest to assess whether subclinical structural renal
abnormalities have impact on renal outcome after donation. Associations have been
described between pre-existent damage – like glomerulosclerosis, interstitial ﬁbrosis and
tubular atrophy – and decreased kidney function and lower graft survival in recipients of
deceased donor kidneys (17-25). 
In this study, we evaluate the eﬀects of pre-existent morphological renal damage in renal
biopsies taken during the donation procedure on donor characteristics prior to donation and
the impact of these pre-existent renal morphological abnormalities on living donor short term
renal function after donation. 
Methods
Eighty-two living donors were included in this study. Biopsies from living donor kidneys
retrieved between November 2005 and July 2008 at the University Medical Center Groningen
were used. In this time period, 125 transplantations using living donors were performed. Nine
of these donors were cross-over donors, and were screened at another university hospital in
the Netherlands. Data of these screenings is unavailable. Screening or follow-up data from
13 donors were missing. Renal biopsies from 21 donors showed mere non-cortical tissue and
were excluded from analyses. Kidney function was measured as the urinary clearance of 125I
iothalamate four months prior and two months post donation. Kidney biopsies were taken at
three time points: just before retrieval of the kidney (with the kidney in situ and before
clamping arterial and venous circulation), at the end of cold ischemia and 45 min after
reperfusion. For analysis, scores from all three time points were averaged; for the number of
macrophages and neutrophillic granulocytes the third time point was excluded from analyses
since reperfusion might enhance the inﬂux of these cells. Procedures were conducted in
accordance with the Helsinki declaration. 
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Kidney function measurements
Glomerular ﬁltration rate (GFR) was measured by constant low-dose infusion of the radio-
labeled tracer 125I iothalamate as described by Visser and Apperloo et al. (26-28).
Simultaneously, eﬀective renal plasma ﬂow (ERPF) was measured as the clearance of 131I-
hippurate. Filtration fraction (FF) was calculated as GFR/ERPF. For the measurements, subjects
were seated in a quiet room in a semi-supine position. After drawing a blank blood sample,
the priming solution containing 0.04 mL/kg body weight of the infusion solution (0.04 MBq
of 125I iothalamate and 0.03 MBq of 131I-hippurate per mL saline) plus an extra of 0.6 MBq of
125I iothalamate was given, followed by constant infusion at 12 mL/h. To attain stable plasma
concentrations of both tracers, a 2 hour stabilization period followed, after which the
clearance periods start. Clearances were measured over the next 2 hours and calculated as
(U*V)/P and (I*V)/P, respectively. U*V represents the urinary excretion of the tracer, I*V
represents the infusion rate of the tracer and P represents the tracer value in plasma at the
end of each clearance period. GFR was calculated from UV/P of 125I-iothalamate and corrected
for voiding errors by multiplying the urinary clearance of 125I iothalamate with the ratio of the
plasma and urinary clearance of 131I-hippurate. The day-to-day variability for GFR is 2.5%. 
Morphological damage
Paraﬃn sections (3 µm) were stained with periodic acid-Schiﬀ (PAS) to evaluate the degree
of glomerulosclerosis, interstitial ﬁbrosis (IF), arterial intima thickness and vascular hyalinosis.
IF was deﬁned as expansion of the interstitial space, with or without the presence of atrophied
and dilated tubules and thickened tubular basement membranes. The renal papilla, glomeruli,
and vessels were excluded from the calculated areas of ﬁbrotic involvement. The degree of
IF was scored on a scale of 5: 0%, 0-10%, 10-25%, 25-50%; 50-75% and 75-100% of biopsy
surface area. A mean score was calculated from the three diﬀerent time-points. Vascular
hyalinosis was scored as none, mild, moderate, or nodular. A mean score was calculated from
the three diﬀerent time-points. At least three vessels had to be present to calculate a mean
score. The renal biopsies were scored by a pathologist blinded for donor characteristics and
clinical outcome. 
Macrophage inﬂux and α-Smooth muscle actin (α-SMA) expression
Deparaﬃnized sections were subjected to heat-induced antigen retrieval by overnight
incubation in a 0.1 M Tris-HCl buﬀer (pH 9.0) at 80°C. Endogenous peroxidase (PO) was
blocked with 0.3% H2O2 in PBS for 30 min, and sections were incubated with either CD68
antibody (clone PGM-1; diluted 1:250; DAKO, Glosstrup, Denmark) for macrophages or α-
SMA antibody (clone 1A4, diluted 1:10,000, Sigma, Saint Louis, Missouri, USA) for 60 min at
room temperature. Binding of the antibody was detected using sequential incubations (30
min each) with PO-labeled rabbit-anti-mouse (RAMPO, diluted 1:100; DAKO) and PO-labeled
goat-anti-rabbit antibodies (GARPO, diluted 1:100, DAKO). PO activity was developed using
3,3’-diaminobenzidine tetrachloride (DAB) for 10 min. Sections stained for macrophages were
counterstained with PAS. Macrophages were manually counted in the interstitium, α-SMA
expression was determined by Positive Pixel Count (Aperio Imagescope version 10.2.2). Scores









from counting and surface area calculation. For analysis of α-SMA expression, scores from
the three time points (provided that all were cortical biopsies) were averaged. For analysis of
the number of macrophages, the scores from the ﬁrst and second time-point (both before
reperfusion) were averaged. 
Neutrophillic granulocytes
Deparaﬃnized sections were subjected to antigen retrieval using protease (diluted 1:1000;
type XXIV, Sigma, Zwijndrecht, the Netherlands). Endogenous peroxidase (PO) was blocked
with 0.3% H2O2 in PBS for 30 min, and sections were incubated with monoclonal antibody
12.8 (29) (clone 12.8; diluted 1:10) for 60 min at  room temperature. Binding of the antibody
was detected using sequential incubations (30 min each) with PO-labeled rabbit-anti-mouse
and PO-labeled goat-anti-rabbit antibodies (both diluted 1:100). PO activity was developed
using 3,3’-diaminobenzidine tetrachloride (DAB) for 10 min. Sections were counterstained
with hematoxylin. Neutrophillic granulocytes were manually counted in the interstitium,
scores were adjusted for biopsy surface area. For analysis, the scores from the ﬁrst and second
time-point (both before reperfusion) were averaged. 
Arterial Intima thickness
To provide a standardized estimation of the severity of intima thickening independent of
vessel size, intima surface was expressed as percentage of the media surface, in which a higher
percentage represents a relatively thicker intima. For this purpose, all arteries present in the
biopsies were analyzed. α-SMA stained sections were used for this purpose. For each vessel,
media, and intima were outlined to calculate individual surfaces. For each donor, the separate
vessel scores of all three biopsy time points were averaged to provide one overall score. At
least three vessels had to be present to calculate an overall score.
Statistical analysis
Analyses were performed using SPSS software version 16.0 and GraphPad Prism version 5 for
Windows. Data are given as mean ± standard deviation or median [IQR]. Donors with only
medulla on their renal biopsy were excluded from analysis. To evaluate for associations of the
damage parameters with donor characteristics and outcome, correlation analysis was used.
Linear regression was used to evaluate the independency of associations found in correlation
analysis from traditional predictors. The number of macrophages and neutrophillic
granulocytes, the expression of α-SMA and the intima thickness showed a skewed distribution.
For correlation and regression analysis, therefore, the natural logarithmic of these parameters
was used. 
Results
Donor characteristics are shown in table 1. After donation, GFR and ERPF fell to 63 and 65%
of the pre-donation values. Sixteen donors (20%) used antihypertensive drugs, mainly
angiotensin converting enzyme inhibitors (75%), prior to donation. Renal damage parameters
are shown in table 2. Donors with interstitial ﬁbrosis exceeding 10% of biopsy surface area
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had higher interstitial α-SMA expression (4.3 [2.5-7.44] vs. 1.4 [0.6-2.4] per µm2, p<0.01) and
a higher number of interstitial macrophages (4.6 [3.2-7.6] vs. 1.2 [0.5-2.2] per µm2, p<0.05). 
Interstitial α-SMA expression 
Interstitial α-SMA expression correlated positively to donor age at donation (R 0.32, p<0.01)
and negatively to donor GFR and ERPF prior to donation (R -0.38 and -0.39, both p<0.01;
ﬁgure 2). The associations with kidney function were both independent of donor age. There
were no signiﬁcant associations with donor gender or BMI. There was no diﬀerence in α-SMA
expression between males and females, hypertensive and normotensive donors and donors
with a BMI above or below 30 kg/m2. 
Interstitial α-SMA expression correlated negatively to early post-donation GFR and ERPF
(R -0.36 and -0.41, both p<0.01), no other associations were found. Again, the associations
Value
N (%) female 82 (46)
Age at donationN 52 ± 11
BMI at donation (kg/m2) 27 ± 4
Pre-donation
Systolic blood pressure (mmHg) 129 ± 14
Diastolic blood pressure (mmHg) 76 ± 9
GFR (mL/min) 118 ± 23
ERPF (mL/min) 437 ± 85
FF (%) 27 ± 3
Urinary protein excretion (g/24h) 0.1 [0.0-0.2]
Two months post-donation
Systolic blood pressure (mmHg) 125 ± 13
Diastolic blood pressure (mmHg) 77 ± 9
GFR (mL/min) 74 ± 15
ERPF (mL/min) 283 ± 53
FF (%) 26 ± 3
Urinary protein excretion (g/24h) 0.1 [0.0-0.2]
∆GFR (mL/min) -44 ± 14
∆ERPF (mL/min) -154 ± 57
Table 1: Donor characteristics prior to and two months after donation. 










Interstitial α-SMA (intensity) 82 (46)
Interstitial macrophages (number) 52 ± 11
Interstitial neutrophillic granulocytes (number) 27 ± 4
Glomerosclerosis (% of total glomeruli)
Interstitial ﬁbrosis > 10% (n, %) 129 ± 14
Vascular hyalinosis (n,%) 76 ± 9
Arterial intima thickness (% of media thickness) 118 ± 23
Figure 1: Representative photographs of kidney biopsies. A: α-SMA staining. B: CD68 staining. C. PAS staining
showing vascular hyalinosis. D. α-SMA staining showing increased arterial intima thickness; red lines represent
the borders of intima and media as determined for the calculation of the intima and media surface.
Values represent n(%), mean ± SD or median [IQR]. The number of macrophages and neutrophillic granulocytes
are expressed as number/10.000 µm2 biopsy surface area. α-SMA expression is expressed as intensity/µm2
biopsy surface area.
Table 2: Damage parameters at time of donation. 
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with post-donation GFR and ERPF were independent of donor age. There were no associations
with the change in kidney function over donation.
Interstitial macrophages and neutrophilic granulocytes
The median number of interstitial macrophages and neutrophillic granulocytes is shown in
table 2. The number of interstitial macrophages did not correlate to donor characteristics 
Nevertheless, donors with a BMI above 30 kg/m2 had a higher density of interstitial
macrophages than leaner donors (0.99 [0.75-1.59] vs. 0.75 [0.51-1.10] per 10,000 µm2,
p<0.05). No correlations were found between the number of macrophages and donor
outcome.
The number of interstitial neutrophillic granulocytes was higher in women (0.10 [0.06-
0.22] vs. 0.05 [0.02-0.20] per 10,000 µm2, p<0.05), and associated negatively to donor systolic
and diastolic blood pressure prior to donation (R -0.25 and -0.29, both p<0.05). There was no
diﬀerence in the number of interstitial neutrophillic granulocytes between donors older and
younger than 60 years, donors with a BMI above or below 30 kg/m2, or between hypertensive
and normotensive donors.
In multivariate analysis, the associations between the number of interstitial neutrophillic
granulocytes and pre- and post-donation blood pressure were adjusted for donor gender and
donor age. The association with pre-donation diastolic blood pressure was independent of
donor gender and age (ﬁgure 2). 
The number of interstitial neutrophillic granulocytes associated negatively post-donation
diastolic blood pressure (R -0.24, p<0.05). This association, however, was dependent of donor
Figure 2: Scatter plots for the associations between damage markers and donor characteristics and outcome.
Figures represent associations between Ln interstitial α-SMA expression and a) GFR prior to donation, b) ERPF
prior to donation, c) age at donation, d) GFR early post-donation, e) ERPF early post-donation; and between f)
Ln interstitial neutrophillic granulocytes and diastolic blood pressure prior to donation. R2 represents adjusted










Glomerulosclerosis and interstitial ﬁbrosis
The average number of sclerosed glomeruli is shown in table 2. The percentage of
glomerulosclerosis showed no associations with donor characteristics or outcome. No
diﬀerences were found between donors older and younger than 60 years, donors with a BMI
above or below 30 kg/m2, or between hypertensive and normotensive donors. 
Eight donors had interstitial ﬁbrosis in more than 10% of the surface area. These
donors had higher diastolic blood pressure prior to donation (82 [70-86] vs. 75 [69-81] mmHg,
p<0.05). No other diﬀerences in donor characteristics or outcome were found.
Vascular hyalinosis and intima thickness
Vascular hyalinosis was present in 13% of donors. Donors with vascular hyalinosis present in
their biopsy had higher systolic blood pressure prior to donation (137 [129-150] vs. 128 [119-
135] mmHg, p<0.05). Donors older than 60, with a BMI > 30kg/m2 or with pre-existent
hypertension had similar presence of hyalinosis as their younger, leaner or normotensive
counterparts. There were no diﬀerences in outcome between donors with and without signs
of hyalinosis.
Intima thickness showed no association to donor characteristics or donor outcome.
Donors with a BMI >30 kg/m2 had higher intima thickness scores than donors with a BMI <
30kg/m2 (p> 0.05).
Prediction of donor outcome
Interstitial α-SMA expression associated negatively with post-donation kidney function,
independently of donor age. When combined with pre-donation characteristics and kidney
function, however, the signiﬁcance of interstitial α-SMA expression was lost. Post-donation
GFR was best predicted by pre-donation GFR and age at donation (std. β 0.68 and -0.27;
adjusted R2 0.68; p<0.01). Post-donation ERPF was best predicted by pre-donation ERPF and
age at donation (std. β 0.66 and -0.27; adjusted R2 0.63; p<0.01). Pre-donation BMI and blood
pressure had no inﬂuence in the multivariate models.
No associations were found between the change in kidney function over donation and
damage parameters.
Discussion 
The most important ﬁnding of this study relates to the presence of mild pro-ﬁbrotic, vascular
and inﬂammatory damage in living kidney donors that does not inﬂuence adaption to the
single kidney state. Renal interstitial damage, as evidenced by α-SMA expression and the
number of neutrophillic granulocytes, shows associations with donor age, blood pressure
prior to donation and kidney function prior to and early post-donation. However, no inﬂuence
on change in kidney function over donation was seen, and, thus, these changes do not seem
to aﬀect adaptive capacity of the remaining kidney. The impact on post-donation outcome
was lost when well-established determinants of post-donation outcome, namely pre-donation
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GFR and age, were taken into account. Thus, within the time frame of this study, no negative
impact of the structural abnormalities could be identiﬁed. 
This is the ﬁrst study that evaluates associations between changes in pre-implantation
biopsies and living donor characteristics and early post-donation outcome with the use of
gold standard kidney function measurements. In these thoroughly screened donors, whom
presented with a good kidney function, mild vascular, pre-ﬁbrotic and inﬂammatory changes
were already present at the time of donation. Our ﬁndings are in line with other studies that
evaluated potential living kidney donors (11-13;15;16). Rule et al. showed in a large series of
living kidney donors the presence of age related nephrosclerosis, that was subclinical and was
only detected by kidney biopsy (13). Others reported associations between morphological
damage – such as interstitial ﬁbrosis and glomerulosclerosis – with donor age, estimated
kidney function and presence of hypertension or blood pressure as such (11;12;15). 
Interstitial α-SMA expression is an early structural marker for interstitial stress. Peri-
tubular ﬁbroblasts under the inﬂuence of cytokines produced by either activated interstitial
inﬂammatory cells or damaged tubular cells are transformed into extracellular matrix
producing myoﬁbroblasts. Interstitial α-SMA showed a positive association to donor age and
a negative association with pre-donation kidney function. Although kidney function declines
with ageing (30-33), the associations between α-SMA expression and pre-donation kidney
function were independent of donor age. The association between interstitial α-SMA
expression and age is in line with previous studies that focused on age related changes. 
Although α-SMA expression associated with post-donation kidney function, no inﬂuence
on the change in kidney function was found. Apparently, adaptive capacity is preserved in the
presence of mild pre-ﬁbrotic changes. Early adaptation is to a large extent determined by
hemodynamic adaptation. Prior studies showed that pre-donation kidney function is the
strongest predictor of post-donation kidney function. In the present study, the association
between α-SMA expression and post-donation kidney function was lost when pre-donation
kidney function was taken into account. In recipients, however, several studies did show
associations between baseline damage and graft performance (15;17-25). Kidney
transplantation enhances the eﬀects of pre-existent damage, while changes that occur in the
remnant kidney after donation overcome these eﬀects. Furthermore, many of the
abovementioned studies, were performed with deceased donor kidneys. Since living donors
are selected for good health and kidney function, their kidneys are of higher quality than
deceased donor kidneys (4-7). Thus, less damage is expected in living donor kidneys, which
may explain the smaller eﬀect of preexistent changes on living donor outcome.
Our study has some limitations, the most important being the relatively small sample-
size and short duration of follow-up. Furthermore, part of the biopsies had to be rejected
from analysis due to the absence of suﬃcient amount of cortical area. This was partly
compensated by the fact that three biopsies were taken from each kidney covers the greater
part of the quality problems. Although the single center character can be regarded as a
limitation, it provided us with detailed information of all donors prior to and early after
donation. 
In conclusion, mild pre-existent renal damage characterized by pro-ﬁbrotic and
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kidney donors at time of donation. Interstitial α-SMA expression associates with pre-donation
donor age, and kidney function prior to and early post-donation. Nevertheless, no inﬂuence
of pre-existent damage on adaptive capacity was found. Thus, early adaptive capacity
following kidney donation is preserved in the presence of mild pre-ﬁbrotic changes. 
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Part three:
Eﬀect of donor risk proﬁle on 
recipient renal outcome
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Background: Female kidneys and kidneys from small donors have been suggested to perform
worse after kidney transplantation. Here we evaluate impact of gender and body dimensions
on post-transplantation GFR in living donor transplantation. 
Methods: Evaluated were 293 donor-recipient pairs who were transplanted at our centre. All
pairs had detailed renal function measurement (125I-iothalamate; 131I-hippuran) 4 months pre-
donation in the donor, and 2.5 months post-transplantation in donor and recipient. For 88
pairs ﬁve year recipient follow-up was available. Delta GFR was calculated as [recipient GFR
– donor single kidney GFR]. 
Results: Recipients of both male and female kidneys had similar renal function at early and
long term after transplantation. Male recipients had higher ERPF, ∆GFR and ∆ERPF at both
time points. Kidneys of donors smaller than their recipient had higher ∆GFR and ∆ERPF than
kidneys of larger donors at both time points (p<0.05). In multivariate analysis, ∆GFR was
predicted by donor/recipient BSA-ratio together with transplantation related factors (R2 0.19)
irrespective of donor and recipient gender. 
Conclusion: In living donor transplantation, female kidneys perform as well as male donor
kidneys. Kidneys adapt to the recipients body size and demands independent of gender,











Kidney transplantation is the preferred treatment for end-stage renal disease. It has been
suggested that female kidneys perform worse after renal transplantation compared to male
kidneys, especially when transplanted in a male recipient (1;2). This could be due to the fact
that women generally are smaller than men, with consequently smaller kidneys, less nephron
mass (3) and lower GFR, i.e. quantitative diﬀerences in the ﬁltering capacity of the
transplanted kidney. Several studies showing impact of donor body dimensions on transplant
outcome support this assumption (4-11). Alternatively, intrinsic diﬀerences between male
and female kidneys might play a role, as in native kidneys many diﬀerences in renal physiology
and pathophysiology have been described between men and women (12-14), that may be
relevant to outcome after transplantation (15). 
The living donor program, with detailed data on donor characteristics including renal
function before donation, provides an excellent setting to determine the eﬀects of body
dimensions on renal function after transplantation from those of gender. Therefore, in the
current study we evaluated the eﬀect of donor gender, donor body dimensions and the
associated diﬀerences in renal function on short- and long-term renal function of the recipient,
in relation to recipient gender and body dimensions.
Methods
In this study a total of 293 consecutive couples of living donors and their recipients, who were
transplanted in the University Medical Center Groningen, were included. Glomerular ﬁltration
rate (GFR) was measured as described below four months prior and two months after
donation for the living donors and a median of 2.5 [0.3] months for the recipients. For 88
couples 5 year recipient follow-up was available as well. Couples not available for 5 year
follow-up had higher donor and recipient BMI, and higher pre-donation donor GFR than
couples with 5 year follow-up. There were no signiﬁcant diﬀerences in demographics such as
donor and recipient age, recipient GFR and GFR/BSA, donor GFR/BSA and recipient urinary
protein excretion early after transplantation (data not shown). Procedures were conducted
in accordance with the Helsinki declaration.
GFR measurement
GFR was measured by constant low-dose infusion of the radio-labelled tracer 125I iothalamate
as described by Visser and Apperloo et al. (16;17). Simultaneously, eﬀective renal plasma ﬂow
(ERPF) was measured as the clearance of 131I-hippurate. Filtration fraction (FF) was calculated
as GFR/ERPF. For the measurements, subjects were seated in a quiet room in a semi-supine
position. After drawing a blank blood sample, the priming solution containing 0.04 mL/kg
body weight of the infusion solution (0.04 MBq of 125I iothalamate and 0.03 MBq of 131I-
hippurate per mL saline) plus an extra of 0.6 MBq of 125I iothalamate was given, followed by
constant infusion at 12 mL/h. To attain stable plasma concentrations of both tracers, a 2 hour
stabilization period followed, after which the clearance periods start. Clearances were
measured over the next 2 hours and calculated as (U*V)/P and (I*V)/P, respectively. U*V
represents the urinary excretion of the tracer, I*V represents the infusion rate of the tracer
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and P represents the tracer value in plasma at the end of each clearance period. GFR was
calculated from UV/P of 125I-iothalamate and corrected for voiding errors by multiplying the
urinary clearance of 125I iothalamate with the ratio of the plasma and urinary clearance of 131I-
hippurate. The day-to-day variability for GFR is 2.5%. Next to basal function, renal reserve
capacity was measured pre- and two months post-donation as part of the screening and early
follow-up. To obtain reserve capacity, the above-mentioned baseline procedure was extended
for two hours. During this period, dopamine was infused at a rate of 1.5 µg/kg per minute.
Treatment regimen after transplantation
Standard immunosuppression consisted of the following: cyclosporine standard formulation
(Sandimmune; Novartis Pharma b.v., Arnhem, The Netherlands; 10 mg/kg; trough levels of
175–200 mg/L for the ﬁrst three months, 150 mg/L between three and twelve months
posttransplant and 100 mg/L thereafter) combined with prednisolone (starting with 20
mg/day, rapidly tapered to 10 mg/day) from January 1988 to February 1993. Cyclosporine
microemulsion (Neoral; Novartis Pharma b.v., Arnhem, The Netherlands; 10 mg/kg; trough
levels idem) and prednisolone from March 1993 to May 1997. Mycophenolate mofetil
(Cellcept; Roche b.v., Woerden, The Netherlands; 2 g/day) was added from May 1997 to date.
Calculations
Body surface area (BSA) was calculated as according to DuBois (18). GFR was normalized by
dividing the raw sample by BSA and multiplying it with 1.73, giving GFR/BSA. Mean arterial
pressure (MAP) was calculated as: MAP = ((2 * diastolic pressure) + systolic pressure)/3. BSA-
ratio was calculated as: donor BSA /recipient BSA. Delta GFR from donor to recipient was
calculated as: recipient value - (donor pre-donation value /2). The donor value/2 represents
a ‘single kidney’ value (GFRSK). Delta GFR from single kidney status was calculated for short
term recipient outcome (ΔGFRST), and long term post-transplantation outcome (ΔGFRLT).
Statistical analysis
Analyses were performed using SPSS software version 16.0 and GraphPad Prism version 5.
Data are given as mean ± standard deviation or median [IQR]. Independent samples t Test,
One-Way ANOVA and Mann-Whitney U test were used to analyse for diﬀerences between
groups. To determine impact of the balance between donor and recipient BSA, data was
analysed by a break-up by donor/recipient BSA-ratio <1 or ≥1. To evaluate which
transplantation related factors were associated with ΔGFRST and ΔERPFST, we performed
univariate regression analysis. Factors with a P-value ≤0.1 in univariate analysis were entered
into a backward linear regression , combined with donor and recipient gender, BSA-ratio and
24 hour creatinine excretion, and removed in successive steps at a threshold of P-value ≤0.05.
Results
Renal function by donor gender
Donor characteristics by a break-up in gender are shown in table 1. Pre- and post-donation,










similar in men and women. The adaptive response in renal function to nephrectomy was
similar for males and females. For couples with ﬁve year follow-up, donor characteristics were
similar, except there was no gender diﬀerence in MAP (data not shown). For a subset of donors
(270 pre-donation and 256 early pos-donation), data on renal reserve capacity was available
as well. As expected, the change in GFR in response to dopamine was lower post-donation
than pre-donation (12 ± 24 vs. 4 ± 18; p<0.01). There were no diﬀerences in reserve capacity
between male and female donors, and donors with BSA-ratio <1 or ≥1. Reserve capacity did
not correlate to donor BSA. 
Transplantation related factors, evolution after transplantation, drug regimen and use of
antihypertensive drugs are listed in table 2, as well as univariate associations between these
factors and ΔGFRST and ΔERPFST. There were no diﬀerences for kidneys of male and female
origin (data not shown). Male recipients had a higher tacrolimus through level, higher total
number of antihypertensive drugs and more often used a calcium channel blocker (all p<0.05).
Total Male Female P value
Pre-donation
N 293 131 162 -
Age (years) 50 ± 11 50 ± 12 49 ± 9 NS
BMI (kg/m2) 26 ± 4 26 ± 4 26 ± 4 NS
BSA (m2) 1.92 ± 0.20 2.06 ± 0.16 1.81 ± 0.15 <0.001
MAP (mmHg) 93 ± 9 95 ± 9 91 ± 9 <0.001
GFR (mL/min) 115 ± 20 123 ± 19 108 ± 19 <0.001
ERPF (mL/min) 430 ± 84 455 ± 86 409 ± 76 <0.001
GFR/BSA (mL/min/1.73m2) 103 ± 15 103 ± 15 104 ± 16 NS
ERPF/BSA (mL/min/1.73m2) 387 ± 71 382 ± 70 392 ± 72 NS
Post-donation
MAP (mmHg) 94 ± 10 96 ± 9 92 ± 9 <0.001
GFR (mL/min) 73 ± 13 77 ± 13 69 ± 12 <0.001
ERPF (mL/min) 279 ± 54 95 ± 55 266 ± 49 <0.001
GFR/BSA (mL/min/1.73m2) 66 ± 10 65 ± 10 66 ± 10 NS
ERPF/BSA (mL/min/1.73m2) 252 ± 46 249 ± 46 254 ± 46 NS
∆GFR (mL/min) 15 ± 8 16 ± 9 15 ± 8 NS
∆ERPF (mL/min) 64 ± 31 68 ± 33 61 ± 29 NS
Table 1: donor characteristics prior and early after donation.
Values represent mean ± SD. p-Values in table represent male compared to female values. ∆GFR: post-
donation GFR – pre-donation single kidney GFR; ∆ERPF: post-donation ERPF– pre-donation single kidney ERPF.
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∆GFRST ∆ERPFST 5 year follow-up
valueValue Std. β P value Std. β P value
Primary renal disease (n, %)
Primary glomerular disease 26 (9) Ref Ref Ref Ref 9 (10)
Glomerulonephritis 78 (27) 0.07 0.24 0.18 <0.01 25 (28
Tubular interstitial disease 9 (3) -0.06 0.39 -0.11 0.10 0 (0)
Polycystic kidney disease 53 (18) 0.04 0.57 -0.08 0.22 14 (16)
Dysplasia and hypoplasia 45 (16) -0.04 0.55 0.05 0.41 16 (18)
Renovascular disease 33 (11) -0.05 0.39 0.09 0.15 11 (13)
Diabetes Mellitus 10 (3) 0.04 0.53 0.05 0.40 3 (4)
Other or unknown cause 39 (13) -0.03 0.60 -0.05 0.40 10 (11)
Related donor (n, %) 174 (59) -0.01 0.84 -0.10 0.13 60 (68)
Pre-emptive procedure (n, %) 97 (33) 0.05 0.44 0.11 0.10 19 (22)
Previous transplant (n, %) 14 (5) -0.07 0.30 -0.10 0.14 7 (8)
Warm ischemia times (min) 44 ± 18 -0.05 0.42 0.05 0.44 36 ± 17 
Cold ischemia times (min) 156 ± 103 -0.05 0.45 0.01 0.82 160 ± 93 
HLA-AB mismatches (n) 1.9 ± 1.1 0.07 0.28 0.05 0.48 1.8 ± 1.2
HLA-DR mismatches (n) 1.0 ± 0.7 -0.05 0.44 -0.03 0.70 0.8 ± 0.7
Panel reactive antibodies 0-5 % (n, %) 255 (87) - - - - 76 (86)
Panel reactive antibodies >5 % (n, %) 38 (13) - - - - 12 (14)
Delayed graft function (days) 0 [0-0] - - - - 0 [0-0]
Acute rejection (n, %) 77 (26) -0.20 <0.01 -0.18 0.01 61 (69)
Drug use
Cyclosporine (n, %) 233 (80) 0.07 0.27 0.07 0.21 34 (39)
Trough-level (µg/L) 203 ± 73 -0.08 0.25 -0.15 0.04 97 ± 44
Tacrolimus (n, %) 60 (20) -0.08 0.19 -0.07 0.24 19 (22)
Trough-level (µg/L) 13 ± 5 0.12 0.40 0.02 0.91 8 ± 4
Prednisolone dose (mg/day) 10 ± 1 0.12 0.07 0.06 0.41 9.1 ± 1. 4
Azathioprine (n, %) 10 (3) 0.02 0.77 0.11 0.07 12 (14)
Mycophenolate  mofetil (n, %) 268 (91) 0.14 0.02 0.15 0.01 71 (81)
Number of antihypertensives 1.3 ± 0.9 -0.06 0.38 0.06 0.41 1.3 ± 0.9
ACE-inhibitor or AII-antagonist (n, %) 65 (22) 0.08 0.24 0.12 0.08 39 (44)
β-blocker 164 (56) -0.04 0.52 -0.03 0.65 59 (67)
Calcium channel blocker 82 (28) 0.21 <0.01 0.27 <0.01 21 (24)
Statin 113 (39) -0.09 0.20 -0.05 0.44 41 (47)
Total cholesterol (mmol/L) %) 5.4 ± 1.1 -0.17 0.01 -0.19 0.02 5.2 ± 1.2
Table 2: transplantation related characteristics, evolution post-transplantation and drug use for the whole group
(middle column, n=293) and the group with ﬁve year follow-up (right column, n=88). 
Values represent mean ± SD and median [IQR].  Standardized β (Std. β) and P-value were obtained by univariate










Female recipients more often used a statin, and had higher percentages of panel reactive
antibodies (PRA; p<0.01).
Recipient renal function by a break-up in donor gender is shown in table 3.  Among the
recipients of a female kidney the majority was male (p<0.01 compared to recipients of male
donors), as also reﬂected by a higher BSA and 24 hour creatinine excretion among these
recipients. Early after transplantation, mean GFR and ERPF were similar for recipients of male
Total Male donor Female donor P value
Short term recipient outcome
N 293 131 162 -
Male recipients (%) 60 45 73 <0.01
Age (years) 44 ± 15 43 ± 16 44 ± 14 NS
BSA (m2) 1.93 ± 0.21 1.91 ± 0.21 1.95 ± 0.21 NS
Creatinine excretion (µmol/24h) 12.4 ± 3.6 11.9 ± 3.5 12.9 ± 3.6 0.029
MAP (mmHg) 104 ± 12 103 ± 12 105 ± 11 NS
GFR (mL/min) 59 ± 17 61 ± 18 58 ± 16 NS
ERPF (mL/min) 239 ± 64 247 ± 66 233 ± 62 NS
GFR/BSA (mL/min/1.73m2) 53 ± 16 56 ± 17 52 ± 15 0.033
ERPF/BSA (mL/min/1.73m2) 216 ± 60 224 ± 61 209 ± 58 0.027
FF (%) 25 ± 5 25 ± 4 25 ± 5 NS
UPE (g/24h) 0.3 [0.2-0.4] 0.2 [0..02-0.4] 0.3 [0.2-0.5] <0.01
∆GFR (mL/min) 2 ± 16 0 ± 15 3 ± 16 0.033
∆ERPF (mL/min) 23 ± 58 19 ± 56 27 ± 60 NS
Five year recipient outcome
N 88 31 57 NS
Male recipients (%) 65 58 68 NS
Age (years) 46 ± 14 43 ± 13 46 ± 14 NS
BSA (m2) 1.95 ± 0.19 1.98 ± 0.20 1.94 ± 0.18 NS
Creatinine excretion (µmol/24h) 12.7 ± 3.7 13.1 ± 4.1 12.5 ± 3.6 NS
MAP (mmHg) 100 ± 11 100 ± 12 101 ± 11 NS
GFR (mL/min) 57 ± 18 55 ± 23 57 ± 16 NS
ERPF (mL/min) 223 ± 59 213 ± 66 229 ± 54 NS
GFR/BSA (mL/min/1.73m2) 50 ± 16 48 ± 19 51 ± 14 NS
ERPF/BSA (mL/min/1.73m2) 200 ± 51 191 ± 55 204 ± 49 NS
FF (%) 25 ± 5 26 ± 6 25 ± 4 NS
UPE (g/24h) 0.2 [0.0-0.4] 0.2 [0.0-0.4] 0.2 [0.0-0.4] NS
∆GFR (mL/min) 1 ± 17 -3 ± 20 3 ± 15 NS
∆ERPF (mL/min) 9 ± 58 -9 ± 53 19 ± 58 0.032
Table 3: short term and 5 year recipient outcome by a break-up by donor gender.
Values represent mean ± SD and median [IQR].  P-Values in table represent male compared to female values.
UPE: urinary protein excretion; ∆GFR: recipient GFR – donor single kidney GFR. 
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and female donor kidneys. The rise in single kidney GFR (∆GFRST) was higher in kidneys of
female origin, but the resulting GFR/BSA and ERPF/BSA were higher in kidneys of male origin.
Recipients of a female kidney had slightly higher urinary protein excretion at this point in
time.
Five year post transplantation no diﬀerence in renal function between recipients of male
and female kidneys was observed, neither for the nominal value, nor after correction for 
Total Male recipient Female recipient P value
Short term recipient outcome
N 293 177 166 -
Male recipients (%) 45 33 62 <0.01
Age (years) 44 ± 15 43 ± 14 44 ± 15 NS 
BSA (m2) 1.93 ± 0.21 2.00 ± 0.18 1.83 ± 0.22 <0.01
Creatinine excretion (µmol/24h) 12.4 ± 3.6 13.7 ± 3.4 10.5 ± 2.9 <0.01
MAP (mmHg) 104 ± 12 105 ± 11 103 ± 12 NS
GFR (mL/min) 59 ±17 60 ± 17 58 ± 16 NS
ERPF (mL/min) 239 ± 64 246 ± 66 229 ± 59 0.03
GFR/BSA (mL/min/1.73m2) 53 ± 13 52 ± 15 56 ± 16 NS
ERPF/BSA (mL/min/1.73m2) 216 ± 60 214 ± 62 218 ± 56 NS
FF (%) 25 ± 5 25 ± 5 26 ± 4 NS
UPE (g/24h) 0.3 [0.2-0.4] 0.3 [0.2-0.5] 0.2 [0.0-0.4] NS
∆GFR (mL/min) 2 ± 16 4 ± 16 -2 ± 15 <0.01
∆ERPF (mL/min) 23 ± 58 33 ± 59 9 ± 55 <0.01
Five year recipient outcome
N 88 57 31 -
Male recipients (%) 35 32 42 NS
Age (years) 46 ± 14 45 ± 14 49 ± 12 NS
BSA (m2) 1.95 ± 0.18 2.02 ± 0.14 1.84 ± 0.20 <0.01
Creatinine excretion (µmol/24h) 12.7 ± 3.7 14.1 ± 3.6 10.1 ± 2.4 <0.01
MAP (mmHg) 100 ± 11 101 ± 10 100 ± 13 NS
GFR (mL/min) 57 ± 18 59 ± 20 53 ± 15 NS
ERPF (mL/min) 223 ± 59 233 ± 60 205 ± 53 NS
GFR/BSA (mL/min/1.73m2) 50 ± 16 51 ± 16 49 ± 16 NS
ERPF/BSA (mL/min/1.73m2) 200 ± 51 203 ± 48 195 ± 58 NS
FF (%) 25 ± 5 25 ± 5 26 ± 6 NS
UPE (g/24h) 0.2 [0.0-0.4] 0.2 [0.0-0.5] 0.0 [0.0-0.2] <0.01
∆GFR (mL/min) 1 ± 17 4 ± 17 -5 ± 15 0.01
∆ERPF (mL/min) 9 ± 58 23 ± 59 -16 ± 47 <0.01
Table 4: short term and 5 year recipient outcome by a break-up by recipient gender.
Values represent mean ± SD and median [IQR].  P-Values in table represent male compared to female values.










recipient BSA. However, the rise from pre-donation values for ERPF (∆ERPFLT) was larger in
kidneys from female origin. A corresponding diﬀerence for GFR did not reach statistical
signiﬁcance at ﬁve year outcome.
Renal function by donor and recipient gender
To evaluate the eﬀect of recipient gender on recipient renal function, table 4 shows recipient
renal function by a break-up in recipient gender. Male recipients received a kidney of female
origin more often than female recipients (p<0.01). Male recipients were generally larger than
female recipients, reﬂected by a higher BSA and 24 hour creatinine excretion. Although crude
ERPF was higher in male recipients, renal function corrected for BSA was similar between
men and women. However, the rise from pre-donation values for GFR and ERPF (∆GFRST and
∆ERPFST) was larger in male recipients.
Five year post-donation a similar pattern was seen. Furthermore, male recipients showed
higher urinary protein excretion than female recipients. 
Impact of donor and recipient body surface area and their ratio on renal function
Female donors donate more often to male recipients and vice versa, which results in a
relatively large body size disparity between donor and recipient. To analyse for the eﬀect of
body size disparity on recipient outcome we calculated donor/recipient BSA ratio. Mean donor
to recipient BSA ratio for female donors was 0.97 ± 0.12 compared to 1.06 ± 0.13 for male
donors (p<0.01). Table 5 shows recipient renal function early and late after transplantation
according to BSA-ratio. Both early and long term after transplantation, the net performance
of kidneys from donors who are smaller than their recipient (BSA-ratio <1) was similar to
kidneys from donors larger than their recipients. Early after donation, GFR/BSA and ERPF/BSA
were signiﬁcantly lower in recipients of a kidney from a small donor. This diﬀerence was not
TabTable 5: recipient renal function short and long term after transplantation by a break-up in BSA-ratio. BSA-
ratio < 1 reﬂects a couple with a donor smaller than its recipient and vice versa. 
Values represent mean ± SD or median [IQR]. P-Values in table represent BSA-ratio<1 compared to BSA-ratio 
≥ 1 values. BSA-ratio: donor BSA / recipient BS; ∆GFR: recipient GFR – donor single kidney GFR; UPE: urinary
protein excretion. 
Short term outcome Five year outcome
BSA ratio <1 ≥1 P value <1 ≥1 P value
N 146 147 - -
GFR (mL/min) 59 ± 17 60 ± 18 NS 59 ± 19 54 ± 17 NS
GFR/BSA (mL/min/1.73m2) 49 ± 14 57 ± 16 <0.01 51 ± 16 50 ± 16 NS
ERPF (mL/min) 238 ± 63 242 ± 67 NS 228 ± 61 218 ± 56 NS
ERPF/BSA (mL/min/1.73m2) 201 ± 54 231± 62 <0.01 197 ± 50 203 ± 53 NS
∆GFR (mL/min) 3.7± 16 -0.2 ± 15 0.03 4.4 ± 17 -3.0 ± 16 0.04
∆GFR (mL/min) 32 ± 59 15 ± 57 0.02 20 ± 62 -3.0 ± 51 0.06
FF (%) 25 ± 4 24 ± 5 NS 25 ± 4 25 ± 6 NS
MAP (mmHg) 105 ± 15 102 ± 12 NS 101 ± 11 100 ± 12 NS
UPE (g/24h) 0.3 [0.2] 0.2 [0.3] <0.01 0.2 [0.2] 0.2 [0.4] NS
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found any more at ﬁve years. The change in renal function from pre-donation values was
signiﬁcantly larger in kidneys from donors smaller than their recipients for both GFR and ERPF,
for the short and long term (table 5, ﬁgure 1). Also, this was associated with slightly higher
urinary protein loss early after transplantation (p<0.01), that was no longer apparent on ﬁve
year follow-up. There were no diﬀerences in the occurrence of rejection, graft failure or death
of the recipient between the groups (data not shown). These data indicate that kidneys from
donor with smaller body dimensions increase there function after transplantation more than
kidneys of larger donors.
Combined impact of donor and recipient gender and body size dimensions on recipient
outcome
Since the abovementioned results might be explained by either gender diﬀerences or
diﬀerences in body size dimensions between the genders or their combination, we also
analysed for the combined eﬀects of these factors. 
Short term recipient renal function by a break-up in donor and recipient gender is shown
in ﬁgure 2. Although ERPF showed a decrease over the categories (p<0.01, ANOVA), ERPF/BSA
was similar, as were GFR and GFR/BSA. 
To analyse for the combined eﬀect of donor and recipient gender and body size
Figure 1: Change in single kidney GFR early after donation (short term ∆GFRST; left panel) and 5 year after 
donation (∆GFRLT right panel) by a break-up by the ratio of donor to recipient BSA. (BSA-ratio) *: p<0.05 for 
diﬀerence between the groups with BSA ratio < 1 (donor < recipient) vs. BSA-ratio >1 (donor > recipient). 
Figure 2: Short term recipient outcome by a break-up in donor and recipient gender. Categories represent donor










dimensions we used backward linear regression. Donor and recipient gender, BSA-ratio and
24 hour creatinine excretion were entered in the model. To adjust for transplantation related
factors, all factors with a P-value ≤0.1 in univariate analysis (table 2) were entered in the
backward regression model as well. For ∆GFRST the model consisted of BSA-ratio (standardized
[std.] β -0.20), occurrence of rejection (std. β -0.16), prednisolone dose (std. β 0.17), use of
mycophenolate mofetil (std. β 0.19 ), use of a calcium channel blocker (std. β 0.18) and total
cholesterol level (std. β -0.16); adjusted R2 0.19, p<0.01. For ∆ERPFST the model consisted of
BSA-ratio (std. β -0.24), cyclosporine through level (std. β -0.26), pre-emptive character of the
procedure (std. β 0.15), use of calcium channel blocker (std. β 0.32) and total cholesterol level
(std. β -0.17); adjusted R2 0.27, p<0.01. In both models, donor and recipient gender were lost
as predictors. 
For long term recipient renal function, the group sizes for the diﬀerent gender
combinations were too small to perform backward regression analysis. In linear regression,
the strongest prediction of ∆GFR was provided by BSA-ratio (adjusted R2 0.08, p<0.01). For
∆ERPF, the strongest prediction was obtained by 24 hour creatinine excretion (adjusted R2
0.09, p<0.01). 
Discussion
In this study we demonstrate that female kidneys perform as well as male kidneys after living
kidney donation. Gender eﬀects on recipient outcome can be explained by diﬀerences in body
size between the sexes. The balance between donor and recipient body size appears to play
a more important role than gender diﬀerences. Grafts of donors smaller than their recipients
have a lower nominal GFR before donation, but increase their function after transplantation
more in response to the recipient body dimensions than grafts from a larger donor. Thus, the
kidney adapts to recipient body size, independent of donor and recipient gender. 
This study is the ﬁrst to evaluate eﬀects of gender and body size disparity in living kidney
donation with measurement of GFR in donor and recipient, in the short- and long-term follow-
up. Previous studies on the eﬀects of body and renal size disparity in renal transplantation
focused mainly on hard end-points such as delayed graft function, donor and graft survival,
and recipient estimated renal function (eGFR). Here we chose to evaluate recipient renal
function and especially post-transplantation gain in renal function calculated from the renal
function before donation. Our living kidney donor program provides us with detailed data on
donor renal function. Unfortunately, we have no data on graft weight. Therefore, we used
donor BSA as a substitute, since BSA has been shown to have a good correlation with kidney
weight (19). Also, in this study we showed a strong relation between donor BSA and renal
function. 
In our population, body size disparity was shown to have substantial eﬀects on gain in
graft function after transplantation, independent of donor and recipient gender. Kidneys
derived from donors smaller than their recipient gain more renal function than kidneys from
larger donors which results in similar renal function in the long term. Thus, the kidney is able
to adapt to its new body size, living up to the new metabolic demands. This does not seem
to occur at the expense of hyperﬁltration, since no diﬀerence in ﬁltration fraction was
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observed (table 4). Rather, adaptation occurs proportionally for perfusion and ﬁltration, as
shown from the stable ﬁltration fraction. Probably, the superior quality and low damage
impact in the living transplant kidney enables the graft to serve demand by an increase in
perfusion and hence ﬁltration, rather than ﬁltration pressure. Furthermore, in the remnant
donor kidney the capability to respond to dopamine post-donation is preserved, suggesting
that the adaptative response in the donor has not pushed the kidney to the limits of its reserve
capacity.  However, in the short term a slightly higher urinary protein excretion was seen,
which may reﬂect short term stress from a graft which is forced to meet the recipient
demands. In the interpretation of renal hemodynamics, however, it should be noted that
transplantation related factors, like the use of cyclosporine, could impact on renal
hemodynamics and thus mask, or annihilate a possible hyper ﬁltration pattern. For neither
short- nor long-term were diﬀerences seen in absolute renal function between recipient with
a BSA-ratio <1 and ≥1. 
Previous studies have demonstrated a lower (graft) survival and lower renal function in
recipients receiving a female kidney (1;2;7;20). Others showed a deﬁnite inﬂuence of recipient
gender (21;22). Gender diﬀerences were explained by higher metabolic demands in males
(10;22), and graft/recipient weight ratio (4;6;7;10;11). In our study, we attribute gender-
related diﬀerences to diﬀerences in body size and thus BSA. Although previous studies showed
that BSA indexing cannot resolve gender diﬀerences (17;23), our indexing of GFR for BSA did
result in similar renal function for both sexes. 
Studies on the eﬀects of body size disparity have found more delayed graft function,
lower renal function, higher mortality and graft loss due to diﬀerences in body size in deceased
(6;8;9) and living donor transplantation (5;11). On the other hand, some studies did not show
any eﬀect on medium to long-term outcome (22;24;25). Diﬀerences between our and
previous ﬁndings may be explained by the use of actual GFR measurement instead of
calculation of eGFR or creatinine clearance. The relatively short duration of follow-up may
play a role as well. Giral et al.  showed detrimental eﬀects of a low kidney weight to recipient
weight ratio on long-term renal function, when eﬀects were ﬁrst seen after seven years of
follow-up (6). Another explanation could be that we restricted analyses to recipients of a living
donor kidney. Due to better organ viability compared to deceased donor kidneys with less
ischemia-reperfusion injury, recipient outcome of living kidney donor organs is superior to
outcome of deceased donor organs. This low damage impact and superior quality could mask
gender and body size-related eﬀects. 
In this study we saw no detrimental eﬀects of mismatch in gender or body size at the
ﬁve year follow-up. However, we do ﬁnd slightly higher urinary protein excretion in kidneys
of small donors early after transplantation. This may be an early sign of a maladaptive
response, but this diﬀerence is lost at ﬁve year. Possibly the living kidney can overcome the
stress of the initial response to injury related to retrieval, short preservation and reperfusion
at time of transplantation. Further damage may occur many years after transplantation. Thus,
more reprised analyses are needed to elucidate eﬀects of body size and gender disparity on
the very long term.
Limitations of this study are the homogenous population, the single center character and










slightly overweight and only 11% of donors was older than 60 years at time of donation. This
hampers the generalizability of our data to populations where weight excess is more common
among donors, or to populations with a higher donor age. Furthermore, generalizability to
populations with endemic metabolic disorders is not feasible. 
In summary, this study shows that with respect to recipient renal function female kidneys
perform as well as male kidneys in living kidney donation. Kidneys of living donors adapt to
the recipient’s body size and demands without detrimental eﬀects in renal function and
outcome up to mid-long term. 
137
Kidneys adapt to body size irrespective of gender
8
Reference List
1 Vereerstraeten P, Wissing M, De Pauw L, Abramowicz D, Kinnaert P. Male recipients of kidneys from female donors 
are at increased risk of graft loss from both rejection and technical failure. Clin Transplant 1999 Apr;13(2):181-6.
2 Zeier M, Dohler B, Opelz G, Ritz E. The eﬀect of donor gender on graft survival. J Am Soc Nephrol 2002 
Oct;13(10):2570-6.
3 Kasiske BL, Umen AJ. The inﬂuence of age, sex, race, and body habitus on kidney weight in humans. Arch Pathol Lab 
Med 1986 Jan;110(1):55-60.
4 Douverny JB, Baptista-Silva JC, Pestana JO, Sesso R. Importance of renal mass on graft function outcome after 12 
months of living donor kidney transplantation. Nephrol Dial Transplant 2007 Dec;22(12):3646-51.
5 el Agroudy AE, Hassan NA, Bakr MA, Foda MA, Shokeir AA, Shehab el-Dein AB. Eﬀect of donor/recipient body weight 
mismatch on patient and graft outcome in living-donor kidney transplantation. Am J Nephrol 2003 Sep;23(5):294-
9.
6 Giral M, Foucher Y, Karam G, Labrune Y, Kessler M, de Ligny BH, et al. Kidney and recipient weight incompatibility 
reduces long-term graft survival. J Am Soc Nephrol 2010 Jun;21(6):1022-9.
7 Jacobs SC, Nogueira JM, Phelan MW, Bartlett ST, Cooper M. Transplant recipient renal function is donor renal mass- 
and recipient gender-dependent. Transpl Int 2008 Apr;21(4):340-5.
8 Kasiske BL, Snyder JJ, Gilbertson D. Inadequate donor size in cadaver kidney transplantation. J Am Soc Nephrol 2002 
Aug;13(8):2152-9.
9 Moreso F, Seron D, Anunciada AI, Hueso M, Ramon JM, Fulladosa X, et al. Recipient body surface area as a predictor 
of posttransplant renal allograft evolution. Transplantation 1998 Mar 15;65(5):671-6.
10 Oh CK, Jeon KO, Kim HJ, Kim SI, Kim YS, Pelletier SJ. Metabolic demand and renal mass supply aﬀecting the early 
graft function after living donor kidney transplantation. Kidney Int 2005 Feb;67(2):744-9.
11 Poggio ED, Hila S, Stephany B, Fatica R, Krishnamurthi V, del Bosque C, et al. Donor kidney volume and outcomes 
following live donor kidney transplantation. Am J Transplant 2006 Mar;6(3):616-24.
12 Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, et al. The eﬀects of dietary protein restriction and 
blood-pressure control on the progression of chronic renal disease. Modiﬁcation of Diet in Renal Disease Study 
Group. N Engl J Med 1994 Mar 31;330(13):877-84.
13 Neugarten J, Acharya A, Silbiger SR. Eﬀect of gender on the progression of nondiabetic renal disease: a meta-analysis. 
J Am Soc Nephrol 2000 Feb;11(2):319-29.
14 Wiinberg N, Hoegholm A, Christensen HR, Bang LE, Mikkelsen KL, Nielsen PE, et al. 24-h ambulatory blood pressure 
in 352 normal Danish subjects, related to age and gender. Am J Hypertens 1995 Oct;8(10 Pt 1):978-86.
15 Muller V, Szabo A, Viklicky O, Gaul I, Portl S, Philipp T, et al. Sex hormones and gender-related diﬀerences: their 
inﬂuence on chronic renal allograft rejection. Kidney Int 1999 May;55(5):2011-20.
16 Apperloo AJ, de ZD, Donker AJ, de Jong PE. Precision of glomerular ﬁltration rate determinations for long-term slope 
calculations is improved by simultaneous infusion of 125I-iothalamate and 131I-hippuran. J Am Soc Nephrol 1996 
Apr;7(4):567-72.
17 Visser FW, Muntinga JH, Dierckx RA, Navis G. Feasibility and impact of the measurement of extracellular ﬂuid volume 
simultaneous with GFR by 125I-iothalamate. Clin J Am Soc Nephrol 2008 Sep;3(5):1308-15.
18 DuBois B, DuBois E. A formula to estimate the approximate surface area if height and weight be known. Archives of 
Internal Medicine 1916;(17):863-71.
19 Nyengaard JR, Bendtsen TF. Glomerular number and size in relation to age, kidney weight, and body surface in 
normal man. Anat Rec 1992 Feb;232(2):194-201.
20 Kwon OJ, Kwak JY. The impact of sex and age matching for long-term graft survival in living donor renal 
transplantation. Transplant Proc 2004 Sep;36(7):2040-2
21 Oh CK, Kim SJ, Kim JH, Shin GT, Kim HS. Inﬂuence of donor and recipient gender on early graft function after living 
donor kidney transplantation. Transplant Proc 2004 Sep;36(7):2015-7.
22 Oh CK, Lee BM, Jeon KO, Kim HJ, Pelletier SJ, Kim SI, et al. Gender-related diﬀerences of renal mass supply and 
metabolic demand after living donor kidney transplantation. Clin Transplant 2006 Mar;20(2):163-70.
23 Turner ST, Reilly SL. Fallacy of indexing renal and systemic hemodynamic measurements for body surface area. Am 
J Physiol 1995 Apr;268(4 Pt 2):R978-R988.
24 Gaston RS, Hudson SL, Julian BA, Laskow DA, Deierhoi MH, Sanders CE, et al. Impact of donor/recipient size matching 
on outcomes in renal transplantation. Transplantation 1996 Feb 15;61(3):383-8.
25 Vianello A, Calconi G, Amici G, Chiara G, Pignata G, Maresca MC. Importance of donor/recipient body weight ratio 





















Inﬂuence of living donor risk proﬁle





Background: Due to more liberal donor selection, current living kidney donors are older, more
overweight and even hypertensive, which might impact recipient outcome. Here we evaluate
the inﬂuence of the pre-donation donor risk proﬁle on recipient renal outcome. 
Methods: Evaluated were 113 donor-recipient pairs. All had GFR measurements 
(125I-iothalamate) and ERPF measurements (131I-hippurate) one year and ﬁve year post-
transplantation.
Results: Overall recipient GFR at one and ﬁve year was good (59±15 and 58±19 mL/min).
Donor GFR and ERPF associated positively to recipient GFR and ERPF at one and ﬁve years
post-transplantation (R 0.30 and 0.39 for GFR, R 0.36 and 0.32 for ERPF). Donor age associated
negatively to recipient GFR and ERPF at ﬁve year post-transplantation (R -0.24 and -0.20).
Donor BMI, blood pressure and smoking behavior were not associated to recipient outcome.
There were no diﬀerences in one and ﬁve year GFR and ERPF between recipients of older,
overweight, hypertensive or smoking donors compared to recipients of younger, normal
weigh, normotensive or non smoking donors. 
Conclusion: In a well-screened population the donor risk proﬁle exerts only a modest eﬀect
on recipient outcome in the medium term. This provides opportunities to expand the living











Living kidney donors have become increasingly important in kidney transplantation. To enlarge
the donor pool, selection of potential donors became more liberal. Previously, potential
donors had to live up to strict selection criteria, and represented the healthiest part of the
population (1). Kidney donors nowadays, however, are older, more overweight, and even
slightly hypertensive (2). These characteristics are all established risk factors for the
development of kidney function impairment. Higher donor age is a risk factor for worse kidney
function and worse transplant outcome for transplants from deceased donors. Moreover,
higher donor age negatively inﬂuences recipient estimated kidney function in living kidney
donation (3-6). Hypertension (7-10), overweight (11-13) and smoking (14-19) are also
associated with an increased risk for progressive kidney function loss in native as well as
transplanted kidneys. However, there is no data on the impact of hypertension, overweight
and smoking in the living donor on kidney function and transplant outcome in the recipients. 
Therefore, in the current study, we evaluate the inﬂuence of the living donor risk
proﬁle, in particular with respect to age, blood pressure, smoking behavior and body mass
index (BMI), on recipient kidney function one and ﬁve year post-transplantation, in a single
center cohort.
Methods
We evaluated 113 pairs of living donors and their recipients, who were transplanted in the
University Medical Center Groningen between 1988 and 2006. Kidney function was measured
as described below, four months prior to donation for the donors, and one and ﬁve years
after transplantation for the recipients. Procedures were conducted in accordance with the
Helsinki declaration. 
Routine donor screening
In donors, the basal kidney function measurement is extended by two hours in which the
kidney function is stimulated by dopamine, to measure the so called reserve capacity. Donors
were eligible to donate with a glomerular ﬁltration rate (GFR) > 80 mL/min. For older subjects
or small females, an exception could be made based on a good response to dopamine
infusion, with a stimulated GFR > 80 mL/min. Since 2002, donors who use antihypertensive
drugs are allowed to donate. There is no maximum for age. A maximum of two
antihypertensive drugs is tolerated, provided ambulatory blood pressure does not exceed
150/85 mmHg. Blood pressure was measured for 30 minutes during kidney function
measurement, with a semi-automated device (Dinamap; Criticon Inc, Tampa, FL). Donors with
a body mass index (BMI) exceeding 30 kg/m2 are encouraged to lose weight. Potential donors
with a disturbed glucose tolerance test are rejected, as well as donors with severe
atherosclerotic lesions. Smoking behavior has never been a selection criterion at our center.
Kidney function measurement
Glomerular ﬁltration rate (GFR) was measured by constant low-dose infusion of the radio-
labelled tracer 125I iothalamate, as originally described by Donker, and more recenly by Visser
et al. (20-22). Simultaneously, eﬀective renal plasma ﬂow (ERPF) was measured as the
clearance of 131I-hippurate. For the measurements, subjects were seated in a quiet room in,
in a semi-supine position. After drawing a blank blood sample, the priming solution containing
0.04 mL/kg body weight of the infusion solution, (0.04 MBq of 125I iothalamate and 0.03 MBq
of 131I-hippurate per mL saline) plus an extra 0.6 MBq of 125I iothalamate, was given, followed
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by constant infusion at twelve mL/h. To attain stable plasma concentrations of both tracers,
a two hour stabilization period followed, after which the clearance periods start. Clearances
were measured over the next two hours and calculated as (U*V)/P and (I*V)/P, respectively.
U*V represents the urinary excretion of the tracer, I*V represents the infusion rate of the
tracer, and P represents the tracer value in plasma at the end of each clearance period. GFR
was calculated from UV/P of 125I iothalamate and corrected for voiding errors by multiplying
the urinary clearance of 125I iothalamate with the ratio of the plasma and urinary clearance
of 131I-hippurate. The day-to-day variability for GFR is 2.5%. 
Treatment regimen after transplantation
From January 1988 to February 1993, standard immunosuppression consisted of the
following: cyclosporine standard formulation (Sandimmune; Novartis Pharma b.v., Arnhem,
The Netherlands; 10 mg/kg; trough levels of 175–200 mg/L for the ﬁrst three months, 150
mg/L between three and twelve months post-transplant and 100 mg/L thereafter) combined
with prednisolone (starting with 20 mg/day, rapidly tapered to 10 mg/day). From March 1993
to May 1997, standard immunosuppression consisted of cyclosporine microemulsion (Neoral;
Novartis Pharma b.v., Arnhem, The Netherlands; 10 mg/kg; trough levels idem) and
prednisolone. From May 1997 to date, Mycophenolate mofetil (Cellcept; Roche b.v., Woerden,
The Netherlands; 2 g/day) was added.
Calculations 
Mean arterial pressure (MAP), was calculated as: MAP = (1/3[systolic pressure – diastolic
pressure] + diastolic pressure). Donor single kidney GFR was calculated as: (basal GFR / 2). 
Data analyses
Analyses were performed using PASW statistics version 18.0 and GraphPad Prism version 5
for Windows. Data are given as mean ± standard deviation or median [IQR]. Independent
samples t Test, One-Way ANOVA and Mann-Whitney U test were used to analyze diﬀerences
between groups. 
Data on underlying kidney disease, pre-emptive character of the transplantation,
ischemia times, HLA mismatches, occurrence of rejection, immunosuppressant and
antihypertensive drug use and statin use were collected for all recipients. To evaluate which
transplantation related factors were associated with one and ﬁve year recipient GFR and ERPF,
we performed univariate regression analysis. Factors with a P-value ≤ 0.05 in univariate
analysis were entered into a backward linear regression analysis combined with donor age,
BMI, GFR and MAP, and were removed in successive steps at a threshold of P-value ≤ 0.05. 
Results
Donor and recipient characteristics are shown in tables 1 and 2. Of the 195 recipients who
received a kidney more than ﬁve years ago, 49 recipients had no ﬁve year follow-up due to
death of the recipient (n=12), graft failure (n=14), or unknown reasons (n=21). There was no
diﬀerence in donor and recipient baseline characteristics between pairs available and
unavailable for follow-up. Of all 113 recipients, 28% went through a rejection episode and 6
and 3% developed graft failure and died more than ﬁve year after transplantation.
Transplantation related factors, evolution after transplantation, drug regimen and
use of antihypertensive drugs are listed in table 3, as well as univariate associations between










Recipient outcome by donor risk factors
Occurrence of donor risk factors is shown in table 1. Although only 10-15% of donors were
above 60 years of age, obese or hypertensive, 55% had one risk factor and 15% had two risk
factors combined. Recipient kidney function at one and ﬁve year post-donation by a break-
up in donor risk factors is shown in ﬁgure 1. No signiﬁcant diﬀerences were found between
recipients of donors with or without the diﬀerent risk factors, albeit numerical diﬀerences
were observed for donor age and hypertension. For neither of the time points, a diﬀerence
in the occurrence of rejection, graft failure and recipient death could be detected between
the groups.
Regression analysis
In univariate regression analysis, recipient glomerular ﬁltration rate (GFR) at one and ﬁve year
post-transplantation positively related to donor pre-donation GFR (R 0.30 and 0.39, both
p<0.01). Similarly, recipient ERPF at one and ﬁve year after transplantation related to donor
ERPF (R 0.36 and 0.32, both p<0.01). Donor age correlated negatively to recipient GFR and
Total
N (% male) 113 (39)
Age at Unx (years) 49 ± 10
Age > 50 years (n, %) 16 (15)
BMI (kg/m2) 25 ± 4
Obesity (n, %) 11 (10)
MAP (mmHG) 92 ± 9
Hypertension (n, %) 18 (16)
Smoking behavior
Current smoking (n, %) 37 (33)
Former smoking (n, %) 28 (25)
No smoking (n, %) 48 (42)
GFR (mL/min) 114 ± 19
ERPF (mL/min) 432 ± 80
Risk factors
0 risk factors (n, %) 30 (26)
1 risk factor (n, %) 62 (55)
2 risk factors (n, %) 17 (15)
3 risk factors (n, %) 4 (4)
Table 1: pre-donation donor characteristics and donor risk proﬁle.
Values represent N (%), mean ± SD or median [IQR]. Obesity is deﬁned as BMI>30 kg/m2, hypertension as donor
antihypertensive drug use or a blood pressure > 150/85 mmHg. 
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ERPF at ﬁve year post-donation (R -0.24 and -0.20, p<0.01), but not to one year kidney
function. Donor BMI and MAP did not associate to recipient outcome at one or ﬁve years
post-transplantation. 
One year follow-up Five year follow-up
Duration of follow-up (years) 1.1 ± 0.2 5.1 ± 0.2
N (% male) 113 (60) 113 (60)
Age (years) 41 ± 13 45 ± 13
BMI (kg/m2) 26 ± 4 26 ± 5
Systolic BP (mmHg) 140 ± 15 134 ± 17
Diastolic BP(mmHg) 85 ± 11 82 ± 10
MAP (mmHG) 103 ± 11 99 ± 12
GFR (mL/min) 59 ± 15 58 ± 19
ERPF (mL/min) 238 ± 53 226 ± 62
Urinary protein excretion (g/24h) 0.2 [0.0-0.3] 0.2 [0.0-0.4]
Table 2: recipient characteristics at one and ﬁve year post transplantation. 
Values represent N (%), mean ± SD or median [IQR].
Figure 1: one and ﬁve year recipient GFR (left bars) and ERPF (right bars) by a break-up in donor characteristics:
a) donor age, b) donor BMI c) donor smoking behavior and d) donor hypertensive status. Bars represent median










Five year outcome Five year outcome
GFR ERPF GFR ERPF
Value Std. β P value Std. β P value Std. β P value Std. β P value
Primary renal disease (n, %)
Primary glomerular disease 12 (11) Ref Ref Ref Ref Ref Ref Ref Ref
Glomerulonephritis 32 (28) -0.04 0.69 -0.01 0.94 -0.06 0.50 -0.01 0.96
Tubular interstitial disease 3 (3) -0.01 0.93 -0.01 0.92 0.11 0.23 0.01 0.95
Polycystic kidney disease 17 (15) -0.05 0.62 -0.09 0.37 -0.11 0.23 -0.09 0.34
Dysplasia and hypoplasia 19 (17) 0.12 0.22 0.22 0.02 0.15 0.11 0.14 0.16
Renovascular disease 13 (11) -0.15 0.12 -0.13 0.19 -0.10 0.32 -0.07 0.47
Diabetes Mellitus 3 (3) -0.03 0.75 -0.06 0.67 -0.14 0.14 -0.10 0.30
Other or unknown cause 14 (12) -0.11 0.25 -0.07 0.47 0.03 0.80 -0.01 0.91
Related donor (n, %) 81 (72) 0.06 0.52 -0.04 0.67 0.03 0.77 -0.01 0.91
Pre-emptive procedure (n, %) 34 (30) -0.06 0.51 -0.12 0.23 -0.09 0.33 -0.09 0.36
Previous transplant (n, %) 8 (7) -0.03 0.75 -0.10 0.30 0.01 0.96 0.02 0.86
Warm ischemia times (min) 40 ± 18 0.11 0.23 0.08 0.38 0.10 0.32 0.04 0.67
Cold ischemia times (min) 157 ± 83 -0.12 0.19 -0.15 0.11 -0.17 0.08 -0.13 0.18
HLA-AB mismatches (n) 1.8 ± 1.1 -0.02 0.88 -0.02 0.83 -0.03 0.76 -0.06 0.67
HLA-DR mismatches (n) 0.8 ± 0.7 -0.18 0.06 -0.17 0.07 -0.14 0.15 -0.19 0.05
Acute rejection (n, %) 33 (29) -0.08 0.44 -0.10 0.32 -0.09 0.37 -0.01 0.92
Drug use
Cyclosporine (n, %) 46 (41) 0.02 0.80 0.09 0.35 -0.06 0.53 0.09 0.36
Trough-level (µg/L) 95 ± 45 -0.03 0.82 0.15 0.18 -0.21 0.15 -0.20 0.18
Tacrolimus (n, %) 18 (16) -0.03 0.80 -0.09 0.37 0.08 0.39 -0.06 0.50
Trough-level (µg/L) 8.0 ± 3.0 -0.41 0.04 -0.14 0.50 -0.22 0.41 -0.24 0.37
Prednisolone dose (mg/day) 9.0 ± 1.6 -0.02 0.90 0.00 0.99 0.02 0.83 0.03 0.79
Azathioprine (n, %) 17 (15) -0.13 0.26 -0.17 0.12 -0.12 0.22 -0.09 0.38
Mycophenolate  mofetil (n, %) 89 (79) 0.11 0.32 0.15 0.17 0.12 0.23 0.05 0.62
Number of antihypertensives 1.7 ± 1.0 0.06 0.60 0.00 0.98 -0.33 0.01 -0.25 0.01
ACE-inhibitor or 
AII-antagonist (n, %)
59 (52) 0.25 0.02 0.26 0.02 -0.13 0.19 -0.03 0.76
β-blocker 71 (63) -0.12 0.27 -0.22 0.05 -0.17 0.09 -0.17 0.10
Calcium channel blocker 23 (20) 0.13 0.24 0.10 0.40 -0.01 0.92 0.03 0.75
Statin 5.1 ± 1.2 -0.0- 0.36 -0.07 0.44 -0.12 0.20 -0.14 0.16
Total cholesterol (mmol/L; %) 52 (46) -0.03 0.82 -0.15 0.19 -0.01 0.94 -0.15 0.15
Table 3: Transplantation related characteristics, evolution post-transplantation and drug use in recipients. 
Values represent mean ± SD and median [IQR].  Standardized β (Std. β) and P-value were obtained by univariate
regression analysis with either recipient GFR or ERPF one or ﬁve year post-transplantation as dependent variable.
ACEi: angiotensin converting enzyme inhibitor; AII: angiotensin II.
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Combined eﬀect of donor characteristics
Univariate associations between transplantation related factors, post-transplantation
evolution and drug use and recipient GFR and ERPF are shown in table 3. To evaluate the
combined eﬀects of donor factors and transplantation related factors, linear regression was
used. For one-year recipient GFR, the strongest model was formed by solely the tacrolimus
trough level (std. β -0.42; adjusted R2 0.14; p<0.01). For recipient ERPF, the model contained
only donor ERPF (std. β 0.36; adjusted R2 0.12; p<0.01). For ﬁve-year recipient outcome, GFR
was best predicted by donor GFR and the number of antihypertensive drugs (std. β 0.36 and
-0.31; adjusted R2 0.22; p<0.01). Recipient ERPF was predicted by donor ERPF (std. β 0.32;
adjusted R2 0.10; p<0.01). Other donor risk factors and transplantation related factors had no
signiﬁcant inﬂuence in the abovementioned models.
Discussion
In this study, we evaluated the inﬂuence of living donor renal risk proﬁle, i.e. donor age, BMI,
smoking behavior and blood pressure, on recipient renal function. One-year recipient
outcome was solely related to donor kidney function and not to other donor characteristics.
For ﬁve-year recipient outcome, higher donor age associated recipient kidney function as
well, though in a negative manner. Overall recipient kidney function was good both in
recipients of high and of low risk donors.
This is the ﬁrst study that evaluates inﬂuence of the donor renal risk proﬁle on
recipient renal outcome in living kidney donation with detailed renal function measurements
in both donor and recipient. Although overall recipient renal function was good, with a GFR
of approximately 60 mL/min, we found a negative inﬂuence of higher donor age on recipient
renal outcome. 
Previous studies evaluating the importance of donor factors for recipient outcome
focused mainly on donor age. Though higher age is a risk factor for lower GFR in the recipient
(3,5,6,25,28), older donors are an important extension of the donor pool (4,23,24,29-31).
Here, we reported a negative association between donor age and recipient renal function, at
ﬁve year post-transplantation. However, quantitatively the eﬀect was modest, amounting to
an average 5 mL/min for each additional 10 years of donor age. Accordingly, neither at one
nor at ﬁve years post-transplantation the diﬀerence seen between recipients of older and
younger donors reached statistical signiﬁcance.
Donor overweight and/or obesity is associated with more delayed graft function,
more acute rejection and lower renal function in the recipient, although graft and patient
survival are similar (26,27). Here, we show no eﬀect of donor BMI on short-term outcome,
neither for kidney function nor for rejection or graft failure. 
Smoking is recognized as a potential risk factor for the development of CKD (15-
18). Smoking of the recipient prior to kidney transplantation increases the risk for graft loss
(32) and mortality (19). Autopsy studies suggested that smoking may aﬀect the renal
vasculature (14). Such lesions may not be reﬂected in renal function due to the large
compensatory capability of the kidney. Thus, donors who smoke may have mild, non-
detectable, kidney damage. Previously, Leunissen found that renal histological lesions amplify
the nephrotoxic eﬀects of calcineurin inhibiting drugs (33). Hereby, recipients of smoking
donors may bear more nephrotoxic eﬀects with subsequent graft damage. This is in line with
a study in lung transplant recipients, which showed a dose dependent association between
former smoking and the development of CKD after lung transplantation (34). Here, however,










relative good health of our living donors, who are selected for good renal function.
Issa et al. found that higher donor blood pressure was associated with lower
estimated GFR in the recipient (5). In our center, donors with pre-existent hypertension were
not accepted for donation before 2002, resulting in only a small number of recipients of
hypertensive donors with long term follow-up, which resulted in low power to detect an eﬀect
of donor blood pressure on long term recipient renal function. This low power may explain
the apparent lack of inﬂuence of donor blood pressure on long-term recipient outcome.
Alternatively, selection for a true GFR > 80 mL/min may have selected donors whose kidneys
are relatively resistant to the eﬀects of higher blood pressure, as suggested by our recent
observation that hypertensive donors have a renal outcome that is indistinguishable from
that in normotensive donors (35).
Our study has several limitations, the most important being the small sample size
of the follow-up cohort, and the mono-centric character, that may limit the generalizabllity
of our data. As our patients were predominantly Caucasian, the conclusions do not apply to
patients with African or other ethnicity. Furthermore, our follow-up may have been too short
to detect any detrimental eﬀects of donor characteristics, since Giral et al. recently showed
that detrimental eﬀects may not appear earlier than seven years post-donation (36).  
What are the implications of this study? Here, we evaluated the eﬀect of the donor
risk proﬁle on recipient renal outcome, i.e. the eﬀect of the use of more marginal living kidney
donors. Higher donor age, blood pressure and body mass index were associated with lower
recipient renal function. The eﬀects, however, were limited, and overall recipient renal
function was suﬃcient. Thus, in the population presented here, no major detrimental eﬀects
of the donor risk proﬁle were seen. However, caution is warranted in the interpretation of
these results. First, we would like to emphasize that donors at our centre undergo thorough
screening, with the use of gold standard renal function measurements, and the eligibility to
donate is based on a true GFR > 80 mL/min, or, in exceptional cases, like subjects older than
70 years of small females, with a GFR > 70 mL/min which responses very well to dopamine
infusion (stimulated GFR > 80 mL/min). Thus, accepted donors with one or more risk factors
represent a healthy subset of their peers, as also apparent from the small or absent impact
of the named risk factors on pre-donation renal function. So, even the older and hypertensive
donors presented in this study have good renal function. Mean BMI was 26, which may
hamper extrapolation to other populations, for instance United States donors, where the
proportion of overtly obese donors is considerable. Here, we choose the cutoﬀs for donor
age and BMI in according to the literature, a donor age of 60 years (3,23-25) and BMI of 30
kg/m2 (26,27). In our population, however, an age of 50 years and BMI of 25 kg/m2 creates
more equal sized groups. When we performed analyses with the latter cutoﬀs, we found
similar results as with the more severe cutoﬀs (data not shown). Based on our data, we
conclude that accepting living donors with extended criteria is a safe way to enlarge the donor
organ pool, without detrimental eﬀects for the recipient, provided that careful screening is
performed.
In summary, this study shows modest negative eﬀects of donor age, and no eﬀect
of donor BMI, blood pressure or smoking behavior on recipient renal outcome, with a good
overall recipient renal function. Therefore, we conclude that the change in donor
characteristics has not resulted in worse recipient outcome in the medium term. Studies with
more long term follow-up, in a donor population with more extended characteristics, are
necessary to ensure long term safety. 
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Since the ﬁrst successful transplantation in Boston, 1954, kidney transplantation has evolved
to the preferred treatment of end stage kidney failure, with superior quality of life and survival
compared to dialysis (1-5). While deceased donor organs have been the main source for
transplantation for many years, living kidney donors have become increasingly important in
many countries and constitute now half of the kidney transplants performed in the
Netherlands (6). As outcome after living donation is substantially better than with deceased
donor kidneys, the living donation program has become of major importance in renal
replacement therapy. Against the background of the persistent deceased donor shortage
many centers aim to maximize the living donor pool, without compromising donor safety.
Although living kidney donation is a safe procedure, the fact that the donor is left with a single
kidney renders him or her more vulnerable to injury or functional loss of the remnant kidney.
Therefore, in general, potential donors are obliged to have excellent kidney function, and also
be in excellent health to be accepted for kidney donation. Considering the rigorous selection
criteria, it is not surprising that studies evaluating long term donor outcome all report good
outcome long term and show no increased risk for the development of kidney damage
compared to the general population. With growing experience and a growing request for
donor organs, selection criteria for potential donors have become more liberal (7;8). Although
the required renal functional limits remained unchanged, with a lower clearance limit of 80
mL/min for kidney donation, many centers have now extended their upper limit for age
accepting donors beyond 65 years. In fact, even donors over 70 years are considered for
recipients older than 60 years in special programs. For BMI, the upper limit of 30 kg/m2 was
adjusted according to national prevalence of obesity, which is rising worldwide. Since a few
years, many centers started to accept donors with a past medical history of regulated
hypertension as well. The changes in the selection of the donor population may have
consequences for donor as well as recipient outcome and it becomes more and more
important to monitor the living donation program for such consequences. In this thesis we
investigate the impact of the changes in risk proﬁle of the donor population on donor and
recipient outcome at the University Medical Center Groningen.
Kidney function
Kidney function assessment is one of the cornerstones of donor evaluation. To allow living
donation for both donor and recipient, kidney function prior to donation has to be suﬃcient
to ensure adequate renal function with one kidney. In the  past the cutoﬀ was set at a
clearance of 40-60 mL/min, but due to a publication by Bia et al. in 1995 consensus was
reached to use the threshold of 80 mL/min (9). Nowadays, about 75% of centers still use 80
mL/min as the lower limit for kidney donation. The remaining 25% requires kidney function
to be within two standard deviations of the mean kidney function for the donor’s age, or even
have a cutoﬀ of 90 mL/min (8). Donors in our center are selected with a lower threshold of
80 mL/min. To date no functional kidney impairment after donation has been documented.
Of note is that the level of kidney function prior to donation mainly predicts post-donation
kidney function, both for donor and recipient.
Gold standard assessment of kidney function using radioactive isotopes or iodinated
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tracers is expensive, and is therefore only applied by 10% of all centers evaluating potential
donors. The majority relies on estimates of kidney function by 24 h creatinine clearance or
creatinine-based kidney function equations. Both methods, however, have distinct
shortcomings. Whereas creatinine-clearance and creatinine-based equation have a large non-
systematic error, the equations, moreover, systematically underestimate kidney function,
especially when the latter is in the normal range, as it is with potential kidney donors.
Collection of 24 h urine has the beneﬁt that other renal parameters such as proteinuria, can
be evaluated as well. For most centers, proteinuria measurement is part of the standardized
donor screening. Cutoﬀs for proteinuria vary between 150 and 300 mg/day (8).
Donor age
Increasing age is associated with a decline in kidney function (10-14). This raises the question
about the suitability of older individuals for kidney donation, from a donor perspective as
well as for recipient outcome. With ageing, the number of functioning nephrons declines and
changes in the tubuli, glomeruli and vascular bed occur (15-23) that can aﬀect the
compensatory response to nephron loss. In chapter ﬁve and nine, we found a lower GFR prior
to donation in older donors, with age being an independent determinant of GFR. In line with
this lower pre-donation GFR, in older donors early post-donation GFR is lower as well.
Fortunately, the long-term compensatory response to nephrectomy in older donors was
similar to younger donors with a parallel increase in GFR from early post-donation up to 5
years after donation for donors older or younger than 55 years. Other studies reported good
post-donation adaption as well (24-27) supporting the safety of donation in terms of kidney
function for older donors.
Donor age is a main consideration from a recipient perspective as well. Since older donors
have lower kidney function, less kidney function is transplanted with the graft of an older
donor. Accordingly, higher donor age results in lower recipient kidney function (28-33). In
line, we found that donor age was the most important donor factor next to donor GFR in
predicting recipient GFR (chapter 9). Although kidney function of recipients of older donors
is lower, it is suﬃcient, and there was no increased rate of function decline or incidence of
graft loss in our study. Thus, older donors can be an important extension of the donor pool.
Further studies are, however, necessary to evaluate the eﬀects on long-term. 
Inﬂuence of gender and body size
Inﬂuence of donor gender on donor and recipient outcome was debated in several studies.
In the past the majority of living donors in the University Medical Center Groningen was
female, while gender distribution is more equal nowadays. Although gender has never been
a selection criterion, some believe that female kidneys perform worse after transplantation,
especially when transplanted into a male recipient, as shown in deceased donors (34;35).
Women are generally smaller than men, and, hence, have less nephron mass with a lower
kidney function compared to men. Rather than a structural property of the kidney, this lower
kidney function simply reﬂects lower body dimensions, and, consequently, a lower metabolic
demand in women. This is not likely to aﬀect donor outcome, but might be relevant to kidney






those of the donor. We ﬁnd a lower kidney function in female donors than in male donors.
When GFR was normalized for BSA, however, the diﬀerence between male and female donors
disappeared suggesting that the diﬀerence is due to diﬀerences in body dimension rather
than to intrinsic renal diﬀerences. 
After donation, male donors may be at a higher risk of loss of kidney function than female
donors in the very long term (36;37). This risk, however, is similar to the risk in the general
population, where men are at higher risk as well (38-41).
Several studies have shown a negative inﬂuence of female donor gender on recipient
outcome (34;35;42;43), others demonstrated a deﬁnite inﬂuence of recipient gender (44;45).
Gender diﬀerences were explained by higher metabolic demands in male recipients, and by
the graft/recipient weight ratio (42;44;46-48). As female kidneys are smaller (49), they may
not be able to live up to the high metabolic demands of male recipients. Body size disparity
between donor and recipient may lead to lower graft function due to smaller kidney
dimensions. This may explain the diﬀerence in outcome between female and male kidneys
after post-mortal transplantation. Whether this also applies to a healthy donor kidney has
been subject of discussion (45;48;50-52). In chapter eight we found no inﬂuence of donor or
recipient gender on recipient outcome up to ﬁve year after transplantation. The kidney
appears to adapt to body size of the recipient, irrespective of donor or recipient gender. In
fact, kidneys of smaller donors show a larger increase in kidney function after transplantation
than kidneys of larger donors, demonstrating that the transplanted kidney adapts to the
metabolic demands of its new environment, both on short and long term. This is associated
however, with a slightly higher urinary protein excretion early after donation.  This could be
a subtle sign of hyperﬁltration and a maladaptive response, but fortunately, it disappears in
the long term follow-up, suggesting that in our population the adaption of a small kidney to
a large recipient’s metabolic demand  did not have harmful consequences long-term. We
must emphasize,however, that our donor population is thoroughly screened, has an excellent
kidney function before donation and the generalizability of our ﬁndings to settings where
donor screening is less strict is uncertain. 
Donor overweight and obesity
Overweight and obesity is a growing problem worldwide and it also aﬀects potential donors
rendering them to  a possibly increased risk for kidney damage. As in the general Dutch
population, the body mass index of the donor pool has risen during the last decade. Although
a BMI < 30 kg/m2 is preferable for surgery, not all centers have the luxury to be able to reject
potential donors when their BMI exceeds 30 kg/m2. The risk of excess weight, however,
already starts at values of BMI in the overweight range. Already in the overweight range BMI
is an independent determinant of an unfavorable renal hemodynamic proﬁle, already in the
overweight range, and several studies in the general population have shown a link between
overweight and long-term risk for end stage kidney failure (38;53-58). In donors, higher BMI
was associated with lower kidney function and lower reserve capacity post-donation (11;59).
Furthermore, obesity was reported as a risk factor for post-donation kidney function
impairment (60;61). Others, however, found no inﬂuence of BMI on post-donation outcome
(62-64). In chapter ﬁve we saw no inﬂuence of BMI on donor outcome ﬁve years after living
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donation. Post-donation kidney function, as well as the adaption to nephrectomy was similar
between normal and overweight donors, and no signs of hyperﬁltration were found.
While overweight and obesity in the recipient are clearly associated with the risk of graft
failure (65;66), the eﬀects of donor BMI on recipient outcome are less clear. Although
recipients of very obese donors (BMI > 35 kg/m2) show more delayed graft function and acute
rejection episodes (67;68), there were no diﬀerences in occurrence of graft failure or in
recipient kidney function. In chapter nine we found no eﬀect of donor BMI on recipient
outcome, neither for kidney function, nor for the occurrence of rejection or graft failure. There
were, however, no very obese donors operated in our population, which somewhat limits the
generalizability and comparison of our data to other populations, with more prominent
obesity, such as in the US. 
Donor blood pressure and hypertension
Hypertension is one of the best well known risk factors for the development of kidney damage
in the general population (69-73). The acceptance of hypertensive individuals for kidney
donation, therefore, has long been a subject of debate. While in the past it was absolutely
unthinkable to accept a donor with pre-existent hypertension, since 2002, the University
Medical Center Groningen accepts potential donors who use antihypertensive drugs, provided
blood pressure is well controlled. Whether these donors are at increased risk for kidney
function loss remains unknown. Many studies reported an increase in blood pressure in
previously normotensive donors post-donation (59;74-78), although not invariably so (79).
Donors who developed hypertension after donation had higher macro albuminuria and
urinary protein excretion in three studies (78;80;81), and were at higher risk for a low kidney
function (82). A follow-up study of pre-existent hypertensive donors, however, found similar
outcome in hypertensive and normotensive donors (83). However, only three of these donors
had hypertension that warranted antihypertensive treatment, so the relevance of these data
to the current donor population is uncertain. 
In chapter four, we compare outcome of 49 donors using antihypertensive drugs prior
to donation, to matched, normotensive, controls. We found no detrimental eﬀects of pre-
existent hypertension on short term and ﬁve year post-donation outcome. Remarkably,
control donors had an increase in blood pressure post-donation, but the hypertensive donors
maintained stable blood pressure. Moreover, post-donation course of kidney function was
similar in hypertensive and normotensive donors and none of the donors developed
proteinuria (chapter 5). This favorable outcome in hypertensive donors might come as a
surprise, considering the role of hypertension as a renal risk factor.  Whereas these results
are encouraging, we must emphasize that our donors were selected for a GFR over 80 mL/min.
In particular in hypertensive individuals this may have selected those in whom the kidney is
not particularly susceptible to renal damage.
In kidney transplantation, hypertensive traits of the donor may be transferred to the
recipient, as shown in animal studies and human transplantation. Several studies have
demonstrated that higher donor blood pressure is associated with lower kidney function in
the recipient (30;84-87). In chapter nine, we found a similar negative correlation between






Furthermore, donor hypertension increased the risk of a GFR < 60 mL/min in the recipient.
Nevertheless, outcome of recipients from a hypertensive donor was good. As noted above,
the hypertensive donors were selected for good kidney function, and may have represented
a speciﬁc selection of the hypertensive population. Under these conditions, donation of
hypertensive donors was safe for donor and recipient. 
Donor smoking behavior
The eﬀects of smoking on donor outcome are largely unknown. Next to the known eﬀects of
smoking on the development of cardiovascular disease and malignancies, smoking is
recognized as a potential risk factor for the development of chronic kidney disease (58;88-
93). Smoking can aﬀect the kidney vasculature, and such lesions may make a kidney more
prone to nephrotoxicity of calcineurin inhibitors (94). Thus, recipients of smoking donors may
bear more nephrotoxic eﬀects with subsequent graft damage. In line, recipient smoking
increases the risk for graft loss and mortality (95;96), and in lung transplant recipients a dose
dependent association between former smoking and the development of CKD after lung
transplantation was found, demonstrating a long-lasting eﬀect of prior smoking (97). Smoking,
however, is not a selection criterion for potential kidney donors. Fortunately, in chapter nine
we found no harmful eﬀects of smoking prior to donation on post-donation kidney function
course, and, moreover, we ﬁnd no eﬀect of the donors’ smoking behavior on recipient
outcome, neither on short, nor on long term post-transplantation. 
Implications for donor screening
To justify living donor programs, long-term donor safety needs to be ensured. This emphasizes
the need of thorough screening of potential donors. As mentioned above, we found no eﬀects
of pre-donation BMI, hypertension or smoking behavior on post-donation outcome in donors
or recipients. These favorable ﬁndings should be interpreted in the context of the thorough
screening for overall health, and particularly, kidney function. Pre-donation kidney function
is the main predictor of post-donation kidney function in donor and recipient. Accurate kidney
function measurements are therefore of major importance for donor screening. Since true
kidney function measurement is expensive, and requires speciﬁc expertise, many centers rely
on an estimation of kidney function (eGFR) for donor screening by use of kidney function
equations. The two most widely used equations, the Modiﬁcation of Diet in Renal Disease
(MDRD) Study equation and Cockcroft-Gault (CG) equation (98;99), however, were derived
from populations with kidney function impairment, and perform poorly in individuals with
normal kidney function (100-107).  More recently, the Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI) equation was developed in a large data set in diﬀerent populations
including subjects without renal disease (108), to aim for better performance in subjects
without overt renal disease. In chapter one, we found that the CKD-EPI equation was indeed
more accurate and precise than the MDRD Study and CG equation in estimating pre-donation
kidney function. Nevertheless, kidney function was signiﬁcantly underestimated by all three
equations. Thus, use of these equations will lead to rejection of many potential donors that
actually have adequate kidney function.  If a cut-oﬀ of an eGFR <80 mL/min/1.73m2 would
have been used in the 253 donors presented in chapter one, 55, 31 an 25% of donors would
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have been rejected by use of MDRD, CKD-EPI and CG, while all had suﬃcient pre- and post-
donation kidney function! Thus, the use of kidney function equations many lead to
unwarranted and substantial reduction of the donor pool, putting unnecessary pressure on
the waiting lists for kidney transplantation. Therefore, we plead for thorough donor screening
with preferably gold standard kidney function measurement, or, alternatively, repeated
creatinine clearances. 
Although kidney donors are selected because of good health and kidney function, minor
morphological damage, like glomerulosclerosis, interstitial ﬁbrosis and tubular atrophy, may
be present at time of donation (18;19;109-112). Due to the large reserve capacity of the
kidney, such changes may not be reﬂected in lower kidney function. Consequences for post-
donation donor outcome are unclear. Associations have been described between mild
baseline damage and graft performance in the recipient (112-121). Thus, kidney biopsies may
be an important tool to assess the risks for the donor and recipient. Chapter seven evaluates
whether morphological, pro-ﬁbrotic and pro-inﬂammatory changes in baseline kidney
biopsies associate to donor characteristics and early post-donation outcome. The pro-ﬁbrotic
marker α-smooth muscle actin (α-SMA) associated to donor age and kidney function prior to
and early post-donation. Older donors had higher α-SMA expression, while donors with a BMI
> 30 kg/m2 had a higher number of interstitial macrophages and more vascular intima-
thickening than leaner donors. None of the baseline changes, however, associated with the
change in kidney functio over donation. Thus, although baseline damage is present these
changes appear to be too mild to aﬀect early post-donation renal adaptive capacity. Eﬀects
on long term donor and recipient outcome, however, need to be evaluated by future studies. 
Implications for donor follow-up
Although thorough screening should assure long-term donor safety, accurate donor follow-
up remains of major importance. With increasing age, donors may develop hypertension,
glucose intolerance or micro-albuminuria, all undesirable in the single kidney situation, but
may be treated well when early detected. Furthermore, any decrease in kidney function
should be detected early, so that early intervention can be started. As described above, many
centers use kidney function equations to monitor kidney function. These equations perform
poorly in subjects with normal kidney function such as kidney donors. After donation, when
kidney function is lower, performance is somewhat better (chapter one). To be feasible for
donor follow-up, however, the kidney function equations should be reliable to detect kidney
function loss over time. Somewhat surprisingly, validation studies on kidney function
equations so far almost exclusively focused on cross-sectional data. Therefore, we evaluated
the use of kidney function equations for monitoring of kidney function over time, in CKD
patients and former kidney donors respectively. In both populations we found that mean
performance of the equations is acceptable (chapter two and three). However, progressive
kidney function decline is not detected reliably, which is a major drawback for its clinical use
in the clinic. Therefore, for donor follow-up, kidney function equations should be interpreted
with caution. Preferably, gold standard methods, or serial creatinine clearances should be
used. Furthermore, other markers for kidney damage should be evaluated during donor







Many former kidney donors have an estimated or measured GFR below 60 mL/min/1.73m2,
the upper limit of CKD stage 3 kidney disease (122). Former kidney donors with a kidney
function below this threshold, therefore, may be marked as CKD patient, with possible
negative socio-economic consequences. The current CKD staging, however, is based on the
presence of two kidneys. A low GFR in a subject with two kidneys may reﬂect kidney disease,
while the same GFR in a former donor reﬂects the presence of a single, healthy, kidney, as
supported by the excellent long term donor outcome. The prognostic impact of a given level
of GFR is one of the main factors underlying the current CKD staging system. In chapter six,
therefore, we compare the kidney function course of former donors to that of matched CKD
patients to evaluate the impact of CKD staging for prediction of donor outcome. As expected,
CKD patients show progression of their CKD stage over time. In former donors, by contrast
the CKD stage improves from early post-donation to long term. Thus, the CKD staging has no
predictive value in donors, And former donors with a GFR <60 mL/min/1.73m2 should not be
regarded as CKD patients. Yet, one should be aware of their reduced kidney function in
conditions where drug toxicity is related to reduced kidney function.  
In summary, the population of living donors has evolved over the last decades, with older,
more overweight and even hypertensive donors. In this thesis we have evaluated the eﬀects
of these factors on living donor and recipient outcome in the donor population of our center.
Fortunately, we found no detrimental eﬀects of donor age, BMI, blood pressure or smoking
behaviour on donor and recipient outcome. It is important, however, to mention that our
donors are thoroughly screened, including gold standard kidney function measurements.
Thus, even donors with an adverse risk proﬁle are ensured of good kidney function prior to
donation, which is probably a main factor in the encouraging outcome in donor and recipient.
This emphasizes the importance thorough screening of potential donors. Thus, when pre-
donation kidney function is good, acceptation of older, overweight and hypertensive donors
is safe for donor and recipient. Although post-donation outcome of donors presented here
was good, we would like to plead for structural, long term donor follow-up, including overall
health assessment as well as a reliable follow-up of kidney function. Taken together, this will
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Wereldwijd stijgt het aantal patiënten met een nierziekte. Niertransplantatie is de
voorkeursbehandeling van eind stadium nierfalen. Gezonde mensen kunnen veilig een nier
afstaan voor transplantatie. Doordat er een groot tekort is aan donornieren van overleden
donoren, zijn levende nierdonoren steeds belangrijker geworden voor niertransplantatie. In
Nederland wordt de helft van alle niertransplantaties verricht met behulp van een levende
donor. Nieren van levende donoren zijn kwalitatief beter dan nieren van overleden donoren,
wat voor de ontvanger van de nier veel voordelen biedt. 
Gezonde nieren hebben veel reservecapaciteit. Wanneer één nier verwijderd wordt kan
de andere nier dit compenseren door harder te gaan werken. Lange termijn studies naar
donor en ontvanger uitkomst laten dan ook goede resultaten zien. Om aan de groeiende vraag
naar donornieren te voldoen, zijn de criteria voor potentiële donoren de afgelopen tien jaar
echter versoepeld. Voorheen kwamen alleen zeer ﬁtte, volledig gezonde mensen in
aanmerking voor nierdonatie. De afgelopen jaren is de leeftijdsgrens voor potentiële donoren
verdwenen, worden donoren met overgewicht en zelfs obesitas geaccepteerd, en sinds 2002
worden ook donoren die bloeddrukverlagende medicatie gebruiken geaccepteerd.
Hiertegenover staat wel dat de nierfunctie van een potentiële donor voldoende hoog moet
zijn. Het is bekend dat de nierfunctie daalt met de leeftijd. Overgewicht, obesitas en een hoge
bloeddruk zijn bekende risicofactoren voor het ontwikkelen van nierschade op de lange
termijn. De verschuiving in de donorkarakteristieken, naar oudere donoren die vaker
overgewicht of een hoge bloeddruk hebben, zet dus vraagtekens bij de lange termijn uitkomst
van de donor én de ontvanger van de nier. In dit proefschrift onderzoeken we daarom de
eﬀecten van de nieuwe donor karakteristieken op de nierfunctie van donor en ontvanger
uitkomst vijf jaar na de transplantatie. Daarnaast proberen we een antwoord te geven op hoe
we de levende donor het beste kunnen volgen na donatie.
Om antwoord te geven op onze vragen hebben we de nierfunctie gemeten van de
levende donoren en hun ontvangers. In de donoren hebben we de nierfunctie vier maand
voor donatie en twee maand en ongeveer vijf jaar na donatie gemeten. In de ontvanger is de
nierfunctie drie maanden, één jaar en vijf jaar na transplantatie gemeten.
Deel I: geschatte nierfunctie voor screening en follow-up
In de dagelijkse praktijk wordt de nierfunctie op verschillende manieren gemeten. De meest
nauwkeurige ‘gouden standaard’ methode maakt gebruik van radioactieve stoﬀen. Dit is een
tijdrovende en kostbare manier van nierfunctie meten. Een andere methode is het meten van
de ‘creatinineklaring’. Hiervoor moet echter 24 uur urine verzameld worden, wat helaas vaak
tot meetfouten leidt. Daarom wordt veelvuldig gebruik gemaakt van formules die de
nierfunctie kunnen schatten met behulp van één bloedwaarde. Deze formules zijn goedkoop
en gemakkelijk in het gebruik. Uit eerdere studies is echter gebleken dat de schatting van de
nierfunctie minder precies wordt naarmate de nierfunctie hoger is, met een onderschatting
van de echte nierfunctie. In het eerste deel van dit proefschrift laten we zien dat in levende
donoren de schatting van de nierfunctie voor donatie – bij een hoge nierfunctie op twee
gezonde nieren – meer afwijkt van de gouden standaard waarde dan na donatie, wanneer de
nierfunctie lager is. Het presteren van de formules is dus afhankelijk van de hoogte van de
Nederlandse samenvatting
168
echte nierfunctie. Tevens laten we zien dat wanneer de formules gebruikt worden voor het
screenen van potentiële donoren, bijna de helft van de donoren zou worden afgewezen omdat
de nierfunctie te laag wordt ingeschat terwijl de echte nierfunctie voldoende is. 
Omdat de nierfunctie na donatie lager is dan voor donatie – er is immers een nier
verwijderd – geven de formules na donatie een redelijk goede schatting van de nierfunctie.
Voor het volgen van de nierfunctie na donatie zouden de formules dus een goedkoop en
gebruiksvriendelijk alternatief kunnen zijn. We hebben zowel in nierpatiënten als in donoren
na donatie onderzocht hoe goed de formules het nierfunctieverloop over langere termijn
kunnen inschatten. Zowel in de nierpatiënten als in de nierdonoren schatten de formules het
nierfunctieverloop goed in. Wanneer de nierfunctie echter snel daalt wordt dit niet opgepikt
door de formules. Dit zet vraagtekens bij de toepasbaarheid van de formules voor het
vervolgen van de nierfunctie van donoren.
Deel II: eﬀecten van het donor risico proﬁel op uitkomst van de donor
In dit tweede deel van het proefschrift onderzoeken we de eﬀecten van de donor
karakteristieken voor donatie op de korte en lange termijn uitkomst van de donor na donatie.
Allereerst hebben we een groep donoren die voor donatie bloeddrukverlagende medicatie
gebruikten vergeleken met een groep controle donoren die voor donatie dergelijke medicatie
niet gebruikten. Omdat donoren met bloeddrukverlagende medicatie in ons centrum pas
sinds 2002 worden geaccepteerd voor donatie, is de lange termijn uitkomst nog zeer beperkt.
Op korte termijn, twee maand en één jaar na donatie, zien we geen verschillen in de
nierfunctie van donoren met of zonder bloeddrukverlagende medicatie. Ook zien we dat bij
de donoren met medicatie de bloeddruk niet méér stijgt dan bij de controle donoren en dat
er niet meer medicijnen nodig zijn na donatie. 
Vervolgens hebben we de invloed van het pre-donatie risicoproﬁel op de lange termijn
uitkomst van de donor onderzocht. Risicofactoren waren een leeftijd boven 55 jaar,
overgewicht en obesitas, hoge bloeddruk en roken. Donoren ouder dan 55 hadden zoals
verwacht voor en na donatie een lagere nierfunctie dan jongere donoren. De daling in
nierfunctie over de donatie en het herstel van de nierfunctie naar de langere termijn was
echter gelijk tussen oude en jongere donoren. Overgewicht, hoge bloeddruk en roken lieten
geen negatieve eﬀecten op de donor uitkomst zien.
Na donatie is de nierfunctie van een deel van de donoren dusdanig verlaagd dat deze
donoren volgens de meest gebruikelijke classiﬁcatie voor nierziekten, die berust op bepaalde
afkappunten van nierfunctie, een nierziekte zouden hebben. Deze classiﬁcatie gaat er echter
van uit dat de nierfunctie verlaagd is bij twee zieke nieren, terwijl donoren na donatie een
lagere nierfunctie hebben met één gezonde nier. We hebben daarom het nierfunctie verloop
van donoren van twee maand na donatie tot vijf jaar na donatie vergeleken met dat in
nierpatiënten. Waar de donoren echter na vijf jaar follow-up een toename in nierfunctie laten
zien, daalt in de nierpatiënten de nierfunctie over de tijd. Hoewel donoren na donatie een
lage(re) nierfunctie hebben, is dit dus geen teken van nierziekte.
Hogere leeftijd, overgewicht en hoge bloeddruk zijn risicofactoren voor het ontwikkelen
van nierschade. Ook in gezonde nieren kan lichte schade aanwezig zijn, zonder dat dit de


















genomen. In deze biopten blijkt ook in gezonde donoren zeer milde schade aanwezig. Bij
oudere donoren is er meer schade aanwezig in de nier dan bij jongere donoren, op grond van
het normale verouderingsproces. We zagen geen invloed van overgewicht of hoge bloeddruk.
Hoewel meer schade samenging met een lichte verlaging in de nierfunctie, werd het
aanpassingsvermogen van de nier, en dus de uitkomst van nierfunctie na donatie, niet
beïnvloed door de aanwezigheid van die schade. 
Deel III: eﬀecten van het donor risico proﬁel op de uitkomst van de ontvanger
In het derde deel onderzoeken we de eﬀecten van het donor proﬁel op de uitkomst van de
ontvanger van de nier. Er zijn veel discussies over de invloed van het geslacht en de
lichaamsgrootte van de donor en ontvanger op de uitkomst van de transplantatie: zo wordt
wel beweerd dat de kwaliteit van vrouwennieren slechter is dan van mannennieren. Daarom
hebben wij naar het eﬀect van de geslachts- en lichaamsgrootteverhouding tussen de donor
en ontvanger op de nierfunctie van de ontvanger vijf jaar na transplantatie gekeken. Uit onze
studie blijkt dat de nierfunctie zich aanpast aan de lichaamsgrootte van de ontvanger: een
nier van een kleine donor gaat harder werken in een grote ontvanger dan in een kleine
ontvanger. Het geslacht van de donor en de ontvanger lijkt hierin geen rol te hebben.
In het tweede deel hebben we gezien dat donor leeftijd, overgewicht, bloeddruk en
rookgedrag geen invloed hebben op de aanpassing van de nier na donatie. In het laatste
hoofdstuk verbreden we ons onderzoek naar de eﬀecten op de uitkomst van de ontvanger
vijf jaar na transplantatie. Hoewel we wel een negatief eﬀect vonden van hogere leeftijd en
hogere bloeddruk van de donor op de nierfunctie van de ontvanger, hebben de ontvangers
van oudere donoren en donoren met een hoge bloeddruk wel een goede – zij het iets lagere
– nierfunctie vijf jaar na transplantatie. Er was geen invloed op de overleving van de ontvanger.
Donor overgewicht en rookgedrag hadden geen invloed op de overleving en nierfunctie van
de ontvanger. 
Conclusies en implicaties
Samenvattend vinden we in dit proefschrift geen nadelige eﬀecten van de nieuwe
donorkarakteristieken – oudere leeftijd, overgewicht en hoge bloeddruk – op de uitkomst van
de donor en de ontvanger vijf jaar na de donatie of transplantatie. De nierfunctie van de
donor vóór donatie blijkt de belangrijkste voorspeller van de uitkomst van de donor en
ontvanger. Deze resultaten werden verkregen in een cohort donoren waarin zorgvuldige
screening plaatsvond, met een ondergrens voor pre-donatie nierfunctie van 80 mL/min.
Mogelijk speelt deze selectie een rol bij de gunstige uitkomsten. Mits de donor goed
gescreend is voor donatie lijken de huidige selectiecriteria dus veilig op de middellange
termijn. Verdere studies zijn echter nodig om de eﬀecten op de lange termijn vast te stellen.
Daarom blijft het belangrijk om donoren na donatie goed te volgen om bij eventueel
nierfunctie verlies vroeg te kunnen ingrijpen. Hier ligt ook potentieel een belangrijke rol voor
leefstijlinterventie, hoewel het onderzoek naar de eﬀecten hiervan nog in volle gang is. Voor
het volgen van donor nierfunctie na donatie zijn nierfunctieformules een goedkoop en
gebruiksvriendelijk alternatief voor gouden standaard metingen. Hierbij moeten de





















Aan het einde van dit proefschrift krijg ik gelukkig de gelegenheid om iedereen te bedanken
die heeft bijgedragen aan de totstandkoming ervan. Doordat ik met zo veel mensen heb
samengewerkt en er zoveel mensen direct en indirect aan hebben bijgedragen is de kans dat
ik iemand vergeet te noemen helaas aanwezig. Daarom wil ik iedereen die heeft bijgedragen
aan dit proefschrift hartelijk danken voor zijn/haar hulp, mocht ik iemand overslaan dan ligt
dat duidelijk aan mijn falen en niet aan uw/jouw inzet. Bedankt iedereen!
Allereerst wil ik graag alle donoren bedanken die speciaal voor dit onderzoek van heinde en
verre weer een hele dag naar Groningen wilden komen. Zonder de bereidheid van de donoren
had dit project niet kunnen bestaan.
Dan uiteraard mijn promotoren. Ooit begonnen met twee promotoren en twee co-
promotoren, maar inmiddels uitgegroeid tot een heus ‘promotorenkwartet’. Als team
representeren jullie de sterke samenwerking tussen Nefrologie, Chirurgie en Pathologie, een
onderzoekslijn die nog lang niet is uitgeput!
Mijn eerste promotor, prof. dr. Navis, beste Gerjan, bedankt dat ik dit project kon overnemen
en in alle vrijheid zelf verder kon ontwikkelen. Als leading lady van het team wist je alle losse
projecten altijd goed bij elkaar te houden. Door je frisse en eigen kijk op onderzoek weet je
alles altijd net een draai te geven om het pakkend en sexy te maken. Bedankt voor de mix
van bevlogen begeleiding en vrijheid om mezelf te ontwikkelen.
Mijn tweede promotor, prof. dr. Ploeg, beste Rutger, bedankt voor alle mogelijkheden die de
samenwerking tussen chirurgie en nefrologie geboden heeft. Met minimale, verhelderende,
correcties weet u teksten altijd zó aan te passen dat er wel precies staat wat ik bedoelde. 
Mijn derde promotor, prof. dr. Homan van der Heide, beste Jaap, met je voorliefde voor
simpele klinische boodschappen weet jij altijd precies waar behoefte aan is in ‘donorland’.
Bedankt voor je enthousiasme over het levende donortraject en je vele ideeën voor nieuwe
projecten. Ik hoop dat met jouw vertrek naar Amsterdam het donoronderzoek alleen maar
groter en sterker zal worden. 
Mijn vierde promotor, prof. dr. van Goor, beste Harry, bedankt voor alle gezelligheid binnen
én buiten het UMCG. Al was je niet bij alle stukken direct betrokken, je bleef altijd goed op
de hoogte van wat er verder speelde in mijn traject. Bedankt voor alle ondersteuning en
adviezen, ook buiten de biopten om. Met je vele ideeën en nieuwe plannen wist je Marian
en mij altijd weer te enthousiasmeren voor nieuwe monsterklussen met de nierbiopten. 
Prof. dr. ter Wee, prof. dr. Weimar en prof. dr. van Son wil ik hartelijk danken voor het
beoordelen van mijn proefschrift en vele adviezen en discussies vanaf de zijlijn en op
congressen.
Dan zijn er vier dames zonder wie dit proefschrift er helemaal niet was geweest. Lieve Roelie,
Marian en Dirkina, bedankt voor al het werk dat jullie op de nierfunctiekamer hebben verricht
en de geweldige zorg voor alle donoren, jullie zijn toppers! Dankzij jullie zijn alle
nierfunctiemetingen van planning tot uitzwaaien altijd soepel verlopen. Ook bedankt voor










Marian Bulthuis, lieve Marian, bedankt dat je mij hebt ingewijd in de wereld van plakken,
kleuren, scannen en tellen (en nog meer tellen). Met veel enthousiasme en nog meer geduld
heb je me alles geleerd zodat ook ik me veilig en verantwoord in het lab kon begeven. De
monsterkleursessies waren niet alleen erg eﬃciënt, maar ook altijd erg gezellig. Ik heb veel
bewondering voor je altijd opgewekte aard, zelfs als je voor de zesde keer alle SMA coupes
gaat omcirkelen. 
Lieve Mieneke, zonder jou was dit hele project er nooit geweest! Dat ik dit project van jou
mocht overnemen was een geweldige en vliegende start voor mijn promotietraject. De
periode als student Tent onder jouw hoede heeft een goede basis gelegd voor de rest van
mijn promotie. Bedankt voor alles wat je me geleerd hebt, maar vooral voor alle gezelligheid
en betrokkenheid bij dit project. 
In mijn tijd bij de Nefrologie heb ik heel wat collega’s zien komen en gaan. Allereerst de ‘oude
garde’, Femke, Folkert, Titia, Inge, Leendert, Rutger, Nynke en Marije: bedankt voor een
geweldige begintijd, alle gezelligheid en vele adviezen. Femke, bedankt voor alle mooie
opmerkingen, slechte grappen en goede borrels, en natuurlijk de topsamenwerking voor het
druivenstuk. Titia, bedankt voor al je adviezen en zetten in de goede richting wanneer deze
nodig waren, ons gezamenlijke stuk hebben we toch maar mooi in AJT gekregen! Rutger, ik
mis je nog steeds als buurman.
Laura, ik vind het echt geweldig dat ik het donorproject bij jou heb kunnen achterlaten, bij
jou is het zeker in goede handen! We gaan hopelijk nog wat mooie plannetjes maken en
borrels drinken op de donoren. Michel, bedankt voor je eeuwige enthousiasme en vele hulp
bij meerdere projecten. Ik ken niemand die zoveel bizarre dingen meemaakt als jij. Je was
werkelijk een top ‘student’!
Dan mijn kamergenoten die tijdens mijn wisselende aanwezigheid een stabiele factor
vormden. Else, bedankt voor een geweldige gezamenlijke beginperiode, nooit gedacht dat je
zo veel lol kunt hebben met onderzoek. Voor jou komt het einde nu ook in zicht, succes met
de laatste loodjes. Arjan, bedankt voor je bijzondere verhalen en mooie grappen. Jij weet
echt alles signiﬁcant te maken! Steef, doordat we onze trajecten tegengesteld hebben
ingedeeld hebben we uiteindelijke niet zo veel op één kamer gezeten maar des te meer
geborreld en geouwehoerd. Kunnen we mooi voortzetten bij de cardiologie! Dorien, ook altijd
vol mooie verhalen en altijd in voor mooie reisjes en uitstapjes. En bedankt voor het opdrinken
van al mijn vieze thee.
De buurdames, Maartje en Solmaz, jullie zijn de echte ladies van de Nefrologie. Dank voor
alle gezelligheid, interesse en mooie grappen met of zonder droogijs. Marco, bedankt voor
alle hulp met de donoren, veel succes met je eigen onderzoek. De collega’s uit het
Triadegebouw, Ferdau, Esther, Wendy, Lieneke en Hanneke, dank voor de gezamenlijke reizen,
borrels en ontbijtjes. Ferdau, naast inderdaad veel mooie mailconversaties hebben we toch
ook menig vrijdagavond borrelend doorgebracht, altijd een goed begin van het weekend!
Dank voor je bijzondere kijk op de wereld en mooie grappen. Esther, met jou erbij wordt het
al snel een feestje, bedankt voor alle gezelligheid! Wendy, bedankt voor alle gezamenlijke




Alle collega’s bij de pathologie en medische biologie: Eelke, Gemma, Jelena, Miriam, Heleen,
Pauline, Anne-Roos, Gerda, Yuan en Welmoet, bedankt voor de gezelligheid op het lab en
tijdens congressen en jullie hulp bij mijn frequente zoektochten naar Marian. Welmoet, wat
ontzettend ﬁjn dat je het bioptenproject hebt overgenomen! Heel veel succes met alle
puinhopen die ik daar heb achtergelaten. 
Er zijn natuurlijk nog vele anderen met wie ik heb samengewerkt en congressen bezocht heb:
Alaa, Anna, Azadeh, Bettine, Carolien, Hiddo, Janna, Kiran, Lucia, Maaike, Merel, Michel,
Pramod en Stefan, bedankt voor een gezellige tijd! Alle nieuwe collega’s: Ineke, Edwin,
Janneke, Willem, Debbie en Anne Marijn, heel veel succes met jullie projecten!
Mijn eerdere ervaring met onderzoek hebben de basis gelegd voor mijn MD/PhD traject. Prof.
dr. The, Cresje Wachters en de Junior Scientiﬁc Masterclass, bedankt voor jullie stimulering
om onderzoek te gaan doen.
Prof. de Jong, beste Paul, bedankt voor alle interesse en goede adviezen tijdens besprekingen
en op congressen. Beste Ron, als buurman was je zowel binnen als buiten het UMCG een bron
van gezelligheid. De andere wijze heren op de gang: Coen Stegeman, Marc Seelen, Willem
van Son, Casper Franssen, Jaap van der Born en Stephan Bakker en ook Goos Laverman en
Akin Ozyilmaz, bedankt voor alle samenwerking en bijdrage aan de werksfeer. Jan-Stephan,
al werd je wat laat in het donorproject betrokken met je frisse kijk heb je er wel een draai
aan weten te geven.
Tegenover de wijze heren staan een aantal dames die zorgen dat alles altijd goed verloopt.
Winie, bedankt dat je altijd tijd had voor een praatje en voor alles wat je altijd maar weer
weet te regelen. Annemarie, Regien en nu ook Ellen, bedankt voor de prettige samenwerking
met de donoren, zonder jullie goede zorgen waren er ongetwijfeld niet zo veel voor follow-
up gekomen. Geertien, als mijn vaste aanspreekpunt voor alles wat met transplantatie
patiënten te maken had heb je ook een belangrijke bijdrage geleverd aan de donor follow-
up, bedankt! 
Door de brede inzet van dit project heb ik ook met velen buiten de Nefrologie mogen
samenwerken. Sijbrand, bedankt dat je altijd bereikbaar was  voor vragen over donoren of
over procedures, veel succes met jouw onderzoek! Hans Vos, Lydia, Tineke, Marjan en Wolter
wil ik bedanken voor alle hulp op het O&O lab. Henri Leuvenink en Jan-Luuk Hillebrands,
bedankt voor jullie bijdragen voor de donor biopten. Marcory, bedankt voor de super snelle
scoorsessies en alle adviezen. De heren Simon Lems, en Bouke Hepkema, bedankt voor een
korte inwijding in de transplantatie immunologie en voor de PRA’s. 
Ook al heeft onze dierproef helaas geen onderzoeksresultaten opgeleverd, ik heb er wel
ontzettend veel van geleerd en een mooie tijd gehad. De medewerkers van het dierenlab en
de histologie wil ik bedanken voor alle hulp, steun en gezelligheid.
Dr. Inker, dear Lesley, thanks for the pleasant cooperation on the eGFR papers and all you
have taught me about statistics. 
De staf van de Cardiologie van het UMCG en alle nieuwe collega’s wil ik bedanken voor een
soepele overstap van Nefronerd naar arts-assistent. Bedankt voor een leerzame maar ook
plezierige werkomgeving. 
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De heer van Schaik, beste Martin, bedankt voor de snelle maar vooral mooie realisatie van
de kaft van dit boekje!
En dan zijn er een heleboel anderen die vanaf de ‘zijlijn’ de totstandkoming van dit proefschrift
hebben meegemaakt en vooral ook voor een mooie tijd naast het onderzoek hebben gezorgd.
De dames van mijn geneeskundestudie, Ira, Marie-Anne, Aafke en Carleyn, bedankt voor de
gezellige avondjes stappen, eten en theeën en natuurlijk voor alle support en altijd uistekende
verzorging, we moeten elkaar weer vaker zien! Ira, ik blijf het bijzonder vinden dat we elkaar
weer zijn tegengekomen; van cavia’s wassen tot beide een promotietraject bij de Nefrologie,
wie had dat gedacht?! Heel veel succes met dansen!
Marjon, bedankt voor de muzikale omlijsting van mijn leven. Maar ook voor je verfrissende
kijk op de wereld en relativerende aard. Johan, bedankt voor de vele kilometers, ingehaalde
staarten en bereikte ﬁnishes. Die 2.00 grens gaan we dit jaar nog halen!
Alle Essenaren, bedankt dat ik als geboren en getogen Groningse ook Essen altijd als ‘thuis’
zal beschouwen.
Lieve Annet, je bent werkelijk een topper! Jij zal altijd klaar staan wanneer dat nodig is.
Bedankt voor alle hulp, maar ook voor alle gezelligheid, de 4 mijl en gezellige etentjes. We
moeten gauw weer aan de pizza.
Lieve Jeanine, wat een luxe om nóg een grote zus te hebben! Bedankt voor de snelle hulp
voor de kaft, maar vooral dat je al jaren mijn lieve zus wilt zijn.
Mijn paranimfen, Nynke en Tsjitske, wat geweldig dat jullie straks aan mijn zijde willen staan!
Lieve Nynke, in de loop der jaren hebben we al heel wat lief en leed met elkaar gedeeld,
bedankt dat je er altijd voor me bent. Fijn dat jij straks mijn paraNymps bent! En nu je straks
weer naar Groningen komt kunnen we nog vaker theeën, kletsen en drankjes drinken! Lieve
Tsjitske, als nuchtere Friesin bracht je een frisse wind door de Nefrologie. Met je voorliefde
voor gezelligheid, samen eten en drinken heb je de saamhorigheid bij de Nefrologie een ﬂinke
boost gegeven. Met jou naast me moet het wel een mooi feestje worden!
Familie Krikken, Joke en Albert, Baukje, Theo, Bart en Elisa en Janneke, bedankt dat ik mag
aanschuiven bij jullie familie. Dank voor alle gezelligheid en interesse.
Lieve Alf en Eva, bedankt voor alle gezelligheid, mooie verhalen en (soms ook mooie) ﬁlmpjes.
Lieve Hans en Marjanne bedankt voor jullie eeuwige steun en support, of het nou om
onderzoek ging of de badkamer verbouwen, jullie zijn er altijd! Lieve Oscar en Renée, bedankt
voor de vele aﬂeiding die jullie altijd weten te bieden. Lieve Bert en Wija, bedankt voor jullie
liefde en steun en de geweldige zorg voor al mijn dames. Bedankt dat altijd alles mogelijk was
en is, en jullie steun bij alles wat ik doe. Ik ben er trots op een Tent te zijn!
Lieve Jan, nu is het eindelijk klaar. Bedankt voor alles, laat de toekomst maar beginnen!
Hilde
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